



Italian Conference on AIDS and Antiviral Research

Presidenza del Congresso
Andrea Gori, Monza
Adriano Lazzarin, Milano
Franco Maggiolo, Bergamo

6-8 giugno 2016
MILANO
Università Milano-Bicocca

SCIENTIFIC PROGRAMME

Promosso da



e da

INMI, Istituto Nazionale per le Malattie Infettive
ISS, Istituto Superiore di Sanità
AMCLI, Associazione Microbiologi Clinici Italiani
SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia
SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili
SIMET, Società Italiana di Medicina Tropicale
SITA, Società italiana per la Terapia Antinfettiva
SIV, Società Italiana di Virologia

SIVIM, Società Italiana di Virologia Medica
ANLAIDS, Associazione Nazionale per la lotta all'AIDS
ARCIGAY, Associazione LGBT Italiana
EpaC Onlus, Associazione EpaC Onlus
LILA, Lega Italiana per la lotta contro l'AIDS
NADIR, Associazione Nadir Onlus
NPS Italia Onlus, Network Persone Sieropositive
PLUS Onlus, Persone LGBT sieropositive Onlus

Con il Patrocinio di



Promoted by

SIMIT Società Italiana di Malattie Infettive e Tropicali

and by

INMI, Istituto Nazionale per le Malattie Infettive

ISS, Istituto Superiore di Sanità

AMCLI, Associazione Microbiologi Clinici Italiani

SIICA, Società Italiana di Immunologia, Immunologia Clinica e Allergologia

SIMaST, Società Interdisciplinare per lo Studio delle Malattie Sessualmente Trasmissibili

SIMET, Società Italiana di Medicina Tropicale

SITA, Società italiana per la Terapia Antinfettiva

SIV, Società Italiana di Virologia

SIVIM, Società Italiana di Virologia Medica

ANLAIDS, Associazione Nazionale per la lotta contro l'AIDS

ARCIGAY, Associazione LGBT Italiana

EpaC, Educazione, Prevenzione e Ricerca sull'Epatite C

LILA, Lega Italiana per la lotta contro l'AIDS

NADIR, Associazione Nadir Onlus

NPS Italia Onlus, Network Persone Sieropositive

PLUS Onlus, Persone LGBT sieropositive Onlus

Endorsements

INSTITUTIONS

Ministero della Salute

AIFA, Agenzia Italiana del Farmaco

CNR, Consiglio Nazionale delle Ricerche

Regione Lombardia

Città Metropolitana di Milano

Comune di Milano

Comune di Bergamo

Comune di Monza

ASST Papa Giovanni XXIII Bergamo

ASST San Gerardo Monza

Ospedale San Raffaele Milano

Università degli Studi di Milano

Università degli Studi di Milano-Bicocca

Università Vita-Salute San Raffaele

SCIENTIFIC SOCIETIES AND ASSOCIATIONS

AIMI, Associazione Infermieri Malattie Infettive

AISF, Associazione Italiana per lo Studio del Fegato

ASA, Associazione Solidarietà AIDS

ASPE, Associazione Studio Patologie Epatiche

Aviralia, Fondazione Aviralia Onlus

Cittadinanzattiva

SIMPIOS, Società Italiana Multidisciplinare per la Prevenzione delle Infezioni nelle Organizzazioni Sanitarie

SIV-ISV, Società Italiana di Virologia - Italian Society for Virology

Scientific Committee

CHAIRS

Andrea Gori, Monza

Adriano Lazzarin, Milano

Franco Maggiolo, Bergamo

SCIENTIFIC SECRETARIAT

Alessandra Bandera, Monza

Andrea Calcagno, Torino

Antonella Castagna, Milano

Francesca Ceccherini-Silberstein, Roma

Mario Clerici, Milano

Nicola Coppola, Napoli

Andrea De Luca, Siena

Antonio Di Biagio, Genova

Margherita Errico, Milano

Carlo Ferrari, Parma

Sergio Lo Caputo, Bari

Giulia Marchetti, Milano

Bruno Marchini, Roma

Renato Maserati, Pavia

Cristina Mussini, Modena

Massimo Puoti, Milano

Stefano Rusconi, Milano

Gabriella Scarlatti, Milano

Gloria Taliani, Roma

Giuseppe Tambussi, Milano

Organi di Governo

DIREZIONE DI ICAR

Coordinator

Andrea Antinori, Roma

Secretary

Antonella d'Arminio Monforte, Milano

Members

Massimo Andreoni, Roma

Alessandra Cerioli, Bologna

Antonio Chirianni, Napoli

Adriano Lazzarin, Milano

Carlo Federico Perno, Roma

Massimo Puoti, Milano

Maurizio Zazzi, Siena

SPC (SCIENTIFIC PROGRAMME COMMITTEE)

Massimo Andreoni, Roma

Gioacchino Angarano, Bari

Andrea Antinori, Roma

Guido Antonelli, Roma

Francesco Benanti, Catania

Marco Borderi, Bologna

Michele Breveglieri, Verona

Raffaele Bruno, Pavia

Stefano Buttò, Roma

Maria Capobianchi, Roma

Antonella Castagna, Milano

Francesco Castelli, Brescia

Anna Maria Cattelan, Padova

Alessandra Cerioli, Bologna

Antonio Chirianni, Napoli

Paola Cinque, Milano

Massimo Clementi, Milano

Andrea Cossarizza, Modena

Antonella d'Arminio Monforte, Milano

Andrea De Luca, Siena

Giovanni Di Perri, Torino

Margherita Errico, Milano

Vincenzo Esposito, Napoli

Carlo Ferrari, Parma

Giovanni Battista Gaeta, Napoli

Massimo Galli, Milano

Ivan Gardini, Vercate MB

Enrico Girardi, Roma

Andrea Gori, Monza

Giuseppe Ippolito, Roma

Adriano Lazzarin, Milano

Sergio Lo Caputo, Bari

Paolo Maggi, Bari

Franco Maggiolo, Bergamo

Bruno Marchini, Roma

Claudio M. Mastroianni, Latina

Sandro Mattioli, Bologna

Francesco Mazzotta, Firenze

Cristina Mussini, Modena

Giorgio Palù, Padova

Carlo Federico Perno, Roma

Massimo Puoti, Milano

Giovanni Rezza, Roma

Giuliano Rizzardini, Milano

Stefano Rusconi, Milano

Guido Silvestri, Atlanta USA

Giulio Starnini, Viterbo

Barbara Suligoj, Roma

Gloria Taliani, Roma

Carlo Torti, Catanzaro

Stefano Vella, Roma

Claudio Viscoli, Genova

Filippo von Schloesser, Roma

Maurizio Zazzi, Siena

CSC (COMMUNITY SUB-COMMITTEE)

Michele Breveglieri, Verona (Arcigay)

Alessandra Cerioli, Bologna (LILA)

Margherita Errico, Milano (NPS Italia

Onlus)

Ivan Gardini, Vercate MB (EpaC Onlus)

Bruno Marchini, Roma (ANLAIDS)

Sandro Mattioli, Bologna (PLUS Onlus)

Filippo von Schloesser, Roma (Nadir Onlus)

ANNUAL PROGRAMME COMMITTEE

Andrea Gori, Monza

Adriano Lazzarin, Milano

Franco Maggiolo, Bergamo

Margherita Errico, Milano

Giovanni Battista Gaeta, Napoli

Enrico Girardi, Roma

Bruno Marchini, Roma

Carlo Torti, Catanzaro

FACULTY

Alessio Aghemo, Milano
Claudia Alteri, Roma
Adriana Ammassari, Roma
Pietro Andreone, Bologna
Massimo Andreoni, Roma
Giacchino Angarano, Bari
Andrea Antinori, Roma
Guido Antonelli, Roma
Orlando Armignacco, Viterbo
Sergio Babudieri, Sassari
Alessandra Bandera, Monza
Francesco Benanti, Catania
Eleonora Beretta, Monza
Alessandra Bianchi, Milano
Teresa Bini, Milano
Paolo Bonfanti, Lecco
Stefano Bonora, Torino
Marco Borderi, Bologna
Michele Breveglieri, Verona
Raffaele Bruno, Pavia
Bianca Bruzzone, Genova
Cesara Buonamici, Roma
Stefano Buttò, Roma
Andrea Calcagno, Torino
Anna Paola Callegaro, Bergamo
Maria Rosaria Capobianchi, Roma
Giampiero Carosi, Brescia
Mario Cascio, Palermo
Antonella Castagna, Milano
Francesco Castelli, Brescia
Anna Maria Cattelan, Padova
Roberto Cauda, Roma
Francesca Ceccherini – Silberstein, Roma
Benedetto Maurizio Celesia, Catania
Valeria Cento, Roma
Massimo Cernuschi, Milano
Antonio Chirianni, Napoli
Antonella Cingolani, Roma
Massimo Clementi, Milano
Mario Clerici, Milano
Calvin Cohen, San Francisco USA
Nicola Coppola, Napoli
Giulio Maria Corbelli, Roma
Andrea Cossarizza, Modena

Antonella d'Arminio Monforte, Milano
Gabriella d'Ettore, Roma
Gianpiero D'Offizi, Roma
Andrea De Luca, Siena
Andrea De Maria, Genova
Antonio Di Biagio, Genova
Simona Di Giambenedetto, Roma
Stefania Di Mauro, Milano
Giovanni Di Perri, Torino
Margherita Errico, Milano
Vincenzo Esposito, Napoli
Stefano Fagioli, Bergamo
Cesare Fassari, Roma
Giovanni Fattore, Milano
Carlo Ferrari, Parma
Tiziana Ferrario, Milano
Marzia Fiorino, London UK
Emanuela Foglia, Castellanza VA
John Frater, Oxford UK
Giovanni Battista Gaeta, Napoli
Massimo Galli, Milano
Ivan Gardini, Vercate MB
Cristina Gervasoni, Milano
Nicola Gianotti, Milano
Enrico Girardi, Roma
Andrea Gori, Monza
Paolo Grossi, Varese
Giovanni Guaraldi, Modena
Luca Guidotti, Milano
Ophelia Haanyama, Stockholm S
Maria Rosaria Iardino, Milano
Giuseppe Ippolito, Roma
Michel Kazatchkine, Geneva CH
Adriano Lazzarin, Milano
Giovanni Leonardi, Roma
Massimo Levrero, Roma
Miriam Lichtner, Latina
Sergio Lo Caputo, Bari
Lucia Lopalco, Milano
Giordano Madeddu, Sassari
Paolo Maggi, Bari
Franco Maggiolo, Bergamo
Josep Mallolas, Barcelona E
Giulia Marchetti, Milano
Bruno Marchini, Roma

Simone Marcotullio, Roma
Renato Maserati, Pavia
Claudio Maria Mastroianni, Latina
Alberto Matteelli, Brescia
Sandro Mattioli, Bologna
Francesco Mazzotta, Firenze
Mario Melazzini, Roma
Maria Cristina Messa, Milano
Michael Meulbroek, Barcelona E
Laura Milazzo, Milano
Amanda Mocroft, London UK
Mario Mondelli, Pavia
Santiago Moreno, Madrid E
Cristina Mussini, Modena
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
Giovanna Nuzzo, Legnano MI
Massimo Oldrini, Como
Giancarlo Orofino, Torino
Mirko Paiardini, Atlanta USA
Giorgio Palù, Padova
Giustino Parruti, Pescara
Stefano Patrucco, Torino
Carlo Federico Perno, Roma
Massimo Pizzato, Trento
Guido Poli, Milano
Massimo Puoti, Milano
Vincenzo Puro, Roma
Tiziana Quirino, Busto Arsizio VA
Laura Rancilio, Milano
Diego Ripamonti, Bergamo
Giuliano Rizzardini, Milano
Roberto Rossotti, Milano
Stefano Rusconi, Milano
Romina Salpini, Roma
Tiziana Santambrogio, Legnano MI
Teresa Santantonio, Foggia
Giancarlo Santone, Roma
Angela Santoni, Roma
Maria Santoro, Roma
Gabriella Scarlatti, Milano
Laura Sighinolfi, Ferrara
Roberta Silva, Milano
Guido Silvestri, Atlanta USA
Manuela Sironi, Bosisio Parini LC

Alessandro Soria, Monza
Chiara Spada, Bergamo
Maria Stagnitta, Firenze
Giulio Starnini, Viterbo
Mario Strazzabosco, Milano
Gloria Taliani, Roma
Giuseppe Tambussi, Milano
Marcello Tavio, Ancona
Camilla Terzoli, Milano
Carlo Torti, Catanzaro
Caterina Uberti Foppa, Milano
Ard van Sighem, Amsterdam NL
Claudio Viscoli, Genova
Vincenzo Vullo, Roma
Mauro Zaccarelli, Roma
Maurizio Zazzi, Siena

ABSTRACT REVIEWERS

Adriana Ammassari, Roma
Mauro Andreotti, Roma
Guido Antonelli, Roma
Alessandra Bandera, Monza
Dario Bartolozzi, Firenze
Teresa Bini, Milano
Paolo Bonfanti, Lecco
Stefano Bonora, Torino
Marco Borderi, Bologna
Vanni Borghi, Modena
Michele Breveglieri, Verona
Raffaele Bruno, Pavia
Andrea Calcagno, Torino
Anna Paola Callegaro, Bergamo
Leonardo Calza, Bologna
Maria Rosaria Capobianchi, Roma
Antonella Castagna, Milano
Francesco Castelli, Brescia
Francesca Ceccherini – Silberstein, Roma
Benedetto Maurizio Celesia, Catania
Massimo Cernuschi, Milano
Antonella Cingolani, Roma
Paola Cinque, Milano
Mario Clerici, Milano
Nicola Coppola, Napoli
Giulio Maria Corbelli, Roma
Andrea Cossarizza, Modena

Gabriella d'Ettore, Roma
Gianpiero D'Offizi, Roma
Andrea De Luca, Siena
Andrea De Maria, Genova
Antonio Di Biagio, Genova
Simona Di Giambenedetto, Roma
Giovanni Di Perri, Torino
Margherita Errico, Milano
Carlo Ferrari, Parma
Giovanni Battista Gaeta, Napoli
Ivan Gardini, Vercate MB
Cristina Gervasoni, Milano
Nicola Gianotti, Milano
Enrico Girardi, Roma
Maria Rosaria Iardino, Milano
Giuseppe Lapadula, Monza
Miriam Lichtner, Latina
Giuseppina Liuzzi, Roma
Sergio Lo Caputo, Bari
Giordano Madeddu, Sassari
Paolo Maggi, Bari
Giulia Marchetti, Milano
Bruno Marchini, Roma
Simone Marcotullio, Roma
Renato Maserati, Pavia
Claudio Maria Mastroianni, Latina
Alberto Matteelli, Brescia
Laura Monno, Bari
Cristina Mussini, Modena
Emanuele Nicastrì, Roma
Silvia Nozza, Milano
Giuseppe Nunnari, Messina
Giancarlo Orofino, Torino
Lucia Palmisano, Roma
Saverio Parisi, Padova
Giustino Parruti, Pescara
Stefania Piconi, Milano
Massimo Puoti, Milano
Vincenzo Puro, Roma
Tiziana Quirino, Busto Arsizio VA
Agostino Riva, Milano
Giuliano Rizzardini, Milano
Stefano Rusconi, Milano
Annalisa Saracino, Bari
Loredana Sarmati, Roma

Gabriella Scarlatti, Milano
Laura Sighinolfi, Ferrara
Alessandro Soria, Monza
Nicola Squillace, Monza
Gaetana Sterrantino, Firenze
Valentina Svicher, Roma
Gloria Taliani, Roma
Giuseppe Tambussi, Milano
Marcello Tavio, Ancona
Camilla Tincati, Milano
Carlo Torti, Catanzaro
Daria Trabattoni, Milano
Francesca Vichi, Firenze
Mauro Zaccarelli, Roma
Maurizio Zazzi, Siena

HIV: GUARDIAMO OLTRE

La soppressione virologica è l'unico parametro per un trattamento a lungo termine?

Guarda oltre e parla con i tuoi pazienti della loro salute a lungo termine

Dear Friends,

It's a great pleasure to welcome you on occasion of the **8th ICAR**, the Italian Conference on AIDS and Antiviral Research which take place in Milano-Bicocca University and to share with you this important moment which we hope provides you with a forum to exchange scientific ideas, inspire new research and new contacts for closer scientific co-operation.

As you know, ICAR grown rapidly in number of participants, abstracts (with 366 abstract received, this year we have reached the record of all ICAR editions) and quality of the submissions. In the three days of the Conference, ICAR provides a wide range of topics including basic science, clinical and virological research and a significant contribution from the Community of patient associations: 46 Scientific Sessions, 6 Keynote Lectures, 85 Oral Communications, 28 Poster Discussions and 3 Advances Courses. We expect around 1.500 participants among physicians, researchers, members of patient associations and health professionals.

A central feature of ICAR 2016 is the contribution of Italian young researchers who will present mainly original works during the various sessions. To support them, the Conference hosts a new edition of the **ICAR-CROI Awards** and other prizes granted by **SIMIT** and **SIVIM**.

In addition, special events are planned: **RaccontART**, the art competition launched by ICAR to students who are invited to presents their views on HIV/AIDS through various forms of expression; **HIV and HCV Tests**, performed during the Congress at the request of citizens; **Piazza ICAR**, where a famous artist and students will paint original works; the **Community Village** to host patient associations' meeting points.

Finally, special thanks to the Scientific Secretariat and the Abstract Reviewers for their commitment, to our Faculty members, to the ICAR Governing Board, to the schools and students and to our sponsors who enabled us to involve and host hundreds of young researchers and representatives of the Community of patient associations.

We are greatly honored and pleased to welcome you in Milan and wish you a pleasant and interesting stay.

Nice to ICAR you 2016!

Andrea Gori



The Chairs
Adriano Lazzarin



Franco Maggiolo



HCV
UNA SFIDA GLOBALE
UN IMPEGNO DURATURO

LA NOSTRA MISSION È AVERE
UN IMPATTO SIGNIFICATIVO
SULLA VITA DEI PAZIENTI.

LUNEDI' 6 GIUGNO

PROGRAMME AT A GLANCE

	AULA MAGNA	AULA U6 - 06	AULA U6 - 07	AULA U6 - 08
10:00 12:00	Secretariat Opening and Registration			
12:00 13:00	Lunch			
13:00 13:30	13:00 - 16:00 Incontro Scuole "RaccontART HIV" <i>pag. 18</i>	13:30 - 16:00 Pre-conference advance course LE PREMESSE VIROLOGICHE PER IL SUCCESSO CLINICO <i>pag. 14</i>	13:30 - 16:00 Pre-conference advance course RUOLO DELL'INFERMIERE NELLA RICERCA E NELL'OTTIMIZZAZIONE DEL PERCORSO ASSISTENZIALE <i>pag. 14</i>	13:30 - 16:00 Pre-conference advance course HCV NEL MONOINFETTO E NEL COINFETTO: ANALOGIE E DIFFERENZE <i>pag. 15</i>
13:30 16:00				
16:15 17:00		SATELLITE SYMPOSIUM HIV is going beyond undetectable <i>pag. 19</i>		
17:00 20:00	<p>Opening Session - Aula Magna</p> <p>17.00 - 17.30 Introducing ICAR 2016 Authorities welcome addresses</p> <p>17.30 - 18.00 MAURO MORONI MEMORIAL LECTURE 90-90-90: what has been accomplished and what is left to do - Michel Kazatchkine, Geneva CH</p> <p>18.00 - 18.20 RaccontART HIV contest Awards</p> <p>18.20 - 18.45 ICAR-CROI Awards 2016 for young Italian HIV investigators <i>pag. 20</i></p> <p>18.45 - 20.00 ROUND TABLE Shaping the future of research: which perspectives for young researchers? <i>Moderator: Cesara Buonamici - Vicedirettore TG5</i> <i>Andrea Gori - Professore Straordinario di Malattie Infettive, Università Milano-Bicocca</i> <i>Giovanni Leonardi - Direttore Generale Ricerca e Innovazione in Sanità, Ministero della Salute</i> <i>Mario Melazzini - Presidente AIFA</i> <i>Maria Cristina Messa - Magnifico Rettore, Università Milano-Bicocca</i> <i>Angela Santoni - Rappresentante nazionale italiano del MIUR nel Comitato Horizon</i> <i>pag. 21</i></p>			
20:00 22:30	ICAR 2016 Welcome Reception			

MARTEDI' 7 GIUGNO

PROGRAMME AT A GLANCE

	AULA MAGNA	AULA U6 - 06	AULA U6 - 07	AULA U6 - 08	AULA U6 - 09		
09:00 10:10	KEYNOTE LECTURES Aula Magna Failures and resistance to DAA-based therapies: an old, still always new, problem in antiviral therapy - Carlo Federico Perno, Roma ARV: early treatment for the future goals - Andrea Antinori, Roma <i>pag. 22</i>						
10:15 11:55	SYMPOSIUM HIV maintenance therapy: the switch seduction <i>pag. 22</i>	SYMPOSIUM Lights and shadows in virology <i>pag. 22</i>	ORAL COMMUNICATIONS Community I <i>pag. 23</i>	ORAL COMMUNICATIONS Coinfections <i>pag. 24</i>			
12:00 12:45	SATELLITE SYMPOSIUM INSTI in continuum of care: from engagement to retention in care <i>pag. 25</i>	SATELLITE SYMPOSIUM Comorbidities in HCV: clinical management <i>pag. 25</i>					
12:50 13:35	SATELLITE SYMPOSIUM New frontiers of cART <i>pag. 25</i>	SATELLITE SYMPOSIUM Advancing Hepatitis C for the optimization of cure <i>pag. 26</i>					
Area Poster							
13:40 14:15	POSTER DISCUSSION Hepatitis I <i>pag. 26</i>	POSTER DISCUSSION Hepatitis II <i>pag. 27</i>	POSTER DISCUSSION Clinical HIV I <i>pag. 27</i>	POSTER DISCUSSION Clinical HIV II <i>pag. 28</i>	POSTER DISCUSSION Immunology <i>pag. 28</i>	POSTER DISCUSSION Basic science and virology <i>pag. 29</i>	POSTER DISCUSSION Community <i>pag. 29</i>
14:20 15:45	SYMPOSIUM Host and virus: an ongoing affair <i>pag. 30</i>	ORAL COMMUNICATIONS Hepatitis I <i>pag. 30</i>	SYMPOSIUM Stigma and discrimination in 2016: how to overcome underlying barriers in the real life <i>pag. 31</i>	ORAL COMMUNICATIONS Clinical HIV I <i>pag. 31</i>	ORAL COMMUNICATIONS Complication of cART <i>pag. 32</i>		
15:50 17:25	SYMPOSIUM Emerging challenges in virologically controlled patients <i>pag. 32</i>	ORAL COMMUNICATIONS Hepatitis II <i>pag. 33</i>	SYMPOSIUM PrEP: between clinical evidence and management difficulties <i>pag. 34</i>	ORAL COMMUNICATIONS Clinical HIV II <i>pag. 34</i>			
17:30 18.00	SPECIAL LECTURE Aula Magna Zika: a diabolic juncture? - Giuseppe Ippolito, Roma <i>pag. 35</i>						

MERCOLEDI' 8 GIUGNO

PROGRAMME AT A GLANCE

	AULA MAGNA	AULA U6 - 06	AULA U6 - 07	AULA U6 - 08	AULA U6 - 09
09:00 10:10	KEYNOTE LECTURES Aula Magna Value based medicine in Hepatitis - Mario Strazzabosco, Milano HIV and MSM: community empowerment and the role of acute infection in halting the epidemics - Michael Meulbroek, Barcelona E <i>pag. 36</i>				
10:15 11:55	SYMPOSIUM HCV 2016 update <i>pag. 36</i>	SYMPOSIUM The contribution of epidemiology in tracking new infections <i>pag. 36</i>	ORAL COMMUNICATIONS Immunology <i>pag. 37</i>	ORAL COMMUNICATIONS Clinical HIV III <i>pag. 38</i>	
12:00 12:45	SATELLITE SYMPOSIUM Innovation in a well-known class <i>pag. 39</i>	SATELLITE SYMPOSIUM New DAAs: direct experiences and future perspectives <i>pag. 39</i>			
12:50 13:35	SATELLITE SYMPOSIUM PI evolution: a changing approach for a changing scenario <i>pag. 39</i>				
13:40 15:10	SYMPOSIUM Hepatitis B: the future <i>pag. 40</i>	ORAL COMMUNICATIONS Basic Science and Clinical virology <i>pag. 40</i>	ORAL COMMUNICATIONS Community II <i>pag. 41</i>	ORAL COMMUNICATIONS Clinical HIV IV <i>pag. 42</i>	ORAL COMMUNICATIONS HIV Epidemiology <i>pag. 43</i>
15:15 16:55	SYMPOSIUM Aula Magna Priorities and sustainability of the healthcare system: the stakeholders' view <i>pag. 44</i>				
16:55 17:15	ICAR 2016 SIMIT and SIVIM Special Prizes Awards Closing remarks - Aula Magna <i>pag. 44</i>				

HIV

Per fermarlo non dobbiamo fermarci.



Non se ne parla più, ma il contagio da HIV è tuttora in corso.
Ogni anno in Italia 4 mila persone contraggono il virus. Per fermarlo, dobbiamo continuare a seguire le due fondamentali regole di prevenzione che conosciamo e non dobbiamo mai dimenticare: usare il profilattico nei rapporti sessuali a rischio e fare il test.
Il virus vive e si replica solo se noi glielo permettiamo.



HIV Non fermiamoci →



PRE-CONFERENCE ADVANCED COURSES

13.30 - 16.00 AULA U6 - 06

LE PREMESSE VIROLOGICHE PER IL SUCCESSO CLINICOMODERATORI: **B. Bruzzone** (Genova), **S. Lo Caputo** (Bari)

Nelle malattie infettive, quali HIV, HBV e HCV, il progresso della diagnostica si accompagna al miglioramento della pratica clinica. Le tecnologie biomediche innovative possono inoltre aprire nuovi scenari diagnostici, far emergere il sommerso e consentire il miglioramento nell'approccio terapeutico. L'obiettivo di questo corso pregressuale è quello di mettere a confronto, su tematiche attuali e a volte spinose, medici esperti nella clinica e nella terapia delle malattie infettive e laboratoristi esperti nel mettere in campo le tecnologie più avanzate nella virologia.

HIV: questioni aperte per il monitoraggio virologico13.30 - 13.45 **Il punto di vista del clinico**13.45 - 14.00 **Il punto di vista del virologo**

14.00 - 14.20 Discussione

Andrea De Luca, Siena
Anna Paola Callegaro, Bergamo

Come evidenziare il sommerso di HBV14.20 - 14.35 **Il punto di vista del clinico**14.35 - 14.50 **Il punto di vista del virologo**

14.50 - 15.10 Discussione

Carlo Torti, Catanzaro
Romina Salpini, Roma

HCV: terapia personalizzata?15.10 - 15.25 **Il punto di vista del clinico**15.25 - 15.40 **Il punto di vista del virologo**

15.40 - 16.00 Discussione

Laura Milazzo, Milano
Valeria Cento, Roma

13.30 - 16.00 AULA U6 - 07

RUOLO DELL'INFERMIERE NELLA RICERCA E NELL'OTTIMIZZAZIONE DEL PERCORSO ASSISTENZIALEMODERATORI: **M. Fiorino** (Londra UK), **T. Santambrogio** (Legnano MI)

L'incontro sinergico tra la preparazione teorica e l'esperienza lavorativa forma un professionista infermiere capace di assistere e di stare vicino al malato in modo "competente" e completo. L'infermiere, attraverso la ricerca, può apportare il suo personale contributo per il miglioramento della pratica clinica e di tutto il processo assistenziale.

Questo è possibile collaborando in protocolli di ricerca e formulando progetti atti ad ottimizzare l'assistenza al paziente, cioè l'essenza di questa professione. Fondamentale è il reciproco "nutrimento" tra contatto diretto col paziente e la continua formazione e ricerca, la possibilità di attingere dall'uno e dall'altra per una costante crescita della professione.

Questo corso si propone di definire il percorso formativo dell'infermiere di ricerca e il suo ruolo nella pratica clinica/assistenziale del panorama italiano e di presentare studi e progetti di interesse infermieristico svolti nelle realtà di Malattie Infettive.

13.30 - 13.40 **Introduzione al Corso**13.40 - 14.10 **Percorso formativo e ruolo dell'infermiere di ricerca**14.10 - 14.30 **Studio osservazionale sulle abitudini di coppia dei pazienti HIV+**14.30 - 14.50 **Terapia antiretrovirale e counselling del personale infermieristico**14.50 - 15.10 **Linee guida sugli isolamenti: istruzione operativa e aspetti organizzativi**15.10 - 15.30 **Riflessologia plantare e shiatsu: due tecniche complementari a confronto per pazienti HIV+ con scarso recupero immunologico**

15.30 - 16.00 Discussione

Eleonora Beretta, Monza
Stefania Di Mauro, Milano
Camilla Terzoli, Milano
Giovanna Nuzzo, Legnano MI
Chiara Spada, Bergamo

Roberta Silva, Milano

13.30 - 16.00 AULA U6 - 08

HCV NEL MONOINFETTO E NEL COINFETTO: ANALOGIE E DIFFERENZEMODERATORI: **T. Santantonio** (Foggia), **C. Taliani** (Roma)

L'infezione da virus dell'epatite C (HCV) è associata non solo alla malattia di fegato ma anche ad una serie di disordini del sistema metabolico, cardiovascolare, nervoso ed emolinfopoietico. Inoltre, HCV è frequente nei soggetti con infezione da HIV ed il decorso clinico della malattia HCV-indotta è condizionato dalla coinfezione. Su questo scenario, si inserisce la possibilità di eradicare HCV con farmaci potenti e ben tollerati che estendono l'accesso alla cura anche a pazienti con malattia avanzata. Ne scaturisce un percorso terapeutico e gestionale che va declinato in base alla presenza della mono o della duplice infezione. Nelle due ore e mezza dedicate ai lavori saranno approfondite le analogie e le differenze delle due condizioni patologiche che forniranno strumenti di grandissima utilità per la gestione della malattia HCV correlata in entrambe le categorie di pazienti.

Rischio metabolico e cardiovascolare13.30 - 13.45 **Paziente monoinfetto**13.45 - 14.00 **Paziente coinfecto**

14.00 - 14.20 Discussione

Roberto Rossotti, Milano
Paolo Maggi, Bari

Gestione clinica del paziente avanzato14.20 - 14.35 **Paziente monoinfetto**14.35 - 14.50 **Paziente coinfecto**

14.50 - 15.10 Discussione


Gianpiero D'Offizi, Roma
Raffaele Bruno, Pavia

Epatocarcinoma15.10 - 15.25 **Paziente monoinfetto**15.25 - 15.40 **Paziente coinfecto**

15.40 - 16.00 Discussione

Stefano Faggioli, Bergamo
Marcello Tavio, Ancona

PRE-CONFERENCE ADVANCED COURSES



Albert Einstein
Albert Einstein used with permission of the HUJ/GreenLight

HARVONI[®]
ledipasvir/sofosbuvir



Italian
Conference on
AIDS and **A**ntiviral
Research



Presidenza del Congresso
Andrea Gori, Monza
Adriano Lazzarin, Milano
Franco Maggiolo, Bergamo

Scientific
Programme

6-8 giugno 2016
MILANO
Università Milano-Bicocca

13.00 - 16.00 AULA MAGNA

INCONTRO SCUOLE "RACCONTART HIV"MODERATORI: **M. Errico** (Milano), **M. Galli** (Milano), **B. Marchini** (Roma), **R. Maserati** (Pavia)13.00 - 13.15 **Introduzione, obiettivi dell'incontro, presentazione della Giuria Artistica e Scientifica e degli Istituti Scolastici in Concorso**

M. Errico, Milano, M. Galli, Milano

LA GIURIA ARTISTICA

- **Andrea Adriatico**, regista di teatro e di cinema
- **Alessandro Gottardo** (alias Shout), illustratore
- **Enzo Porcelli**, produttore cinematografico
- **Stefano Prazzoli**, pittore
- **Antonio Siccardi**, pittore
- **Guido Silvestri** (alias Silver), fumettista
- **Rocco Toscani**, fotografo e videomaker

LA GIURIA SCIENTIFICA

- **Francesca Ceccherini-Silberstein**, Università Tor Vergata di Roma
- **Massimo Galli**, Università degli Studi di Milano
- **Andrea Gori**, Università degli Studi di Milano-Bicocca
- **Adriano Lazzarin**, Università Vita-Salute San Raffaele, Milano
- **Franco Maggiolo**, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo
- **Renato Maserati**, Fondazione IRCCS Policlinico San Matteo, Pavia
- **Laura Sighinolfi**, Azienda Ospedaliero-Universitaria di Ferrara
- **Margherita Errico** NPS Italia, Milano
- **Bruno Marchini** ANLAIDS, Roma
- **Simona Nasta** NPS sezione Sicilia, Palermo
- **Domenico Salierno** NPS sezione Campania, Napoli
- **Filippo von Schloesser** NADIR, Roma

GLI ISTITUTI SCOLASTICI

- IISS F. Besta, Milano – Ref. Scolastico Silvia Gulberti
- ISS Falcone-Righi, Corsico – Ref. Scolastici Maria Pia Cantoni e Piero Passaniti
- Liceo Statale "G. Galilei", Voghera – Ref. Scolastico Anna Lovagnini
- IIS G. Galilei – R. Luxemburg, Milano – Ref. Scolastici Wanda Perrone Capano e Fausto Chiesa
- IISS M.K. Gandhi, Besana Brianza – Ref. Scolastici Sabrina Lignola e Pierangelo Arosio
- IIS Majorana, Cesano Maderno – Ref. Scolastico Valeria Cislighi
- Liceo Collegio Arcivescovile Pio XI, Desio – Ref. Scolastico Giulio Pace
- Istituto Professionale Statale "C. Pollini", Mortara – Ref. Scolastico Rosetta Rossi
- Liceo Artistico Statale della Villa Reale N. Valentini, Monza – Ref. Scolastico Annalisa Azzoni
- Liceo G.B.Vico, Corsico – Ref. Scolastico Vittoria Caracciolo

13.15 - 13.25 **L'influenza dei media nella comunicazione sull'HIV/AIDS e sulle persone con HIV: un cambiamento necessario**

M. Errico, Milano

13.25 - 13.35 **L'esperienza con gli studenti**

T. Ferrario, Milano

13.35 - 15.50 **PRESENTAZIONE DELLE OPERE CANDIDATE AL CONCORSO**13.35 - 13.40 **Categoria "Disegno e Pittura"**

13.40 - 13.45 Commento della Giuria

13.45 - 13.55 **Categoria "Foto e Illustrazione 1"**

13.55 - 14.00 Commento della Giuria

14.00 - 14.10 **Categoria "Animazione interattiva 1"**

14.10 - 14.15 Commento della Giuria

14.15 - 14.25 **Categoria "Foto e Illustrazione 2"**

14.25 - 14.30 Commento della Giuria

14.30 - 14.40 **Categoria "Animazione interattiva 2"**

14.40 - 14.45 Commento della Giuria

14.45 - 15.05 **Categoria "Videofilmati"**

15.05 - 15.10 Commento della Giuria

15.10 - 15.20 **Categoria "Foto e Illustrazione 3"**

15.20 - 15.25 Commento della Giuria

15.25 - 15.30 **Categoria "Altre espressioni artistiche"**

15.30 - 15.35 Commento della Giuria

15.35 - 15.45 **Categoria "Foto e Illustrazione 4"**

15.45 - 15.50 Commento della Giuria

15.50 - 16.00 **Conclusioni**

R. Maserati, Pavia

16.15 - 17.00 **AULA U6 - 06**

Unrestricted educational grant of Gilead Sciences

SATELLITE SYMPOSIUM HIV IS GOING BEYOND UNDETECTABLECHAIR: **G. Angarano** (Bari)

The goal of HIV treatment is to suppress the viral load to undetectable levels. Now that most people with HIV can achieve an undetectable viral load, it's time to go beyond this to reach other long-term health goals for people living with HIV. Improved efficacy of ART has reduced the mortality of HIV-infected persons on treatment and transformed HIV into a long-term chronic illness for many patients, characterized by an ageing HIV-infected population who are increasingly affected by age-related noncommunicable diseases (NCDs). The increasing prevalence of NCDs complicates treatment and care for HIV-infected patients and may increase prevalence and earlier age of onset for many NCDs than do age-matched uninfected individuals. This effect has been shown for several comorbidities including cardiovascular disease, non-AIDS malignancies, liver and kidney disease and osteoporosis.

16.15 - 16.35 **Comorbidities: the Cohorts picture**

Antonella d'Arminio Monforte, Milano

16.35 - 16.55 **How we monitor and manage comorbidities**

Marco Borderi, Bologna

16.55 - 17.00 **Discussion**

AULA MAGNA

ICAR 2016 OPENING SESSION

17.00 - 17.30

Introducing ICAR 2016

A. Gori (Monza), A. Lazzarin (Milano), F. Maggiolo (Bergamo)

Authorities' welcome addresses

M.C. Messa, Magnifico Rettore Università Milano-Bicocca

17.30 - 18.00

MAURO MORONI MEMORIAL LECTURE

CHAIRS: A. Gori (Monza), A. Lazzarin (Milano), F. Maggiolo (Bergamo)

INTRODUCES: A. Antinori (Roma)

90-90-90: what has been accomplished and what is left to do

Michel Kazatchkine, Geneva CH

18.00 - 18.20

RACCONTART HIV CONTEST AWARDS

CHAIRS: B. Marchini (Roma), R. Maserati (Pavia)

18.20 - 18.45

ICAR-CROI AWARDS 2016 FOR YOUNG ITALIAN HIV INVESTIGATORS

CHAIR: G. Silvestri (Atlanta USA)

Selected Italian Investigators:

- HIV-1 Laboratory Contagion during Recombination Procedures with Defective Constructs
- Intracellular Atazanavir Concentrations Remain Stable During Pregnancy in HIV Women
- Predicting Drug Discontinuation in TDF-tolerant Patients: a Prospective PK/PG Study
- Mucosal-Associated Invariant T (MAIT) Cells in HIV/HCV co-infection
- CNS Safety of Simplification to ATV/r+3TC in Virologically Suppressed HIV+ Patients
- Distinct B-cell gene signatures define ability to respond to H1N1 vaccine in HIV+ children
- Bone mineral density after switching to ATV/r+3TC: a sub-study of the AtLaS-M trial
- Inflammasome and Th17 Activation in HIV+ Immunological Non-Responders
- Pharmacokinetics of Dolutegravir and Rilpivirine in Combination With SMV and SOF
- Rapid Improving of Glycemic Control in HCV Patients Treated with IFN-free Regimens
- Role of HCV co-infection on CSF biomarkers in HIV patients
- Multiple HPV Genotypes as a Risk Factor for High Grade AIN in HIV-1 Infected Males
- The Impact of Cannabinoid Receptor2-63 Variants in Liver Biopsy of HIV/HCV Patients
- Impact of PNPLA3 variants on the liver histology of 168 HIV/HCV patients
- 6-amino-acid insertion/deletion polymorphism in TIM1 confers protections against HIV1
- Probiotics Module Th1/Th17 and IFN Response in HIV Patients on Suppressive cART
- Analysis of HIV Proviruses in Clonally Expanded Cells in Vivo
- HBsAg mutations correlate with HCC, affect HBsAg release and favor cell proliferation

Claudia Alteri, Roma
 Andrea Bonito, Brescia
 Andrea Calcagno, Torino
 Maddalena Cerrone, Milano
 Nicoletta Ciccarelli, Roma
 Nicola Cotugno, Roma
 Alessandro D'Avino, Roma
 Michela Masetti, Milano
 Marco Merli, Milano
 Paolo Pavone, Roma
 Carmela Pinnetti, Roma
 Cristina Rovelli, Milano
 Caterina Sagnelli, Napoli
 Caterina Sagnelli, Napoli
 Irma Saulle, Milano
 Ivan Schietroma, Roma
 Francesco Simonetti, Milano
 Valentina Svicher, Roma

18.45 - 20.00

ROUND TABLE

SHAPING THE FUTURE OF RESEARCH: WHICH PERSPECTIVES FOR YOUNG RESEARCHERS?

MODERATOR: Cesara Buonamici, Vicedirettore TG5, Roma

Andrea Gori - Professore Straordinario di Malattie Infettive, Università Milano-Bicocca

Giovanni Leonardi - Direttore Generale Ricerca e Innovazione in Sanità, Ministero della Salute

Mario Melazzini - Presidente AIFA

Maria Cristina Messa - Magnifico Rettore, Università Milano-Bicocca

Angela Santoni - Rappresentante nazionale italiano del MIUR nel Comitato Horizon

20.00 - 22.30

WELCOME RECEPTION

09.00 - 10.10 AULA MAGNA

KEYNOTE LECTURES

CHAIRS: **M. Galli** (Milano), **C. Viscoli** (Genova)

- 09.00 - 09.35 **Failures and resistance to DAA-based therapies: an old, still always new, problem in antiviral therapy**
- 09.35 - 10.10 **ARV: early treatment for the future goals**

Carlo Federico Perno, *Roma*
Andrea Antinori, *Roma*

10.15 - 11.55 AULA MAGNA

SYMPOSIUM HIV MAINTENANCE THERAPY: THE SWITCH SEDUCTION

CHAIRS: **G. Angarano** (Bari), **G. Di Perri** (Torino)

The driver concept is the availability of new INI-based FDCs and STRs, together with new PI/cobi FDCs and the change of TDF for TAF: many clinicians and patients will ask for a therapeutic switch. In this new scenario a switch is legitimate and advantageous but it must be driven by a strong pathogenetic and clinical rationale and not by "fashion" or worthless reasons.

- 10.15 - 10.35 **The LDR and STR debate**
- 10.35 - 10.55 **How to save toxicity**
- 10.55 - 11.15 **Residual viraemia removal temptation**
- 11.15 - 11.55 Discussion

Diego Ripamonti, *Bergamo*
Stefano Bonora, *Torino*
Nicola Gianotti, *Milano*

10.15 - 11.55 AULA U6 - 06

SYMPOSIUM LIGHTS AND SHADOWS IN VIROLOGY

CHAIRS: **M.R. Capobianchi** (Roma), **M. Clementi** (Milano)

Starting from the discovery of HIV-1, the begin of monotherapy, followed by the HAART use, and finally the introduction of single tablet regimens and the new class of integrase inhibitors, we reached in these last decades really a big success. However, still some lights and shadows in virology can be found and they will be here discussed. Even if the majority of treated patients are virologically suppressed, we aim to approach the goal of eradication and therefore we are fighting against the problem of HIV DNA reservoir. Just now it has been discovered the real mechanism of Nef activity in enhancing the infectivity of HIV-1 virions in a hostcell-dependent manner, suggesting a new potent cellular anti-retroviral factor as an anti-HIV-1 therapeutic gene. Finally, it has been recently reported the first evidence of an HIV infection occurring during manipulation of HIV defective constructs in a biosafety level 2 laboratory. This case should suggest a reinforced caution in biosafety measures in laboratories handling multiple different HIV constructs, and should lead to a revision of biosafety practices and rules, in order to limit at best the occurrence of other similar episodes.

- 10.15 - 10.35 **HIV-1 Nef activity**
- 10.35 - 10.55 **HIV DNA reservoir, how much defective or replication competent?**
- 10.55 - 11.15 **HIV-1 laboratory contagion during recombination procedures with defective constructs**
- 11.15 - 11.55 Discussion

Massimo Pizzato, *Trento*
Maurizio Zazzi, *Siena*

Claudia Alteri, *Roma*

10.15 - 11.55 AULA U6 - 07

ORAL COMMUNICATIONS COMMUNITY I

CHAIRS: **G.M. Corbelli** (Roma), **L. Rancilio** (Milano)

- OC1 10.15 - 10.25 Insight into HIV/AIDS and STDs among Italian high-school teens: an unceasing need to inform and to protect**
S. Cutti¹, L. Pavesi², A. Muzzi³, G. Chieffo², M. Annovazzi Lod², A. Malfitano², V. Martinelli⁴, R. Maserati²
¹Specialization School in Hygiene, University of Pavia, ²Infectious Disease Dept. and ³Medical Direction, Foundation I.R.C.C.S. Policlinico "San Matteo", Pavia, ⁴Brain and Behavioral Dept, University of Pavia, Pavia, Italy
- OC2 10.27 - 10.37 Would they benefit from PrEP? An analysis of men who have sex with men seeking post-exposure prophylaxis following sexual exposures at risk of HIV infection**
G. De Carli¹, E. Schifano¹, F. Niero², A. Franco³, M. Maillard⁴, L. Signorini⁵, A. Agresta¹, V. Puro¹, the IRAPEP collaborative group
¹Centro di Riferimento AIDS National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ²A.O. L. Sacco, Milan, Italy, ³AORN Ospedali dei Colli, Naples, Italy, ⁴IRCCS S. Raffaele, Centro S. Luigi, Milan, ⁵A.O. Spedali Riuniti, Brescia, Italy
- OC3 10.39 - 10.49 Saliva Test for the general public: following the objectives of Unaid**
A. Bianchi, G. Fracca, F.M. Esposito, A. Antonino, V. Meneghin, R. Repossi, A. Brambilla, D. Zagato, M. Cernuschi
ASA Associazione Solidarietà AIDS Onlus, Milan, Italy
- OC4 10.51 - 11.01 BLQ Checkpoint: data from first six months of activity**
S. Mattioli, G.M. Corbelli, C. Degli Esposti, C. Franchini, P. Gorgoni, P. Pieralli
Plus onlus
- OC5 11.03 - 11.13 HIV rapid testing targeting MSM: some issues towards the improvement of efficacy in a community-based testing initiative of Arcigay in 11 cities funded by the Unione delle Chiese Metodiste e Valdesi**
M. Breveglieri¹, P. Guarino², E. Albertini³, V. Brescia⁴, D. Deserti⁵, F. Donini⁶, A. Ferrarotto⁷, M. Galdiolo², M. Maffeo⁸, M. Pace⁹, F. Sorbara¹⁰
¹Arcigay Verona, ²Arcigay Padova, ³Arcigay Perugia, ⁴Arcigay Torino, ⁵Arcigay Milano, ⁶Arcigay Modena, ⁷Arcigay Catania, ⁸Arcigay Siena, ⁹Arcigay Palermo, ¹⁰Arcigay Napoli
- OC6 11.15 - 11.25 HIV Toolkits for migrants: tailored information on their right to health, HIV prevention, testing, treatment and care in Italy, given by migrants themselves through video tutorials**
M.L. Cosmaro¹, A. Savio², E.I. Aguebor³, M. Galal³, S. Huang³, T. Karagodina³, C.R. Ynga Pacheco³, M. Oldrini¹
¹Fondazione LILA Milano ONLUS, ²Miral Consulenza, ³Cultural mediators
- OC7 11.27 - 11.37 Transmission of HIV through sexual contact in Italian Criminal Law**
F. Manfredi¹, M. Cappelletti², D. Badodi¹
¹University of Parma, Law – Criminal Law (Prof. A. Codoppi), ²University of Parma, Law – Public Comparative Law (Prof.ssa L. Scaffardi)
- OC8 11.39 - 11.49 Villa Maraini Foundation's HIV/HCV Care Cascade Among Hard to Reach Injection Drug Users in Rome: Meet, Test and Treat**
E. Teti², E. Rossi¹, L. Lambiase³, D. Masci¹, S. Capasso¹, M. Sciarretta¹, R. Sista¹, P. Sammarco¹, M. Andreoni², M. Barra¹
¹Villa Maraini Foundation ONLUS, HIV/HCV Unit, Rome, Italy, ²Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, ³Clinical Infectious Diseases, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy

10.15 - 11.55 AULA U6 - 08

ORAL COMMUNICATIONS COINFECTIONS

CHAIRS: **R. Maserati** (Pavia), **M. Zaccarelli** (Roma)

OC9 10.15-10.25 Evolution and determinants of the prevalence of HCV infection and HCV genotype distribution among HIV-infected patients entering in care between 1997 and 2015 in Italy: data from a prospective nationwide cohort (ICONA)

B. Rossetti¹, F. Bai², A. Tavelli³, M. Galli⁴, A. Antinori⁵, F. Castellini⁶, G. Pellizzer⁷, A. Cozzi-Lepri⁸, S. Bonora⁹, A. d'Arminio Monforte², M. Puoti¹⁰, A. De Luca^{1,11} on behalf of the ICONA Foundation study group

¹University Infectious Diseases Unit, AOU Senese, Siena, Italy, ²San Paolo Hospital, University of Milan, Milan, Italy, ³ICONA Foundation, Milan, Italy, ⁴University of Milan, Milan, Italy, ⁵INMI Spallanzani, Rome, Italy, ⁶University of Brescia, Brescia, Italy, ⁷Infectious Diseases, Hospital of Vicenza, Vicenza, Italy, ⁸University College of London, London, UK, ⁹Clinic of Infectious Diseases, University of Turin, Turin, Italy, ¹⁰Infectious Diseases Maggiore Hospital, Milan, Italy, ¹¹Department of Biotechnologies, University of Siena, Siena, Italy

OC10 10.27 - 10.37 The TM6SF2 E167K variant is an independent predictor of severe steatosis in HIV patients with chronic hepatitis due to HCV genotype non 3

C. Sagnelli¹, M. Merli², C. Uberti-Foppa², H. Hasson², G. Cirillo³, A. Grandone³, S. Salpietro², C. Minichini⁴, E. Messina², M. Parisi², E. Miraglia Del Giudice³, A. Lazzarin², N. Coppola⁴, E. Sagnelli⁴

¹Department Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples, Italy, ²Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy, ³Department of Pediatrics, Second University of Naples, Naples, Italy, ⁴Dept. Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy

OC11 10.39-10.49 Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program

E. Teti¹, A. Ricciardi¹, A. Antinori², M. Galli³, G. Rizzardini⁴, A. Di Biagio⁵, A. Saracino⁶, C. Mussini⁷, R. Bruno⁸, A. Lazzarin⁹, A.M. Cattelan¹⁰, G. Taliani¹¹, A. De Luca¹², C.M. Mastroianni¹³, A. D'Arminio Monforte¹⁴, F. Maggiolo¹⁵, M. Puoti¹⁶, G. Di Perri¹⁷, F. Castellini¹⁸, A. Gori¹⁹, A. Giacometti²⁰, B. Cacopardo²¹, G. Parruti²², V. Vullo²³, N. Boffa²⁴, L. Sighinolfi²⁵, A. Chirianni²⁶, A. Pennica²⁷, C. Pasquazzi²⁷, C.F. Perno²⁸, E. Gentilotti¹, L. Sarmati¹, M. Andreoni¹ and SIMIT (Infectious and Tropical Diseases Italian Society)

¹Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, ²Clinical Dept., National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ³Dept. of Biomedical and Clinical Science, University of Milan, Italy, ⁴Infectious Diseases Unit, DIBIC Luigi Sacco, Milano, Italy, ⁵Infectious Diseases Clinic, IRCCS Azienda Ospedaliera Universitaria San Martino - IST, Genova, Italy, ⁶Institute of Infectious Disease, University of Bari, Bari, Italy, ⁷Infectious Diseases Clinic, Azienda Ospedaliera-Universitaria Policlinico, Modena, Italy, ⁸Division of Infectious and Tropical Diseases, IRCCS Policlinico San Matteo, Pavia, Italy, ⁹Dept. of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ¹⁰Dept. of Infectious and Tropical Diseases, University Hospital, Padova, Italy, ¹¹Dept. of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy, ¹²Dept. of Internal and Specialty Medicine, University Infectious Diseases Unit, AOU Senese, Siena, Italy, ¹³Infectious Diseases Unit, Sapienza University, Latina, Italy, ¹⁴Clinic of Infectious and Tropical Diseases, S. Paolo Hospital, University of Milan, Italy, ¹⁵Division of Infectious Diseases, AO Papa Giovanni XXIII, Bergamo, Italy, ¹⁶Division of Infectious Diseases, AO Ospedale Niguarda Cà Granda, Milan, Italy, ¹⁷Unit of Infectious Diseases, University of Turin, Dept. of Medical Sciences, "Armedeo di Savoia" Hospital, Turin, Italy, ¹⁸Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ¹⁹Division of Infectious Diseases, Dept. of Internal Medicine, "San Gerardo" Hospital, University of Milan-Bicocca, Monza, Italy, ²⁰Clinic of Infectious Diseases, Dept. of Biomedical Sciences and Public Health, Università Politecnica delle Marche - Ospedali Riuniti, Ancona, Italy, ²¹Division of Infectious Diseases, Dept. of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, Catania, Italy, ²²Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ²³Dept. of Clinical Medicine, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy, ²⁴First Division of Infectious Diseases, S. Giovanni di Dio e Ruggi d'Aragona Hospital, Salerno, Italy, ²⁵Unit of Infectious Diseases, University Hospital of Ferrara, Ferrara, Italy, ²⁶III U.O.C. P.O. Cotugno AORN Ospedali dei Colli, Naples, Italy, ²⁷Clinical Infectious Diseases, Sant' Andrea Hospital, Sapienza University of Rome, Rome, Italy, ²⁸Dept. of Experimental Medicine and Surgery, Tor Vergata University, Rome, Italy

OC12 10.51-11.01 SOF/VEL single tablet regimen in HCV mono-infected and HIV/HCV co-infected patients: comparison of efficacy and safety data from phase 3 clinical trials

G. Parruti¹, D. Wyles², N. Brau³, S. Naggie⁴, M. Sulkowski⁵, K. Agarwal⁶, K. Patel⁷, N. Afdhal⁸, L. Liu⁹, X. Ding⁹, K.C. Huang⁹, A. Osinusi⁹, J. McNally⁹, D. M. Brainard⁹, L. Martello⁹ and J.G. McHutchison⁹

¹Unit of Infectious Diseases, Dept. of Internal Medicine, Pescara General Hospital, Pescara, Italy, ²University of California, San Diego, La Jolla, CA, ³James J. Peters VA Medical Center, Bronx, New York; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ⁴Duke Clinical Research Institute; Duke University Medical Center, Durham, NC, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Institute of Liver Studies, Kings College Hospital, London, UK, ⁷Division of Gastroenterology, Duke University Medical Center, Durham, NC, ⁸Hepatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁹Gilead Sciences

OC13 11.03 - 11.13 Efficacy of Directly Acting Antivirals in HCV-3 Patients with advanced Fibrosis: An interim analysis of the Lombardia Regional Network for Viral Hepatitis

G. Rizzardini¹, F. Maggiolo², R. D'Ambrosio³, G. Cologni², C. Magni¹, M. Colpani², L. Minoli⁴, G. Filice⁴, A. Pan⁵, A. Colli⁶, M. Zuin⁷, O. Giglio⁸, L. Valenti⁹, M.G. Rumi⁹, M. Soncini¹⁰, R. Merlini¹¹, M. Borzio¹¹, P. Del Poggio¹², M. Di Marco¹³, M. Puoti¹⁴, L. Pasulo², S. Fagioli², A. Aghemo³

¹A.O. "Luigi Sacco", Milano, ²A.O. Papa Giovanni XXIII, Bergamo, ³Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano, ⁴Fondazione IRCCS Policlinico S. Matteo, Pavia, ⁵A.O. Istituti Ospedalieri, Cremona, ⁶A.O. della Provincia di Lecco, ⁷A.O. "San Paolo", Milano, ⁸A.O. S. Anna, Como, ⁹Ospedale S. Giuseppe, Milano, ¹⁰AO San Carlo, Milano, ¹¹AO Melegnano, ¹²Istituti Ospedalieri Bergamaschi, ¹³AO Bolognini Di Seriate, ¹⁴A.O. "Osp. Niguarda Cà Granda", Milano

OC14 11.15-11.25 Clinical and virological characteristics of HIV and HCV coinfecting versus HCV mono-infected patients: real life evaluation in PITER and ICONA/HepalCONA cohorts

B. Coco on behalf of PITER and ICONA/HepalCONA Studies <https://goo.gl/OPYVeR>

Azienda Ospedaliero-Universitaria Pisano, Pisa, Italy

OC15 11.27-11.37 HPV infection in oral cavity of HIV-positive men: prevalence and predictors

A.R. Garbuglia¹, M. Gentile², F. Del Nonno¹, P. Piselli¹, C. Sias¹, D. Lapa¹, R. Libertone², F. Lupi², A. Baiocchini¹, M.R. Capobianchi¹, A. Ammassari²

¹Epidemiological and Diagnostic Department, ²Clinical Department INMI L Spallanzani IRCCS, Rome

11.40-11.55 **Minilecture: Coinfection in people living with HIV: remember TB**

Alberto Mattelli, Brescia

12.00 - 12.45 AULA MAGNA

Unrestricted educational grant of ViiV Healthcare

SATELLITE SYMPOSIUM INSTI IN CONTINUUM OF CARE: FROM ENGAGEMENT TO RETENTION IN CARE

CHAIR: **A. Castagna** (Milano)

The continuum of care is a particular concept in the long-term care of patients with HIV / AIDS and describes the diagnostic, therapeutic and maintenance care of the HIV positive patient. As reported in the recent Italian Guidelines the continuum of care monitoring is an essential factor to achieve and/or maintain therapeutic success to ensure the long-term health of the person. In this new context the objective of the symposium is the focus on the initial therapeutic choice with new booster-free regimens characterized by a rapid and sustained virologic efficacy associated with high genetic barrier and favorable tolerability profile.

12.00 - 12.15 **Booster-free regimens and their role in different setting population**

Stefano Bonora, Torino

12.15 - 12.30 **Start and stay with high genetic barrier regimen**

Maurizio Zazzi, Siena

12.30 - 12.45 Discussion

12.00 - 12.45 AULA U6 - 06

Sponsored by Abbvie

SATELLITE SYMPOSIUM COMORBIDITIES IN HCV: CLINICAL MANAGEMENT

CHAIR: **M. Andreoni** (Roma)

The availability of IFN-free and RBV-free regimens makes it possible to consider a significantly larger number of candidates who could benefit from HCV eradication and avoid complications of chronic HCV infection. Due to the interactions between virus, liver damage and dysmetabolism, HCV infection itself is to be considered a systemic disease.

In addition, as a consequence of the progressive ageing of population, even more HCV mono-infected and HIV coinfecting patients are likely to present comorbidities and assume multiple drugs. Thus, comorbidities and polytherapy pose emerging issues that are to be carefully considered in the clinical management of HCV infected patients.

12.00 - 12.45 **Comorbidities in HCV: clinical management**

Carlo Federico Perno, Roma

Giuliano Rizzardini, Milano

12.50 - 13.35 AULA MAGNA

Unrestricted educational grant of Gilead Sciences

SATELLITE SYMPOSIUM NEW FRONTIERS OF cART

CHAIR: **G. Silvestri** (Atlanta USA)

Exciting advances in basic and clinical science brought a new strategy for antiretroviral therapy and new hope to people living with HIV. Modern ART regimens are very successful in achieving low viral loads and restoring immunological function in the vast majority of patients and, as a result, the life expectancy of HIV patients now matches that of the general population if appropriate treatment is initiated in time.

Currently, there are two key trends shaping the HIV therapeutic strategies, driven by both patient and physician demand: the first is a move towards simplified INI-based therapies - particularly single-tablet regimens (STRs) - which are becoming increasingly popular due to their favourable efficacy, tolerability. The second one is the novel INI-based STR (elvitegravir/cobicistat/emtricitabine/TAF) that contains tenofovir alafenamide fumarate (TAF) instead of TDF. TAF is advantageous because it requires a 30-fold lower dose to achieve the same virological effect as TDF and, as a result, showed improved renal and bone tolerability in phase III studies.

12.50 - 13.10 **Simplified INI-based therapies**

Cristina Gervasoni, Milano

13.10 - 13.30 **TAF: what are we learning?**

Calvin Cohen, San Francisco USA

13.30 - 13.35 Discussion

12.50 - 13.35 AULA U6 - 06

Unrestricted educational grant of Bristol-Myers Squibb

SATELLITE SYMPOSIUM ADVANCING HEPATITIS C FOR THE OPTIMIZATION OF CURE

CHAIRS: **A. Aghemo** (Milano), **P. Andreone** (Bologna)

Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve > 90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. Together with the rapidly accumulating data about the evolution of treatment landscape, different guidelines from national and international Liver Scientific Societies have been published until today. However, most of these recommendations identify as priority groups only patients with advanced liver disease. Moreover some types of patients pose clinical management problems for which even the guidelines do not always provide useful answers. With the aim to fill the gaps of these guidelines and to respond to unmet needs on treatment optimization, a group of Italian experts met and shared some statements for a few open issues which will be reported during the Symposium.

12.50 - 13.35 **Advancing Hepatitis C for the optimization of cure: recommendations from AdHoc Project**

Francesca Ceccherini - Silberstein, Roma
Massimo Puoti, Milano

13.40 - 14.15 POSTER AREA

POSTER DISCUSSION HEPATITIS I

CHAIRS: **B.M. Celesia** (Catania), **G. Starnini** (Viterbo)

PD 1 13.40 - 13.45 Virological and clinical outcomes of long-term tenofovir disoproxil fumarate (TDF) therapy in HIV/HBV co-infected patients: experience from an Italian cohort

A. Mondì¹, I. Mastroianni¹, S. Di Giambenedetto¹, R. Gagliardini¹, G. Baldin¹, A. D'Avino¹, A. Borghetti¹, A. Ciccullo¹, R. Cauda¹, A. De Luca², M. Fabbiani³

¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ²UOC Malattie Infettive Universitarie, Azienda Ospedaliera Universitaria Senese, Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³San Gerardo Hospital, University of Milano-Bicocca, Division of Infectious Diseases, Department of Internal Medicine, Monza, Italy

PD 2 13.47 - 13.52 The role of Hepatitis C virus sequencing performed on NS3/NS5A/NS5B gene regions in the genotype and subtype assignment

L. Sticchi^{1,2}, P. Canepa¹, E. Rappazzo¹, C. Arcuri¹, L.A. Nicolini^{1,3}, L. Taramasso³, B. Bruzzone², G. Icardi^{1,2}

¹Department of Health Sciences (DISSal), University of Genoa, Italy, ²Igiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ³Infectious Diseases, IRCCS AOU San Martino-IST, Genoa, Italy

PD 3 13.54 - 13.59 Pharmacokinetic analysis of two SOF-based regimens to define DDIs profile in patients with HIV/HCV co-infection

R. Rossotti¹, E. Mogalian², P. German², L. Nè², L.M. Stamm², J.C. Yang², J. McNally², G. Shen², L. Moorehead², K. Sajwani², M. Lenoci², J. Ling², A. Mathias², B. Deodato² and M. Puoti¹

¹Infectious Diseases Unit ASST Ospedale Niguarda, Milano, Italy, ²Gilead Sciences

PD 4 14.01 - 14.06 Natural NS3, NS5A and NS5B HCV resistance prevalence is common and different within the 4 main HCV genotypes in Italy

A. Bertoli¹, V. Cento¹, M.C. Sorbo¹, D. Di Paolo², I. Lenci², E. Polilli³, L. Gianserra⁴, L. Lambiase⁴, E. Teti⁵, E. Biliotti⁶, C.F. Magni⁷, V. Micheli⁸, M. Melis⁹, L. Fondacaro¹⁰, L.A. Nicolini¹¹, S. Marengo¹², V. Calvaruso¹³, F. Morisco¹⁴, M. Siciliano¹⁵, E. Danieli¹⁶, V. Pace Palitti¹⁷, P. Tarquini¹⁸, M. Paoloni¹⁹, P. Andreone²⁰, M. Lichtner²¹, B. Menzaghi²², D. Romagnoli²³, N. Iapadre²⁴, M. Aragri¹, V.C. Di Maio¹, F. De Leonardis², M. Milana², S. Francioso², P. Cacciatore³, A. Pieri³, C. Sarrecchia⁵, S. Sarmati⁵, S. Grieco⁶, G. D'Etto⁶, S. Landonio⁷, I. Maida⁹, C. D'Ambrosio¹⁰, E. D'Amico¹⁶, M.S. Mura⁹, M. Biolato¹⁵, A. Gasbarrini¹⁵, M. Puoti¹⁶, N. Caporaso¹⁴, A. Craxi¹³, A. Picciotto¹², A. Di Biagio¹¹, A. Pellicelli¹⁰, S. Babudieri⁹, G. Rizzardini⁷, V. Vullo⁶, G. Taliani⁶, M. Andreoni⁵, C. Pasquazzi⁴, G. Parruti³, M. Angelico², F. Ceccherini-Silberstein¹, C.F. Perno¹

¹Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Hepatology Unit, University Hospital of Rome "Tor Vergata", Rome, Italy, ³Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, ⁴Infectious Diseases, Sant'Andrea Hospital - "La Sapienza" University, Rome, Italy, ⁵Infectious Diseases, University Hospital of Rome "Tor Vergata", Rome, Italy, ⁶Tropical Diseases, Umberto I Hospital - "La Sapienza" University, Rome, Italy, ⁷Division of Infectious Diseases, "L. Sacco" Hospital, Milan, Italy, ⁸Unit of Microbiology, "L. Sacco" Hospital, Milan, Italy, ⁹Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ¹⁰Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ¹¹Division of Hepatology, S. Martino Hospital, Genova, Italy, ¹²Infectious Disease, S. Martino Hospital, Genova, Italy, ¹³Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ¹⁴Gastroenterology, «Federico II» University, Napoli, Italy, ¹⁵Gastroenterology, Catholic University of Rome, Rome, Italy, ¹⁶Hospital Niguarda Ca' Granda, Milan, Italy, ¹⁷Hepatology Unit, Ospedale San Massimo, Pieve, Italy, ¹⁸Infectious Disease Unit, "Giuseppe Mazzini" Hospital, Teramo, Italy, ¹⁹S.S. Filippo e Nicola Hospital, Infectious Disease Unit, Avezzano, Italy, ²⁰Gastroenterology, AOU Policlinico Sant'Orsola-Malpighi, Bologna, Italy, ²¹Infectious Diseases, "La Sapienza" University, Latina, Italy, ²²Infectious Diseases, Ospedale di circolo di Busto Arsizio, Busto Arsizio, Varese, Italy, ²³Department of Biomedical, Metabolic and Neural Sciences, NCSAE Baggiovara, Italy, ²⁴Infectious Diseases Unit, S. Salvatore Hospital, L'Aquila, Italy

13.40 - 14.15 POSTER AREA

POSTER DISCUSSION HEPATITIS II

CHAIRS: **F. Benanti** (Catania), **C. Uberti Foppa** (Milano)

PD 5 13.40 - 13.45 Kidney involvement in HCV Child-A cirrhosis

D. Palazzo¹, E. Biliotti¹, F. Tinti², A. Bacheloni³, P. Perinelli¹, A. Cappoli², M. Subic⁴, M.D. D'Alessandro³, R. Labriola³, I. Umbro², P. Rucci⁵, A.P. Mitterhofer², G. Taliani¹

¹Clinic of Infectious and Tropical Diseases; Sapienza University of Rome, ²Nefrology and Dialysis unit; Department of Clinical Medicine; Sapienza University of Rome, ³Laboratory of Clinical Pathology Department of General Surgery Paride Stefanini, Sapienza University of Rome, ⁴Department of Internal Medicine, Sapienza University of Rome, ⁵Department of Biomedical and Neuromotor Sciences, University of Bologna

PD 6 13.47 - 13.52 Determinants and evaluation of HCV costs in the Lombardy Region

M.V. Cossu¹, D. Croce^{2,3}, S. Fagioli⁴, L. Ferrario², E. Foglia², E. Garagiola², L. Pasulo⁴, G. Rizzardini^{1,5}

¹Department of Infectious Diseases, Fatebenefratelli Sacco Hospital, Milan, ²Centre for Research on Health Economics, Social and Health Care Management - LUUC - Cattaneo University, Castellanza, Italy, ³School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Department of Gastroenterology, Papa Giovanni XXXIII Hospital Authority, Bergamo, Italy, ⁵School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg

PD 7 13.54 - 13.59 Safety of Simeprevir regimens for Hepatitis C in real practice: Results from the STily Italian observational study

G. Brancaccio¹, M. Russello², P. Forte³, G. Lettieri⁴, L. Milazzo⁵, A. Gasbarrini⁶, A. Ori⁷, M. Palma⁸, R. Termini⁹, M. Colombo⁹

¹Seconda Università di Napoli, Napoli, ²ARNAS Garibaldi - Nesima, Catania, ³A.O.U. Careggi, Firenze, ⁴AORN Ospedali dei Colli P.O. Cotugno, Napoli, ⁵Ospedale Luigi Sacco, Milano, ⁶Policlinico A. Gemelli, Roma, ⁷Medineos, Modena, ⁸Janssen-Cilag SpA, Cologno Monzese, ⁹Ospedale Maggiore Policlinico, Milano

PD 8 14.01 - 14.06 Hepatitis B virus infection in undocumented immigrants or refugees in southern Italy: demographic, virological and clinical features

L. Alessio^{1,2}, L. Gualdieri³, M. Pisaturo^{4,5}, C. Sagnelli^{6,7}, C. Minichini¹, G. Di Caprio^{1,2}, M. Starace¹, L. Onorato^{1,2}, G. Signoriello⁸, I.F. Angelillo⁹, G. Pasquale¹, E. Sagnelli², N. Coppola¹

¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, ITALY, ²Medical Center, Centro Sociale ex Canapificio, Caserta, ³Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, ⁴Medical Center, Centro di Accoglienza "La tenda di Abramo", Caserta, Italy, ⁵Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, ⁶Department of Clinical and Experimental Medicine and Surgery, Second University of Naples, Naples, Italy, ⁷Medical center, Centro Suore Missionarie della Carità, Naples, Italy, ⁸Department of Mental Health and Public Medicine, Section of Statistic, Second University of Naples, Italy, ⁹Department of Experimental Medicine, Second University of Naples

13.40 - 14.15 POSTER AREA

POSTER DISCUSSION CLINICAL HIV I

CHAIRS: **V. Esposito** (Napoli), **S. Nozza** (Milano)

PD 9 13.40 - 13.45 Durability and Virological Efficacy of Less Drug Regimens (LDR) in HIV-Infected, ARV-experienced Patients: data from the San Paolo Infectious Diseases (SPID) cohort

V. Cogliandro¹, L. Gazzola¹, N. Iannotti¹, T. Bini¹, G.C. Marchetti¹, A. d'Arminio Monforte¹

Department of Health Sciences-University of Milan, Clinic of Infectious Diseases, San Paolo Hospital

PD 10 13.47 - 13.52 Residual viremia and inflammation markers: gender difference in ARV treated HIV-1 patients

F. Falasca¹, S. Serafino², N. Giustini², G. D'Etto², I. Mezzaroma³, M. Bucci¹, T. Melengu¹, G. Antonelli¹, O. Turriziani¹

¹Department of Molecular Medicine, Laboratory of Virology, ²Department of Public Health and Infectious Diseases, ³Department of Clinical Medicine, "Sapienza" University of Rome

PD 11 13.54 - 13.59 Impact of EVG/COBI/FTC/TDF on Liver and Kidney: data from the SCOLTA Cohort

N. Squillace¹, P. Bonfanti², E. Ricci³, L. Calza⁴, B.M. Celesia⁵, C. Martinelli⁶, F. Vichi⁷, L. Cordier³, L. Carezzi³, M. Franzetti⁸, G. De Socio⁹, F. Peruzzo¹⁰, G. Orofino¹¹, C. Bellacosa¹², A. Di Biagio¹³, A. Gori¹, T. Quirino¹⁴ on behalf of CISAI group

¹Infectious Diseases Unit, San Gerardo Hospital- University of Milano-Bicocca, Monza, ²Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, ³Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, ⁴Department of Infectious Diseases, S.Orsola Malpighi Hospital, Bologna, ⁵Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ⁶Unit of Infectious Diseases, Careggi Hospital, Firenze, ⁷Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, ⁸Infectious Diseases Clinic, L. ASST Fatebenefratelli Sacco, Milan, ⁹Unit of Infectious Diseases, Santa Maria Hospital, Perugia, ¹⁰Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ¹¹Unit of Infectious Diseases, Amedeo di Savoia Hospital, Torino, ¹²Infectious Disease Clinic, University of Bari, ¹³Infectious Diseases, San Martino Hospital Genoa, University of Genoa, ¹⁴Unit of Infectious Diseases, ASST della Valle Olona - Busto Arsizio

PD 12 14.01 - 14.06 Pill refill a simple and effective method to evaluate long term adherence in patients on cART

M.C. Burla¹, L. Rabatti¹, F. Vichi², S. Lo Caputo³, F. Mazzotta²

¹Hospital Pharmacy, Santa Maria Annunziata Hospital, Florence, Italy, ²Infectious Disease Unit, Santa Maria Annunziata Hospital, Florence, Italy, ³Clinic of Infectious Diseases, University of Bari

13.40 - 14.15 POSTER AREA

POSTER DISCUSSION **CLINICAL HIV II**

CHAIRS: **T. Bini** (Milano), **G. Orofino** (Torino)

- PD 13 13.40 - 13.45 Multicenter experience of heel quantitative ultrasound (QUS) use in HIV-positive women**
P. Vitiello¹, E. Ricci², A. Di Biagio³, L. Taramasso³, S. Rusconi², V. Di Cristo², K. Falasca⁴, P. Maggi⁵, C.R. Santoro⁵, T. Quirino¹ on behalf of CISA group
¹Unit of Infectious Diseases, ASST Valle Olona, Busto Arsizio, ²Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, ³Infectious Diseases, San Martino Hospital Genoa, University of Genoa, ⁴Infectious Disease Clinic, University Of Chieti, ⁵Infectious Disease Clinic, University Of Bari
- PD 14 13.47 - 13.52 Prevalence and risk factors for HPV infection and cervical lesions among 283 HIV+ women at Santa Maria Annunziata Hospital, Florence, 2006-2015**
F.M. Fusco¹, A. degli Esposti¹, C. Blè¹, F. Carozzi², C. Sani², F. Vichi¹, F. Mazzotta¹
¹UO Malattie Infettive, Ospedale Santa Maria Annunziata, ASL Toscana Centro, ²SS Laboratorio HPV e Biologia Molecolare, Laboratorio Regionale Prevenzione Oncologica, ISPO, Firenze
- PD 15 13.54 - 13.59 5-year Survival in HIV-positive Patients with Lymphoma According to Antiretroviral Regimens**
A. Calcagno¹, E. Focà², S. Rusconi³, A. Cascavilla⁴, G. Cenderello⁵, A. Re², G. Cavaglia¹, S. Casari², L. van den Bogaart³, P.L. Zinzani⁴, A. Bonito², A. Lucchini¹, P. Viale⁴, G. Cassola⁵, G. Di Perri¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, ²Department of Infectious & Tropical Diseases, University of Brescia, Brescia, ³Department of Infectious Diseases, Ospedale Luigi Sacco, University of Milano, Milano, ⁴Department of Internal Medicine, Geriatrics and Nephrologic Diseases, Section of Infectious Diseases, "Alma Mater Studiorum" University of Bologna, S. Orsola-Malpighi Hospital, Bologna, ⁵Department of Infectious Diseases, EO Ospedali Galliera, Genova, Italy
- PD 16 14.01 - 14.06 Maraviroc reduces in vivo platelet activation and platelet hyperreactivity in HIV positive patients at high cardiovascular risk (the MVC48 study)**
E. Falcinelli¹, E. Schiaroli¹, D. Francisci¹, G. Guglielmi², P. Gresele², F. Baldelli¹
¹Infectious Disease Clinic, University of Perugia, Perugia, Italy, ²Department of Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy

13.40 - 14.15 POSTER AREA

POSTER DISCUSSION **IMMUNOLOGY**

CHAIRS: **C.M. Mastroianni** (Latina), **G. Nunnari** (Messina)

- PD 17 13.40 - 13.45 Switching to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): effects on Tcell compartment and HIV reservoirs**
E. Merlini¹, F.A. Cazzaniga¹, A. Casabianca², C. Orlandi², G. Ancona¹, V. Cogliandro¹, C. Tincati¹, T. Bini¹, M. Magnani², A. d'Arminio Monforte¹ and G. Marchetti¹
¹University of Milan, Milan, Italy, ²University of Urbino "Carlo Bo", Urbino, Italy
- PD 18 13.47 - 13.52 Modulation of pro-inflammatory cytokines plasma levels and lymphoid hematopoietic progenitor cells reduction in early primary HIV infection**
V. Bordonì¹, D. Viola¹, M. Ramazzotti¹, A. Sacchi¹, F. Besi¹, R. Casetti¹, E. Cimini¹, N. Tumino¹, C. Agrati^{1,3}, M.R. Capobianchi³, A. Ammassari², F. Martini¹
¹Cellular Immunology Laboratory, National Institute for Infectious Diseases "L.Spallanzani", IRCCS, ²Clinical Department, National Institute for Infectious Diseases "L.Spallanzani" IRCCS, ³Laboratory of Virology, National Institute for Infectious Diseases "L.Spallanzani" IRCCS
- PD 19 13.54 - 13.59 Probiotics can be able to reduce immune activation both in the gut and peripheral blood in HIV-treated patients**
I. Schietroma¹, N. Giustini¹, S. Serafino¹, G. De Girolamo¹, G. Corano Scheri¹, S. Najafi Fard¹, A. Mastrangelo¹, G. Fanello⁵, M. Andreotti⁴, C. Scagnolari³, G. Ceccarelli², G. d'Ettore², V. Vullo¹
¹Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy, ²Department of Infectious Diseases, Policlinico Umberto I, University of Rome "Sapienza", Rome, Italy, ³Department of Molecular Medicine, Laboratory of Virology, University of Rome "Sapienza", Rome, Italy, ⁴Department of Therapeutic Research and Medicines Evaluation, Italian Institute of Health, Rome, Italy, ⁵Digestive Endoscopy Surgical Unit, Policlinico Umberto I, University of Rome "Sapienza", Rome, Italy
- PD 20 14.01 - 14.06 HIV reservoir is sustained by central memory CD4+ T cells that have undergone a few rounds of homeostatic proliferation**
M. Nasi¹, S. De Biasi¹, E. Bianchini¹, M. Digaetano^{1,2}, S. Pecorini¹, M. Pinti³, L. Gibellini¹, V. Borghi², C. Mussini^{1,2}, A. Cossarizza¹
¹Department of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, ²Infectious Diseases Clinics, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy, ³Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy

13.40 - 14.15 POSTER AREA

POSTER DISCUSSION **BASIC SCIENCE AND VIROLOGY**

CHAIRS: **G. Scarlatti** (Milano), **A. Soria** (Monza)

- PD 21 13.40 - 13.45 The interferon-inducible restriction factor TRIM22 contributes to HIV-1 latency**
F. Turrini^{1,2}, G. Poli^{2,3}, E. Vicenzi¹
¹Viral Pathogens and Biosafety Unit, San Raffaele Scientific Institute, ²Vita-Salute San Raffaele University School of Medicine, ³AIDS Immunopathogenesis Unit, San Raffaele Scientific Institute
- PD 22 13.47 - 13.52 Peripheral markers of monocyte activation and evolution of cognitive function in HIV-infected patients under suppressive antiretroviral treatment**
A. Bandera¹, M. Fabbiani¹, P. Perseghin², M. Bani³, A. Incontri², D. Mangioni^{1,4}, A. Muscatello¹, G. Lapadula¹, A. Gori¹
¹Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ²Apheresis Unit, Transfusion Medicine Service, San Gerardo Hospital, Monza, Italy, ³Unit of Clinical Neuropsychology, San Gerardo Hospital, Monza, Italy, ⁴Clinic of Infectious Diseases, Brescia University, Brescia, Italy
- PD 23 13.54 - 13.59 CSF to plasma HIV RNA ratio ≥ 1 is associated with HIV-associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-positive patients**
F. Iannuzzi¹, F. Bai¹, E. Merlini¹, L. Borghi², T. Bini¹, G. Marchetti¹ and A. d'Arminio Monforte¹
¹Clinic of Infectious and Tropical Diseases, Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy, ²Unit of Clinical Psychology, Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy
- PD 24 14.01 - 14.06 Predictive role of different plasma and CSF biomarkers of immune activation and neuronal injury for diagnosis of HIV-associated neurocognitive disorders: a cross sectional analysis**
C. Pinnetti¹, V. Fedele¹, P. Balestra¹, S. Carta¹, P. Lorenzini¹, M. Ricottini¹, A. Ammassari¹, V. Bordonì¹, L. Alba¹, V. Mazzotta¹, F. Martini¹, F. Ceccherini-Silberstein², C.F. Perno^{1,2}, A. Antinori¹
¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, ²University of Tor Vergata, Rome, Italy

13.40 - 14.15 POSTER AREA

POSTER DISCUSSION **COMMUNITY**

CHAIRS: **A. Bianchi** (Milano), **S. Patrucco** (Torino)

- PD 25 13.40 - 13.45 HIV testing strategies focused to MSM: are we missing the target?**
G.M. Corbelli¹, E. Albertini², V. Brescia³, M. Breveglieri⁴, N. Catucci⁵, A.M. Covi⁶, D. Deserti⁷, A. Di Lorenzo⁸, F. Di Sora⁹, F. Donini¹⁰, M. Farinella¹¹, A. Ferrarotto¹², M. Galdiolo¹³, S. Giudici¹⁴, M. Maffeo¹⁵, L. Mastropietro¹⁶, L. Nigro¹⁷, M. Pace¹⁸, T. Prestileo¹⁹, G. Sartori²⁰, F. Sorbara²¹
¹Plus onlus, ²Arcigay Perugia, ³Arcigay Torino, ⁴Arcigay Verona, ⁵LILA di Bari, ⁶Lila Trentino Onlus, ⁷Arcigay Milano, ⁸Segretariato Italiano Studenti Medicina - SISM - Palermo, ⁹Immunologia Clinica dell'Ospedale san Giovanni di Roma, ¹⁰Arcigay Modena, ¹¹Circolo di cultura omosessuale "Mario Mieli" Roma, ¹²Arcigay Catania, ¹³Arcigay Padova, ¹⁴Fondazione LILA Milano Onlus, ¹⁵Arcigay Siena, ¹⁶Lila Piemonte onlus, ¹⁷Lila Catania, ¹⁸Arcigay Palermo, ¹⁹Anlaids Sicilia Sezione "Felicia Impastato" Palermo, ²⁰Circolo Tondelli Lgbti, ²¹Arcigay Napoli
- PD 26 13.47 - 13.52 Therapies with DAAs in inmates: functional model in Italy**
S. Dell'Isola¹, A.M. Ialungo¹, E. Caturelli², E. Liguori¹, E. Rastrelli¹, G. Starnini¹
¹UOC Medicina Protetta-Malattie Infettive Ospedale Belcolle Viterbo, ²UOC Gastroenterologia Ospedale Belcolle Viterbo
- PD 27 13.54 - 13.59 The ANLAIDS FORUM is Widely Accessed and Contributes to Raise the Awareness on HIV Prevention**
G.V. Calvino¹, C. Balotta², M. Galli², B. Marchini¹
¹ANLAIDS ONLUS, Rome, ²Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy
- PD 28 14.01 - 14.06 Who is afraid of the boogeyman?**
A. Infante
 UOC di Malattie Infettive, Policlinico Tor Vergata, Roma

14.20 - 15.45 AULA MAGNA

SYMPOSIUM HOST AND VIRUS: AN ONGOING AFFAIR

CHAIRS: **M. Clerici** (Milano), **G. Tambussi** (Milano)

Despite being the objective of more than 25 years of intense research, the immunology of HIV infection is still only partially understood. Some questions, in particular, have not found an answer: how does mucosal transmission of HIV infection really occur, and how can we prevent it? Why does HIV almost inevitably rebound once therapy is interrupted? Why are some individuals protected against HIV infection and/or the progression of HIV infection to AIDS? The talks included in this session will summarize the newest results in these fields of research.

- 14.20 - 14.40 **Mucosal immunity** Mirko Paiardini, Atlanta USA
- 14.40 - 15.00 **HIV restriction factors** Manuela Sironi, Bosisio Parini LC
- 15.00 - 15.20 **Immunological predictors of viral rebound after treatment interruption** John Frater, Oxford UK
- 15.20 - 15.45 **Discussion**

14.20 - 15.45 AULA U6 - 06

ORAL COMMUNICATIONS HEPATITIS I

CHAIRS: **R. Bruno** (Pavia), **G. d'Ettore** (Roma)

- OC16 14.20-14.30 HBV genetic evolution in HBsAg can constrain HDV replicative potential**
L. Colagrossi¹, R. Scutari¹, R. Salpini¹, A. Battisti¹, M. Pollicita¹, A. Bertoli¹, C. Minichini², P. Trimoulet³, H. Fleury³, E. Nebulosa⁴, R. Longo⁴, G. Cappiello⁴, A. Spanò⁴, V. Malagnino⁵, L. Sarmati⁵, T. Marzà⁶, A. Barlattani⁶, N. Iapadre⁷, M. Lichtner⁸, C. Mastroianni⁸, I. Lenci⁹, L. Baiocchi⁹, C. Pasquazzi¹⁰, G.M. De Sanctis¹¹, A.G. Lanza¹², M. Stanzione¹³, G. Stornaiuolo¹³, M. Marignani¹⁰, M. Andreoni², M. Angelico⁹, C.F. Perno¹, N. Coppola², V. Svicher¹
¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²Second University of Naples, Department of Mental Health and Public Medicine, Section of Infectious Diseases, Naples, Italy, ³Hôpital Pellegrin tripode, Laboratoire de Virologie, Bordeaux, France, ⁴Sandro Pertini Hospital, Rome, Italy, ⁵Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ⁶Nuovo Regina Margherita Hospital, Rome, Italy, ⁷San Salvatore Hospital, L'Aquila, Italy, ⁸Sapienza University, Department of Public Health and Infectious Diseases, Rome, Italy, ⁹Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, ¹⁰S. Andrea Hospital, Department of Gastroenterology, Rome, Italy, ¹¹Umberto I Hospital, Rome, Italy, ¹²AO Cardarelli, Gastroenterology Unit, Naples, Italy, ¹³Second University of Naples, Viral Unit, Naples, Italy
- OC17 14.32-14.42 Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a Relevant Risk of Evolution Towards Active Chronic Infection and Death**
R. Salpini¹, A. Battisti¹, L. Colagrossi¹, C. Alteri¹, M. Pollicita¹, A. Ricciardi², C. Cerva², G. Maffongelli², M. Lichtner³, C. Mastroianni³, K. Casinelli⁴, M. Paoloni⁵, M. Marignani⁶, S. Maylin⁷, C. Delaugerre⁷, F. Morisco⁸, N. Coppola⁹, A. Marrone¹⁰, A. Brega¹¹, S. Francioso¹¹, A. Venditti¹², T. Mari¹³, E. Mazzoni¹⁴, N. Iapadre¹⁵, D. Di Paolo¹¹, C. Sarrecchia², L. Sarmati², M. Andreoni², G. Taliani¹⁶, M. Angelico¹¹, C.F. Perno¹, V. Svicher¹
¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ³Sapienza University, Department of Public Health and Infectious Disease, Rome, Italy, ⁴Fabrizio Spaziani Hospital, Infectious Disease Unit, Frosinone, Italy, ⁵S.S. Filippo e Nicola Hospital, Infectious Disease Unit, Avezzano, Italy, ⁶S. Andrea Hospital, Department of Gastroenterology, Rome, Italy, ⁷APHP Hospital Saint-Louis, Laboratoire de Virologie, Paris, France, ⁸University of Naples Federico II, Section of Infectious Diseases, Department of Clinical Medicine and Surgery, Naples, Italy, ⁹Second University of Naples, Department of Mental Health and Public Medicine, Section of Infectious Diseases, Naples, Italy, ¹⁰Second University of Naples, Internal Medicine and Hepatology Unit, Naples, Italy, ¹¹Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, ¹²Tor Vergata University Hospital, Hematology Unit, Rome, Italy, ¹³Nuovo Regina Margherita Hospital, Rome, Italy, ¹⁴Liver Unit Policlinico Casilino, Rome, Italy, ¹⁵San Salvatore Hospital, L'Aquila, Italy, ¹⁶Clinic of Infectious and Tropical Diseases, Department of Clinical Medicine, Policlinico Umberto I, Sapienza University, Rome, Italy
- OC18 14.44-14.54 Direct-acting antivirals (DAA) in HCV-infected and HCV/HIV co-infected patients: real-life safety and efficacy**
F. Binda¹, A. Lai¹, E. Calvi¹, P. Ronzi¹, A. Crippa¹, V. Micheli², A.L. Ridolfo², C. Gervasoni¹, M. Galli¹, S. Antinori¹, S. Sollima¹, L. Milazzo¹
¹Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, ²Clinical Microbiology Virology and Diagnosis of Bioemergency, L. Sacco University Hospital, Milan, Italy
- OC19 14.56-15.06 Adherence to EASL recommendations significantly increased treatment response in 872 patients with hepatitis C treated with combinations of oral antivirals**
M. Puoti¹, A. Aghemo¹, R. D'Ambrosio¹, F. Maggiolo¹, G. Colagni¹, G. Gubertini¹, M. Colpani¹, L. Minoli¹, G. Filice¹, A. Pan¹, A. Colli¹, M. Zuin¹, O. Giglio¹, L. Valenti¹, M.G. Rumi¹, M. Soncini¹, R. Merlini¹, M. Borzio¹, P. Del Poggio¹, M. Di Marco¹, L. Pasulo¹, S. Fagioli¹ for the Lombardia Regional Network for Viral Hepatitis
 Lombardia Regional Network for Viral Hepatitis
- OC20 15.08-15.18 Influence of ITPase activity on decreases of hemoglobin during treatment with Interferon-free DAA-based and ribavirin in HCV-related cirrhosis**
S. De Pascalis¹, I. Gentile², V. Messina³, G. Di Caprio^{3,4}, S. Martini⁵, G. De Stefano⁵, M. Starace¹, G. Stornaiuolo⁶, V. Sangiovanni⁷, M. Stanzione⁶, F. Calò¹, L. Rinaldi⁸, M. Persico⁹, A. Federico¹⁰, G. Borgiata¹¹, G.B. Gaeta⁶, P. Filippini³, N. Coppola^{1,4}
¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy, ²Infectious Diseases Unit, University Federico II, Naples, Italy, ³AO Caserta, Italy, ⁴HIV Unit, Second University of Naples, Naples, Italy, ⁵IX Interventional Ultrasound Unit for Infectious Diseases- AORN dei Colli P.O. Cotugno- Naples, ⁶Infectious Diseases and Viral Hepatitis Unit, Second University of Naples, ⁷Infectious diseases Unit, AORN dei Colli P.O. Cotugno- Naples, ⁸Internal Medicine Unit, AO Marcanise, Italy, ⁹Internal Medicine Unit, University of Salerno, ¹⁰Gastroenterology Unit, Second University of Naples

- OC21 15.20-15.30 Effectiveness of Simeprevir regimens for Hepatitis C in real practice: results from the STily Italian observational study**
B. Menzaghi¹, G. D'Offizi², A. Giorgini³, A. Lazzarin⁴, S. Babudieri⁵, M. Brunetto⁶, S. Fagioli⁷, L. Simoni⁸, M. Palma⁹, R. Termini⁹, G.B. Gaeta¹⁰
¹Ospedale di Circolo, Busto Arsizio, ²IRCCS L. Spallanzani, Roma, ³Azienda Ospedaliera San Paolo, Milano, ⁴Ospedale San Raffaele, Milano, ⁵Università di Sassari, Sassari, ⁶UO Epatologia - Fegato Unità AOUP (Azienda Ospedaliera Universitaria Pisana) - Ospedale Università di Pisa, ⁷A.O. Papa Giovanni XXIII, Bergamo, ⁸Medineos, Modena, ⁹Janssen-Cilag SpA, Cologno Monzese, ¹⁰Seconda Università di Napoli, Napoli
- OC22 15.32-15.42 Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on hepatocellular carcinoma (HCC)**
L. Onorato¹, G. de Stefano², N. Mosca³, V. Iodice², C. Minichini¹, F. Castiello³, N. Farella², M. Starace¹, N. Potenza³, G. Liorre², E. Sagnelli¹, A. Russo³, N. Coppola¹
¹Dept. of Mental Health and Public Medicine, Second University of Naples, ²IX Interventional Ultrasound Unit for Infectious Diseases- AORN dei Colli P.O. Cotugno- Naples, ³Dept. of Life Sciences, Second University of Naples

14.20 - 15.45 AULA U6 - 07

SYMPOSIUM STIGMA AND DISCRIMINATION IN 2016: HOW TO OVERCOME UNDERLYING BARRIERS IN THE REAL LIFE

CHAIRS: **M. Breveglieri** (Verona), **M. Stagnitta** (Firenze)

In Italy we observe a high level of discrimination and stigma in the "real life" of people living with HIV: they are currently hampered by regulatory restrictions in everyday life and also at media communication level. The now established long life expectancy of people living with HIV, thanks to ARVs, is not absolutely taken into consideration in the workplace, or at social or economic level. There are too many cases of denied access to loans, failure to reattain employment and discriminations that vanish the results in terms of good quality of life achieved by people living with HIV.

- 14.20 - 14.40 **Stigma and HIV: underlying barrier** Massimo Cernuschi, Milano
- 14.40 - 15.00 **What Italians think about HIV in 2016 and relationship between mass media and HIV** Cesare Fassari, Roma
- 15.00 - 15.20 **Forced Migrants: how to achieve success in both HIV prevention and retention in care once in treatment?** Giancarlo Santone, Roma
- 15.20 - 15.45 **Discussion**

14.20 - 15.45 AULA U6 - 08

ORAL COMMUNICATIONS CLINICAL HIV I

CHAIRS: **A. Di Biagio** (Genova), **V. Vullo** (Roma)

- OC23 14.20-14.30 Prevalence and effect of polypharmacy on clinical outcome in people living with HIV: a 10-year follow up study**
G. Guaraldi¹, A. Malagoli¹, A. Calcagno², F. Carli¹, L. Guaraldi¹, C. Stentarelli¹, C. Mussini¹, S. Khoo³, G. Dolci¹, M. Cesari⁴
¹Unit of Infectious Diseases, A.O.U. Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ²Unit of Infectious Diseases, Dept. of Medical Sciences, University of Torino, Torino, Italy, ³Dept. of Pharmacology, University of Liverpool, Liverpool, UK, ⁴Gérontopôle, Dept. of Internal Medicine and Geriatrics, Toulouse University Hospital, Toulouse, France; INSERM UMR 1027, Paul Sabatier University Toulouse III, Toulouse, France
- OC24 14.32-14.42 Feasibility, Acceptability and Tolerability of Peri-Conception Antiretroviral Pre-Exposure Prophylaxis (PrEP-C) in HIVSero-discordant Couples**
G. De Carli¹, A. Palummieri¹, A. Ammassari¹, R. Bellagamba¹, S. Cicalini¹, A. Cingolani², R. Libertone¹, G. Liuzzi¹, G. Maffongelli³, S. Mosti¹, C. Pinnetti¹, A. Sampaolesi¹, E. Savalli⁴, E. Tamburrini², M. Zaccarelli¹, V. Puro¹
¹National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy, ²Department of Infectious Diseases, Catholic University, Rome, Italy, ³Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, ⁴Infectious Diseases, AOU Pisano, Pisa, Italy
- OC25 14.44-14.54 Tolerability of different antiretroviral regimens prescribed as HIV Post-Exposure Prophylaxis**
G. De Carli¹, E. Schifano¹, A. Agresta¹, L. Signorini², F. Niero³, A. Franco⁴, V. Puro¹; the IRAPEP Collaborative Group
¹Centro di Riferimento AIDS, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ²AO Spedali Riuniti, Brescia, Italy, ³AO L. Sacco, Milan, Italy, ⁴AORN Ospedali dei Colli, Naples, Italy
- OC26 14.56-15.06 Are Italian people aware of PEP and TasP? A survey among a large sample of people living with HIV/AIDS, non-HIV positive high risk heterosexual people and non-HIV positive MSM**
G. Prati¹, B. Zani¹, L. Pietrantoni¹, D. Scudiero², P. Perone², L. Cosmaro², A. Cerioli², M. Oldrini²
¹Department of Psychology, University of Bologna, Italy, ²LILA - Italian League for the Fight against AIDS, Italy
- OC27 15.08-15.18 Adherence to cART in a large single-center clinical cohort**
E. Di Filippo¹, L. Comi¹, A. Callegaro², G.L. Colombo^{3,4}, S. Di Matteo⁴, D. Valenti¹, M. Rizzi¹, F. Maggiolo¹
¹USC of Infectious Diseases, ²USC of Pharmacy, ASST Papa Giovanni XXIII, Bergamo, ³Department of Drug Sciences, University of Pavia, ⁴S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy

- 15.30 - 15.45 **Minilecture: Pharmacokinetic correlates of effective cART** Andrea Calcagno, Torino

14.20 - 15.45 AULA U6 - 09

ORAL COMMUNICATIONS COMPLICATION OF cART

CHAIRS: **P. Bonfanti** (Lecco), **M. Borderi** (Bologna)

OC28 14.20-14.30 Exercise Stress Testing for Reduced Coronary Reserve Detection in Asymptomatic HIV-infected Subjects with Cardiovascular Risk Factors: the CORDIS Study

V. Spagnuolo¹, **A. Carbone**¹, **L. Galli**¹, **A. Poli**², **D. Bernacchia**¹, **N. Gianotti**¹, **C. Godino**³, **M.C. Giusti**⁴, **C. Vinci**¹, **A. Lazzarin**^{1,2}, **A. Margonato**^{2,3}, **A. Castagna**^{1,2}

¹Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, ²Faculty of Medicine and Surgery, University Vita-Salute San Raffaele, Milan, ³Division of Clinical Cardiology, Cardiothoracovascular Department, San Raffaele Scientific Institute, Milan, ⁴Department of Clinical Neurosciences, San Raffaele Scientific Institute, Milan

OC29 14.32-14.42 Changes with menopause in the distribution of a frailty index (FI) in HIV infected women

S. Zona¹, **N. Riva**¹, **I. Franconi**¹, **T. Brothers**², **A. Malagoli**¹, **M. Menozzi**¹, **A. Santoro**¹, **F. Carli**¹, **C. Mussini**¹, **G. Guaraldi**¹

¹HIV Metabolic Clinic, Infectious Diseases Department, Policlinico University Hospital, Modena, Italy, ²Dalhousie University, Halifax, NS, Canada

OC30 14.44-14.54 Evolution of comorbidities among HIV patients in 2004 and 2014: a cross-sectional analysis from the Italian ICONA Foundation study cohort

A. Cozzi-Leperi¹, **F. Aragao**², **S. Lo Caputo**³, **G. Guaraldi**⁴, **A. Ammassari**⁵, **F. Mazzotta**⁶, **S. Bonora**⁷, **A. Castagna**⁸, **E. Girardi**⁵, **A. Antinori**⁵ and **A. d'Arminio Monforte**⁹ on behalf of Icona Foundation Study group

¹University College London, UK, ²Gilead Sciences Europe, Ltd, ³Azienda Sanitaria di Firenze, Italy, ⁴University of Modena and Reggio Emilia, Italy, ⁵INMI L. Spallanzani, Roma, Italy, ⁶S.M. Annunziata Hospital, Florence, Italy, ⁷University of Turin, Italy, ⁸S. Raffaele Hospital, Milan, Italy, ⁹S. Paolo Hospital, Milan, Italy

OC31 14.56-15.06 Impact of HIV infection on toxicity and outcome of non-Hodgkin lymphoma treatment in the antiretroviral therapy era

A. Bandera¹, **M. Fabbiani**¹, **L. Verga**², **A. Muscatello**¹, **M. Rossi**¹, **S. Benatti**³, **E. Pollastri**¹, **F. Farina**², **P. Pioltelli**², **M. Rizzi**³, **G. Griotti**⁴, **A. Rambaldi**^{4,5}, **A. Gori**¹

¹Division of Infectious Diseases, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ²Haematology Division and BMT Unit, Ospedale San Gerardo, Monza, Italy, ³Division of Infectious Diseases, ASST Papa Giovanni XXIII Bergamo, Bergamo, Italy, ⁴Hematology and Bone Marrow Transplant Unit ASST Papa Giovanni XXIII, Bergamo and ⁵Dipartimento di Scienze Cliniche e di Comunità University of Milano, Italy

OC32 15.08-15.18 Excess mortality with non-AIDS-defining cancers among Italian people with AIDS in the late antiretroviral therapy era

S. Virdone¹, **M. Taborelli**¹, **E. Grande**², **L. Camoni**³, **M. Pappagallo**², **V. Regine**³, **F. Grippo**², **B. Suligo**³, **L. Frova**², **D. Serraino**¹ and **A. Zucchetto**¹

¹Unit of Epidemiology and Biostatistics, CRO Aviano National Cancer Institute, Aviano, Italy, ²Servizio Sanità, Salute ed Assistenza, Istituto Nazionale di Statistica, Rome, Italy, ³Centro Operativo AIDS, Istituto Superiore di Sanità, Rome, Italy

15.30 - 15.45 **Minilecture: Frailty: virus, ART or lifestyle?**

Giovanni Guaraldi, Modena

15.50 - 17.25 AULA MAGNA

SYMPOSIUM EMERGING CHALLENGES IN VIROLOGICALLY CONTROLLED PATIENTS

CHAIRS: **G. Antonelli** (Roma), **G. Parruti** (Pescara)

Antiretroviral treatment has deeply modified morbidity and mortality of patients with HIV and most of the patients have solved problems due to CD4 lymphocytes and detectable viral load. Nevertheless, this success has shown its weakness and really the prognosis of people living with HIV is not equal to that of non-infected subjects. In this session the speakers will show how a noneradicated virus could represent the basis not only for non-AIDS morbidity as that cardiovascular, but also for many other events, which could have a negative impact on the long-term survival of the people living with HIV.

15.50 - 16.10 **Beyond virological control**

Massimo Andreoni, Roma

16.10 - 16.30 **A normal life expectancy on cART: myth or reality**

Amanda Mocroft, London UK

16.30 - 16.50 **Coronary disease: from pathogenesis to treatment**

Antonella Castagna, Milano

16.50 - 17.25 **Discussion**

15.50 - 17.25 AULA U6 - 06

ORAL COMMUNICATIONS HEPATITIS II

CHAIRS: **S. Babudieri** (Sassari), **T. Quirino** (Busto Arsizio VA)

OC33 15.50-16.00 HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically infected patients can impact on HBV transmission and disease progression

L. Colagrossi¹, **L.E. Hermans**^{2,3}, **R. Salpini**¹, **S.D. Pas**³, **M. Alvarez**⁴, **Z. Ben Ari**²⁰, **G. Boland**², **B. Bruzzone**⁵, **N. Coppola**⁶, **C. Seguin-Devaux**⁷, **T. Dyda**⁸, **F. Garcia**⁴, **R. Kaiser**⁹, **S. Köse**¹⁰, **H. Krarup**¹¹, **I. Lazarevic**¹², **M.M. Lunar**¹³, **S. Maylin**¹⁴, **V. Micheli**¹⁵, **O. Mor**¹⁶, **S. Paraschiv**¹⁷, **D. Paraskevis**¹⁸, **M. Poljak**¹³, **E. Puchhammer-Stöckl**¹⁹, **F. Simon**¹⁴, **M. Stanojevic**¹², **K. Stene-Johansen**²¹, **N. Tihic**²², **P. Trimoulet**²³, **J. Verheyen**²⁴, **A. Vince**²⁵, **S. Zidovec Lepej**²⁶, **N. Weis**²⁷, **T. Yalcinkaya**²⁸, **C.A.B. Boucher**³, **A.M.J. Wensing**², **C.F. Perno**¹, **V. Vichet**¹ on behalf of the HEPVIR working group of the European Society for translational antiviral research (ESAR)

¹Dept. of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy, ²Dept. of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands, ³Dept. of Virology, Erasmus Medical Centre, Rotterdam, The Netherlands, ⁴Servicio de Microbiología, Hospital San Cecilio, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada, Granada, Spain, ⁵Hygiene Unit, IRCCS AOU San Martino - IST, Genoa, Italy, ⁶Malattie Infettive, Seconda Università degli studi di Napoli, Naples, Italy, ⁷Laboratory of Retrovirology, CRP-Santé, Luxembourg, Luxembourg, ⁸Molecular Diagnostics Laboratory, Hospital of Infectious Diseases, Warsaw, Poland, ⁹Institute of Virology, University of Cologne, Cologne, Germany, ¹⁰Izmir Tepecik Education and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Izmir, Turkey, ¹¹Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark, ¹²Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, ¹³Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, ¹⁴Service de Microbiologie, University Paris Diderot, Hôpital Saint Louis, Paris, France, ¹⁵"L. Sacco" Hospital, Milan, Italy, ¹⁶National HIV Reference Laboratory, Central Virology Laboratory, Ministry of Health, Tel Hashomer, Ramat Gan, Israel, ¹⁷Molecular Diagnostics Laboratory, National Institute for Infectious Diseases "Matei Bals", Bucharest, Romania, ¹⁸Dept. of Hygiene, Epidemiology and Medical Statistics, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ¹⁹Dept. for Virology, Medical University of Vienna, Vienna, Austria, ²⁰Liver Disease Centre, Sheba Medical Centre, Ramat Gan, Israel, ²¹Dept. of Virology, Norwegian Institute of Public Health, Oslo, Norway, ²²Institute of Microbiology, Polyclinic for Laboratory Diagnostics, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina, ²³Virology Laboratory, Centre Hospitalier Régional et Université "Victor Segalen", Bordeaux, France, ²⁴Institute of Virology, University-Hospital, University Duisburg-Essen, Essen, Germany, ²⁵University of Zagreb School of Medicine and University Hospital for Infectious Diseases, Zagreb, Croatia, ²⁶Dept. of Molecular Diagnostics, University Hospital for Infectious Diseases Dr. Fran Mihaljević, Zagreb, Croatia, ²⁷Dept. of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark, ²⁸Refik Saydam National Public Health Agency, Ankara, Turkey

OC34 16.02-16.12 Virological failures to Direct Acting Antivirals (DAA) in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional regimens

V.C. Di Maio¹, **V. Cento**¹, **I. Lenzi**², **M. Aragni**¹, **P. Rossi**², **S. Barbaliscia**¹, **M. Melis**³, **G. Verucchi**⁴, **C. Magni**⁵, **A. Bertoli**¹, **F.P. Antonucci**¹, **D. Di Paolo**², **S. Landonio**⁵, **S. Francioso**², **C. D'Ambrosio**⁶, **V. Calvaruso**⁷, **C. Pasquazzi**⁸, **S. Babudieri**⁹, **D. Romagnoli**⁹, **R. Cozzolongo**¹⁰, **M. Biolatto**¹¹, **J. Vecchiet**¹², **F. Morisco**¹³, **M. Merli**¹⁴, **G. Brancaccio**¹⁵, **G.B. Gaeta**¹⁵, **S. Brillanti**¹⁶, **P. Andreone**¹⁷, **C. Mastroianni**¹⁸, **V. Pace Palitti**¹⁹, **P. Tarquini**²⁰, **F. Donato**²¹, **M. Puoti**²², **A. Moretti**²³, **V. Sangiovanni**²⁴, **G. D'Adamo**²⁵, **A. Grieco**¹¹, **N. Caporaso**¹³, **M. Paoloni**²⁶, **G. Rizzardini**²⁵, **G. Parruti**²⁷, **A. Craxi**²⁷, **M.S. Mura**³, **A. Pellicelli**²⁸, **M. Angelico**², **C.F. Perno**¹, **F. Ceccherini-Silberstein**¹

¹Dept. of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ²Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ³Infectious Diseases Unit, University of Sassari, Sassari, Italy, ⁴Policlinico S. Orsola-Malpighi, Bologna, Italy, ⁵Division of Infectious Disease, Hospital Sacco di Milano, Milan, Italy, ⁶Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ⁷Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ⁸Infectious Diseases, Sant'Andrea Hospital - "La Sapienza" University, Rome, Italy, ⁹Dept. of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, ¹⁰Dept. of Gastroenterology, Scientific Institute for Digestive Disease "Saverio de Bellis" Hospital, Castellana Grotte, Bari, Italy, ¹¹Gastroenterology, Catholic University of Rome, Rome, Italy, ¹²Infectious Disease Clinic, Hospital of Chieti, Chieti, Italy, ¹³Dept. of Clinical Medicine and Surgery Gastroenterology Unit, University «Federico II», Naples, Italy, ¹⁴Gastroenterology, "La Sapienza" University of Rome, Rome, Italy, ¹⁵Viral Hepatitis Unit, Second University, Naples, Italy, ¹⁶Gastroenterology, Policlinico S. Orsola - Malpighi, Bologna, Italy, ¹⁷Dept. of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, ¹⁸Infectious Diseases, "La Sapienza" University, Latina, Italy, ¹⁹Hepatology Unit, Ospedale San Massimo, Penne, Italy, ²⁰Infectious Disease, Hospital "G. Mazzini", Teramo, Italy, ²¹Gastroenterology and Liver Transplant Units, Fondazione IRCCS Cà Granda Maggiore Hospital Policlinico and University of Milan, Italy, ²²Hospital Niguarda Cà Granda, Milan, Italy, ²³San Filippo Neri Hospital, Rome, Italy, ²⁴Hospital Cotugno, Naples, Italy, ²⁵P.O. Umberto I, Nocera Inferiore, Salerno, Italy, ²⁶Infectious Disease Unit, Avezzano General Hospital, Avezzano, Italy, ²⁷Infectious Disease Unit, Pescara General Hospital, Pescara, Italy

OC35 16.14-16.24 The elderly and DAAs: constraint or challenge?

C. Fabrizio, **E. Milano**, **R. Dell'Acqua**, **G. Bruno**, **L. Monno**, **S. Lo Caputo**, **M. Milella**, **A. Saracino**, **G. Angarano**
Clinica Malattie Infettive, Università di Bari

OC36 16.26-16.36 Striking gender differences in emotional intelligence among HCV cirrhotic patients

M. Spaziente¹, **E. Biliotti**¹, **D. Palazzo**¹, **P. Perinelli**¹, **M. De Angelis**¹, **R. Esvan**¹, **L. Fariselli**², **C. Franchi**¹, **G. Iaiani**¹, **C. Marsiglia**¹, **M. Rivano Capparruccia**¹, **M. Santori**¹, **L. Sulekova**¹, **F. Tamburini**¹, **P. Rucci**³, **G. Taliani**¹

¹Sapienza University of Rome, Infectious and Tropical Diseases Dept., ²Sixseconds Team, ³Department of Medicine and Public Health, University of Bologna

OC37 16.38-16.48 Resistance-Associated Variants of Hepatitis C at baseline and failure during DAA-based therapy

A. Lai¹, **S. Giofrè**¹, **A. Bergna**¹, **M. Polano**², **E. Calvi**³, **V. Micheli**⁴, **P. Ronzi**¹, **F. Binda**¹, **G. Zehender**¹, **S. Sollima**³, **M. Galli**¹, **L. Milazzo**³, **C. Balotta**¹

¹Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ²Experimental Oncology 1, CRO Aviano National Cancer Institute, Aviano, Italy, ³3rd Division of Infectious Diseases, L. Sacco University Hospital, Milan, Italy, ⁴Clinical Microbiology Virology and Diagnosis of Bioemergency, L. Sacco University Hospital, Milan, Italy

OC38 16.50-17.00 Sofosbuvir and Ribavirin for difficult to treat HCV-2 patients: improved SVR rates with prolonged therapy

C. Rossi³, **S. Piovesan**¹, **S. Lobello**², **P. Scotton**³, **F. Russo**⁴, **N. Dal Bò**⁵, **V. Vincenzi**⁶, **S. Panese**⁷, **F. Cattelan**⁷, **L. Chemello**⁸, **L. Cavalletto**⁹, **A. Zanetto**⁹, **A. Romano**⁹, **F. Capra**¹⁰, **D. Ieluzzi**¹⁰, **V. Paoni**¹⁰, **G. Carolo**¹¹, **A. Carlotta**¹², **M. Carrara**¹³, **E. Elke**¹⁴, **E.R. Rizzotto**², **P. Rovere**¹⁵, **M. Felder**¹⁶, **G. Anastassopoulos**¹, **M. Milan**¹, **L. Cavallaro**¹⁷, **P. Burra**⁹, **S. Adami**¹⁸, **C. Roni**¹⁸, **G. Scroccaro**¹⁸, **A. Alberti**¹ and **NAVIGATOREStudyGroup**

¹Medicina generale, University of Padova, ²Gastroenterologia, Ospedale S Antonio, Padova, ³Malattie Infettive, Treviso, ⁴Gastroenterologia, University of Padova, Padova, ⁵Gastroenterologia, Treviso, ⁶Medicina, Belluno, ⁷Malattie Infettive, Venezia Mestre, ⁸Clinica Medica 5, ⁹Traipianto Multiviscerale, Padova, ¹⁰Gastroenterologia, ¹¹Malattie Infettive, Università Verona, Verona, ¹²Malattie Infettive, Santorso, ¹³Gastroenterologia, Bussolengo, ¹⁴Malattie Infettive, Padova, ¹⁵Malattie Infettive, Legnago, ¹⁶Gastroenterologia, Balzano, ¹⁷Gastroenterologia, Belluno, ¹⁸Settore Farmaci, protesica e dispositivi della Regione Veneto, Italia

17.10 - 17.25 **Minilecture: HCV infection in the migrant population**

Nicola Coppola, Napoli

15.50 - 17.25 AULA U6 - 07

SYMPOSIUM PREP: BETWEEN CLINICAL EVIDENCE AND MANAGEMENT DIFFICULTIES

CHAIRS: **G. Carosi** (Brescia), **V. Puro** (Roma)

DISCUSSANT: **M. Oldrini** (Como)

There is an increasing scientific evidence on the possibility to prevent the acquisition of HIV infection with antiretroviral drugs i.e. pre-exposure prophylaxis (PrEP). The scientific evidence is absolute with a marked reduction of the individual risk and a serious possibility to increment the governance of HIV epidemic. Several studies have demonstrated that this measure is cost-effective, too. Despite this within the European Health Systems the attitude toward PrEP is controversial. The symposium table will put on focus the scientific evidence from trials and the impact of PrEP in clinical practice.

15.50 - 16.10 **Differential approaches in PrEP strategies**

Cristina Mussini, Modena

16.10 - 16.30 **How to improve PrEP delivery in clinical setting**

Santiago Moreno, Madrid E

16.30 - 17.25 Discussion

15.50 - 17.25 AULA U6 - 08

ORAL COMMUNICATIONS CLINICAL HIV II

CHAIRS: **A. Cossarizza** (Modena), **S. Rusconi** (Milano)

0C39 15.50-16.00 Results of Italian Network of ACuTe HIV Infection (INACTION) retrospective study

A. Muscatello¹, **A. Bandera**¹, **M. Fabbiani**¹, **A. Ammassari**², **A. Antinori**², **A. Calcagno**³, **M. Campus**⁴, **B.M. Celesia**⁵, **L. Cosco**⁶, **G. D'Ettore**⁷, **M. Ferrara**⁸, **E. Focà**⁹, **A. Franco**⁹, **N. Gandolfo**¹⁰, **A. Gori**¹, **R. Gulminetti**¹¹, **G. Marchetti**¹², **S. Nozza**¹³, **G. Orofino**¹⁴, **M. Ripa**¹³, **D. Ripamonti**¹⁵, **S. Rusconi**¹⁶, **G. Tambussi**¹³, **C. Torti**¹⁷ on behalf of INACTION study group

¹San Gerardo Hospital – Milano-Bicocca University - Monza, ²INMI L. Spallanzani – Rome, ³Amedeo di Savoia Hospital – University of Turin, ⁴Santissima Trinità Hospital – Cagliari, ⁵ARNAS Garibaldi Hospital – Catania, ⁶Pugliese-Ciaccio Hospital – Catanzaro, ⁷Umberto I Hospital – La Sapienza University of Rome, ⁸Department of Infectious and Tropical Diseases – University of Brescia, ⁹Hospital of Siracusa, ¹⁰San Martino Hospital – Genova, ¹¹San Matteo Hospital – Pavia, ¹²San Paolo Hospital – University of Milan, ¹³San Raffaele Hospital – Milan, ¹⁴Amedeo di Savoia Hospital – Turin, ¹⁵Papa Giovanni XXIII Hospital – Bergamo, ¹⁶Sacco Hospital – University of Milan, ¹⁷University “Magna Graecia” – Catanzaro

0C40 16.02-16.12 Virological efficacy of two treatment strategies for Primary HIV Infection (PHI): comparison of (TDF+FTC) associated with either Darunavir/Ritonavir+Raltegravir or Dolutegravir

C. Pinnetti¹, **I. Abbate**³, **P. Lorenzini**¹, **N. Orchi**², **C. Gori**⁴, **A. Amendola**³, **R. Libertone**¹, **G. Rozera**³, **M. Plazzi**¹, **G. Fabbri**¹, **M.R. Capobianchi**³, **A. Antinori**¹, **A. Ammassari**¹

¹Clinical Department, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy, ²Epidemiology Department, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy, ³Laboratory of Virology, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy, ⁴Antiretroviral Drug Monitoring Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy

0C41 16.14-16.24 Virological response and immunological recovery of HIV-1 infected patients starting a first line regimen with plasma HIV-1 RNA >500,000 copies/mL in clinical practice

M.M. Santoro¹, **D. Di Carlo**¹, **D. Armenia**¹, **M. Zaccarelli**², **C. Pinnetti**², **M. Colafigli**³, **F. Prati**⁴, **A. Boschi**⁵, **A. Degli Antoni**⁶, **F. Lagi**⁷, **L. Sighinolfi**⁸, **C. Gervasoni**⁹, **M. Andreoni**¹⁰, **A. Antinori**², **C. Mussini**¹¹, **C.F. Perno**¹², **V. Borghi**¹¹, **G. Sterrantino**¹³

¹University of Rome Tor Vergata, Experimental Medicine and Surgery, Rome, Italy, ²National Institute for Infectious Diseases L. Spallanzani, IRCCS, Infectious Diseases Division, Rome, Italy, ³San Gallicano Dermatological Institute, IRCCS, Rome, Italy, ⁴Azienda Ospedaliera di Reggio Emilia, Infectious Diseases Unit, Reggio Emilia, Italy, ⁵Azienda Ospedaliera di Rimini, Infectious Diseases Unit, Rimini, Italy, ⁶Azienda Ospedaliero-Universitaria di Parma, Infectious Diseases Unit, Parma, Italy, ⁷University of Florence, Tropical and Infectious Diseases, Florence, Italy, ⁸Azienda Ospedaliero-Universitaria di Ferrara, Infectious Diseases Unit, Ferrara, Italy, ⁹L. Sacco University Hospital, Section of Infectious Diseases, Milan, Italy, ¹⁰University of Rome Tor Vergata, Systems Medicine, Rome, Italy, ¹¹Azienda Ospedaliero-Universitaria di Modena, Clinic of Infectious Diseases, Modena, Italy, ¹²National Institute for Infectious Diseases L. Spallanzani-IRCCS, Antiretroviral Drugs Monitoring Unit, Rome, Italy, ¹³Azienda Ospedaliero-Universitaria Careggi, Department of Tropical and Infectious Diseases, Florence, Italy

0C42 16.26-16.36 Drop in CD4+ counts below 200 cells/ L after reaching (or starting from) values higher than 350 cells/ L in HIV-infected patients with virological suppression

N. Gianotti¹, **A. Cozzi-Lepri**², **G. Marchetti**³, **A. Saracino**⁴, **A. Gori**⁵, **A. Antinori**⁶, **G. Rizzardini**⁷, **M. Lichtner**⁸, **A. Bandera**⁵, **C. Mussini**⁹, **E. Girardi**⁶, **A. d'Arminio Monforte**³ on behalf of the ICONA Foundation Study Group

¹Malattie Infettive, IRCCS San Raffaele, Milano, Italy, ²University College London, London UK, ³Clinica Malattie Infettive e Tropicali, Dipartimento di Scienze della Salute, ASST Santi Paolo e Carlo, Milano, Italy, ⁴Clinica delle Malattie Infettive, Università degli Studi di Bari, Bari, Italy, ⁵Clinic of Infectious Diseases, “San Gerardo” Hospital-ASST Monza, University Milano-Bicocca, Milano, Italy, ⁶Istituto Nazionale per le Malattie Infettive L. Spallanzani IRCCS, Roma, Italy, ⁷Malattie Infettive, ASST Fatebenefratelli Sacco, Milano, Italy, ⁸Malattie Infettive, Policlinico Umberto I, Università La Sapienza, Roma, Italy, ⁹Malattie Infettive, Università degli Studi, Policlinico di Modena, Modena, Italy

0C43 16.38-16.48 The Impact of Age at HIV Diagnosis on CD4/CD8 Ratio and Multimorbidity in Elderly HIV-positive Patients

A. Calcagno¹, **S. Piconi**², **B.M. Celesia**³, **A. Riva**⁴, **F. Carli**⁵, **G.V. De Socio**⁶, **A.M. Cattelan**⁷, **G. Orofino**⁸, **E. Focà**⁹, **S. Nozza**¹⁰, **C. Montrucchio**¹, **A. Malagoli**⁵, **G. Di Perri**¹, **G. Guaraldi**⁵ for the GEPPPO Study Group

¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, ²1st Division of Infectious Diseases Unit, University of Milano, Ospedale L. Sacco, Milano, ³Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, ARNAS Garibaldi, Catania, ⁴3rd Division of Infectious Diseases, University of Milano, Ospedale L. Sacco, Milano, ⁵University of Modena and Reggio Emilia, Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Diseases Clinic, Modena, ⁶Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Perugia, Perugia, ⁷Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Padova, Padova, ⁸Unit of Infectious Diseases, “Divisione A”, Ospedale Amedeo di Savoia, ASLTO2, Torino, ⁹Department of Infectious and Tropical Diseases, University of Brescia, ¹⁰Department of Infectious Diseases, San Raffaele Scientific Institute, Milano

0C44 16.50-17.00 Impact of 48 week Atazanavir/Ritonavir Plus Lamivudine Dual Therapy on HIV-DNA Level: a sub-study of ATLAS-M Trial

F. Lombardi¹, **S. Belmonti**¹, **E. Quiros-Roldan**², **A. Latini**³, **A. Castagna**⁴, **V. Vullo**⁵, **M. Fabbiani**¹, **A. De Luca**^{1,6}, **R. Cauda**¹, **S. Di Giambenedetto**¹ and ATLAS study group

¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy, ²University Division of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, ³Infectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome, Italy, ⁴Department of Infectious and Tropical Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁵Department of Infectious Diseases, “La Sapienza” University, Rome, Italy, ⁶Infectious Diseases Unit, Siena University Hospital, Siena, Italy

17.10-17.25 Minilecture: Immunoreconstitution and Inflammation during cART: good and bad news

Alessandra Bandera, Monza

17.30 - 18.00 AULA MAGNA

SPECIAL LECTURE

CHAIRS: **P. Grossi** (Varese), **G. Palù** (Padova)

Zika: a diabolic juncture?

Giuseppe Ippolito, Roma

09:00 - 10:10 AULA MAGNA

KEYNOTE LECTURES

CHAIRS: **A. d'Arminio Monforte** (Milano), **S. Mattioli** (Bologna)

09.00 - 09.35 **Value based medicine in Hepatitis**

Mario Strazzabosco, Milano

09.35 - 10.10 **HIV and MSM: community empowerment and the role of acute infection in halting the epidemics**

Michael Meulbroek, Barcelona E

10.15 - 11.55 AULA MAGNA

SYMPOSIUM HCV 2016 UPDATE

CHAIRS: **R. Cauda** (Roma), **G. Taliani** (Roma)

Treatment of Hepatitis C virus (HCV) infection has reached a turning point due to the availability of new, safe and effective drugs. Long-term benefits of successful HCV treatment translate into less frequent hepatic decompensation and hepatocellular carcinoma development, improvements in liver disease severity, reduction of liver-related mortality, and potential obviation of the need for transplantation.

Nevertheless some concerns and some new critical issues of paramount importance face clinicians who manage HCV treatment, especially in individuals with cirrhosis. Awareness and preparedness are fundamental tools for obtaining the best from the new treatment opportunities.

10.15 - 10.35 **The liver disease beyond HCV cure**

Massimo Puoti, Milano

10.35 - 10.55 **Black holes in the DAAs therapy**

Alessio Aghemo, Milano

10.55 - 11.15 **Resistance to DAAs: emerging pictures form Italian experience**

Francesca Ceccherini-Silberstein, Roma

11.15 - 11.55 Discussion

10.15 - 11.55 AULA U6 - 06

SYMPOSIUM THE CONTRIBUTION OF EPIDEMIOLOGY IN TRACKING NEW INFECTIONS

CHAIRS: **F. Castelli** (Brescia), **F. Mazzotta** (Firenze)

Current HIV prevention strategies are based on different interventions including: increased offer of HIV testing, antiretroviral treatment (ART) initiation regardless of CD4 cell count immediately after diagnosis, improved linkage to care and adherence to ART in order to support patients with attaining and sustaining undetectable viral load, provision of antiretrovirals as preexposure prophylaxis (PrEP) to those at risk of infection.

The potential impact of any of these interventions, relies on how many HIV transmissions originate from different stages in the entire HIV infection and care continuum. In this symposium different approaches to address this issue will be discussed including the use of viral phylogenetic data and the integration of data from surveillance systems and color studies.

10.15 - 10.35 **Molecular epidemiology: a tool to track new infections**

Maria Santoro, Roma

10.35 - 10.55 **Sources of HIV infection today**

Ard van Sighem, Amsterdam NL

10.55 - 11.15 **Cohorts contribution in HIV cascade**

Enrico Girardi, Roma

11.15 - 11.55 Discussion

10.15 - 11.55 AULA U6 - 07

ORAL COMMUNICATIONS IMMUNOLOGY

CHAIRS: **A. De Maria** (Genova), **G. Poli** (Milano)

0C45 10.15 - 10.25 Lack of normalization of inflammatory soluble markers in HCV cirrhotic and non cirrhotic patients undergoing DAA therapy

C. Mascia¹, M. Lichtner², S. Vita¹, R. Marocco², P. Zuccalà¹, M. Campagna², T. Tieghi², F. Mengoni¹, G. D'ettore¹, C. Furlan¹, C.M. Mastroianni², V. Vullo¹

¹Sapienza University of Rome, ²Sapienza University of Rome, Polo Pontino, Latina, Italy

0C46 10.27 - 10.37 Increased osteoclastogenesis in HIV positive cART-treated patients with reduced Bone Mineral Density (BMD): role of Suppressor of Cytokine Signaling-1 (SOCS-1) and Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF-6)

E.S. Cannizzo, F.A. Cazzaniga, N. Iannotti, L. Gazzola, E. Merlini, M. Basilissi, C. Tincati, A. d'Arminio Monforte, G. Marchetti

Dept of Health Sciences, Clinic of Infectious Diseases, University of Milan, ASST San Paolo and Carlo Hospital, Milan

0C47 10.39 - 10.49 Age-dependent dysregulation of IFN response in HIV-1 infected patients on long-term combination antiretroviral therapy

C. Scagnolari¹, G. Corano Scheri², C. Selvaggi¹, N. Giustini², S. Serafino², I. Schietroma², I. Sciandra¹, S. Tozzi¹, I. Mezzaroma³, O. Turriziani¹, G. d'Ettore², V. Vullo², G. Antonelli¹

¹Pasteur Institute-Cenci Bolognetti Foundation, Rome, Italy; Department of Molecular Medicine, Laboratory of Virology, "Sapienza" University of Rome, Rome, Italy, ²Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy; ³Department of Clinical Medicine, Sapienza University of Rome, Italy

0C48 10.51 - 11.01 Neuroasymptomatic cerebrospinal fluid (CSF) viral escape is associated to increased intrathecal immune activation but not with CSF signs of neuronal injury

C. Pinnetti¹, V. Fedele¹, S. Carta¹, P. Lorenzini¹, V. Mazzotta¹, V. Bordoni¹, F. Baldini¹, M. Capobianchi¹, F. Martini¹, F. Ceccherini-Silberstein², A. Ammassari¹, C.F. Perno^{1,2}, A. Antinori¹

¹National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, ²University of Tor Vergata, Rome, Italy

0C49 11.03 - 11.13 A high rate of CD56bright NK cells is associated with poor CD4+ T cell reconstitution in HIV-1-infected immunological non responders on suppressive antiretroviral therapy

E. Giuliani¹, L. Vassena¹, M.G. Desimio¹, S. Di Cesare¹, V. Malagnina², M. Andreoni², M. Doria¹

¹Laboratory of Immunoinfectivology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, ²Department of Medicine of Systems, Tor Vergata University, Rome, Italy

0C50 11.15 - 11.25 β-arrestins specific siRNA inhibits CCR5 signalosome mediated by human serum antibodies in long-term HIV infected subjects

A. Venuti¹, C. Pastori¹, R. Pennisi², A. Riva³, M.T. Sciortino², L. Lopalco¹

¹Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ²Department of Biological and Environmental Sciences, University of Messina, Messina, Italy, ³Third Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy

0C51 11.27 - 11.37 Unconventional T-cells in Chronic Hepatitis B (CHB) Patients on Long-Term Suppressive TDF Treatment prior to and following a PEG-INF Add-On Strategy

C. Tincati¹, E. Stefania Cannizzo¹, F. Binda², P. Ronzi², F.A. Cazzaniga¹, A. d'Arminio Monforte¹, G. Marchetti¹ and L. Milazzo²

¹Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, ²Department of Clinical and Biomedical Sciences Luigi Sacco, III Division of Infectious Diseases, University of Milan

11.40 - 11.55 **Minilecture: Immunology and HIV disease: what a clinician should absolutely consider**

Giulia Marchetti, Milano

10.15 - 11.55 AULA U6 - 08

ORAL COMMUNICATIONS CLINICAL HIV III

CHAIRS: **A.M. Cattelan** (Padova), **L. Sighinolfi** (Ferrara)

OC52 10.15 - 10.25 Z-Score Index to Early Detect and Monitor HIV Brain Damage Using EEG LORETA

L. Sarmati¹, C. Babiloni², E. Teti¹, A. Pennica³, A. Aceti³, P. Onorati², G. Noce², S. Ferracuti⁴, F. Di Campi⁵, M. Andreoni¹

¹Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, ²Department of Physiology, Sapienza University of Rome, Italy, ³Clinical Infectious Diseases, Sant'Andrea Hospital, Sapienza University of Rome, Italy, ⁴Psychiatry, Sant'Andrea Hospital, Sapienza University of Rome, Italy, ⁵Sapienza University

OC53 10.27 - 10.37 High rate of asymptomatic vertebral fractures in a cohort of HIV-infected patients undergoing quantitative morphometric assessment

A. D'Avino¹, A.P. Lassandro¹, A. Emiliozzi¹, S. Lamonica¹, A. Ciccullo¹, G. Baladin¹, A. Mondini¹, R. Cauda¹, A. De Luca², S. Di Giambenedetto¹

¹Università Cattolica del Sacro Cuore Roma, ²Azienda Ospedaliera Universitaria Senese "Policlinico Le Scotte" Siena

OC54 10.39 - 10.49 A co-morbidity approach to cART: the CRISIS study

F. Maggiolo, E. Di Filippo, L. Comi, A. Callegaro, D. Valenti, G. Gregis

ASST Papa Giovanni XXIII, Bergamo

OC55 10.51 - 11.01 HIV-positive subjects treated with single tablet regimens (STR) when ART-naïve in clinical practice

A. Cozzi-Lepri¹, A. Antinori², M. Zaccarelli², F. Maggiolo³, G. Marchetti⁴, A. Di Biagio⁵, A. Cingolani⁶, A. Castagna⁷, A. Costantini⁸, R. Piolini⁹, A. Chiodera¹⁰ and A. d'Arminio Monforte⁴ for the Icona Foundation Study Group

¹University College London, ²INMI L Spallanzani, Roma, Italy, ³AO Papa Giovanni XXIII, Bergamo, Italy, ⁴S. Paolo Hospital, University of Milano Italy, ⁵AO Universitaria S Martino, Genova, Italy, ⁶Cattolica Sacro Cuore University, Roma, Italy, ⁷S. Raffaele Hospital, Milano, Italy, ⁸AO Universitaria Ospedali Riuniti, Ancona, Italy, ⁹Sacco Hospital Milano, Italy, ¹⁰Malattie Infettive, Ospedale Macerata, Italy

OC56 11.03 - 11.13 Dolutegravir (DTG)-containing regimens after failing to raltegravir (RAL) or elvitegravir (EVG): durability and virological response

S. Rusconi¹, F. Adorni², P. Tau¹, V. Borghi³, M. Pecorari⁴, L.I. Bellazzi⁵, D. Francisci⁶, L. Monno⁷, G. Punzi⁸, P. Meraviglia⁹, S. Paolucci¹⁰, A. Di Biagio¹¹, B. Bruzzone¹², A. Manconi¹³, V. Micheli¹³, on behalf of ARCA (Antiviral Response Cohort Analysis)

¹Divisione Malattie Infettive, DIBIC Luigi Sacco, Università degli Studi di Milano, ²ITB-CNR, Segrate, MI, ³Clinica Malattie Infettive, Modena; ⁴Laboratorio di Virologia, Modena, ⁵Ambulatorio Clinica Malattie Infettive, Fondazione Policlinico San Matteo, Pavia, ⁶Clinica Malattie Infettive, Perugia; ⁷Clinica Malattie Infettive, Bari, ⁸Laboratorio di Virologia, Bari, ⁹Prima divisione di Malattie Infettive, Ospedale Luigi Sacco, Milano, ¹⁰Laboratorio di Virologia, Fondazione Policlinico San Matteo, Pavia, ¹¹Clinica Malattie Infettive, Azienda Ospedaliera Universitaria San Martino, Genova, ¹²Laboratorio di Igiene, Azienda Ospedaliera Universitaria San Martino, Genova, ¹³Laboratorio Microbiologia Clinica - Virologia - Bioterrorismo, Ospedale Luigi Sacco, Milano, Italy

OC57 11.15 - 11.25 Virologically suppressed patients switching therapy with PBMCS resistance and insufficient previous virological control have a higher risk of experiencing virological rebound

D. Armenia¹, M. Zaccarelli², V. Borghi³, W. Gennari³, A. Giannetti², F. Forbici⁴, A. Bertoli¹, C. Gori⁴, V. Fedele⁴, C. Pinnetti², R. Marocco⁵, M. Giuliani⁶, A. Latini⁶, F. Ceccherini Silberstein¹, C. Mastroianni⁵, C. Mussini³, C.F. Perno⁴, A. Antinori² and M.M. Santoro¹

¹University of Rome Tor Vergata, Experimental Medicine and Surgery, Rome, Italy, ²National Institute for Infectious Diseases L. Spallanzani, IRCCS, Division of Infectious Diseases, Rome, Italy, ³Polyclinic of Modena, Clinic of Infectious Diseases, Modena, Italy, ⁴National Institute for Infectious Diseases L. Spallanzani, IRCCS, Antiretroviral Drugs Monitoring Unit, Rome, Italy, ⁵La Sapienza University Polo Pontino, Infectious Diseases Unit, Latina, Italy, ⁶San Gallicano Dermatological Institute, IRCCS, Rome, Italy

OC58 11.27 - 11.37 Outcomes of second line antiretroviral therapy in HIV-infected patients: data from the ICONA cohort

A. Di Biagio¹, P. Lorenzini², G. Gustinetti¹, S. Rusconi³, A. De Luca⁴, G. Lapadula⁵, S. Lo Caputo⁶, S. Cicalini⁷, F. Castelli⁷, G. Marchetti⁸, A. Antinori², A. D'Arminio Monforte⁹ on behalf of the ICONA Foundation study group

¹Clinica Malattie Infettive, IRCCS AOU San Martino-IST, Genova, Italy, ²INMI Spallanzani, Roma, Italy, ³Clinica Malattie Infettive, Ospedale Sacco, Università di Milano, Milano, Italy, ⁴Malattie Infettive Universitarie, AOU Senese, Siena, Italy, ⁵Malattie infettive, Ospedale San Gerardo, Monza, Italy, ⁶Clinica di Malattie Infettive, Policlinico di Bari, Italy, ⁷Clinica Malattie Infettive, Università di Brescia, Brescia, Italy, ⁸Clinica di Malattie Infettive, Ospedale San Paolo, Università di Milano, Milano, Italy

11.40 - 11.55 **Minilecture: HIV-associated lymphoma: epidemiology and management today**

Antonella Cingolani, Roma

12.00 - 12.45 AULA MAGNA

SATELLITE SYMPOSIUM INNOVATION IN A WELL-KNOWN CLASS

CHAIR: **C. Mussini** (Modena)

In the past, PIs have changed natural history of HIV disease and today they are still perfectly aligned with scientific community trends. PIs are always virologically effective with new boosters responding to the challenges of the resistance mutations and they meet patient needs through flexibility and versatility providing more personalized combinations.

12.00 - 12.15 **Clinical considerations in switching to Darunavir/Cobicistat**

Josep Mallolas, Barcelona E

12.15 - 12.30 **PIs: is the class omogeneous?**

Andrea De Luca, Siena

12.30 - 12.45 Discussion

12.00 - 12.45 AULA U6 - 06

SATELLITE SYMPOSIUM NEW DAAs: DIRECT EXPERIENCES AND FUTURE PERSPECTIVES

CHAIR: **R. Bruno** (Pavia)

Chronic Hepatitis C virus (HCV) infection is the leading cause of advanced liver disease worldwide. The introduction of sofosbuvir can be regarded as a first step towards a radical change in the antiviral management of chronic HCV infection. For the first time, clinicians were about to hold a DAA that covers all genotypes and shows robust antiviral response in virtually all patients due to high intrahepatocellular concentrations. The excellent safety profile, the high resistance barrier and the lack of significant DDIs allow the broad use of the drug also in more difficult-to-treat situations like co-infections, cirrhosis and the liver transplant setting. When used in combination with ribavirin or another DAA, SOF has revolutionized the HCV treatment spectrum and set the stage for nearly universal HCV antiviral therapy. The future perspectives leads to the once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and velpatasvir (VEL), a pan-genotypic NS5A inhibitor, for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.

12.00 - 12.15 **DAA-based therapy in real-life: mono-infection and HIV/hepatitis C virus co-infection**

Massimo Galli, Milano

12.15 - 12.30 **HCV treatment: another turning point**

Gloria Taliani, Roma

12.30 - 12.45 Discussion

12.50 - 13.35 AULA MAGNA

SATELLITE SYMPOSIUM PI EVOLUTION: A CHANGING APPROACH FOR A CHANGING SCENARIO

EXPERT PANEL: **A. Antinori** (Roma), **S. Di Giambenedetto** (Roma), **S. Rusconi** (Milano)

In the continuum of ART evolution, PI class seems to play a renovated role in HIV infection management. A second generation of PI has shown across studies potent antiviral activity and high genetic barrier, both in HAART-naïve patients and in failing subjects. The use of these drugs is revisited in the light of a changing clinical scenario and new indications from guidelines. The added value of PI to current ART regimens is evaluated both in terms of comorbidities management and of therapeutic optimization including booster options.

12.50 - 13.05 **PI: new role on current ART management**

Andrea Antinori, Roma

13.05 - 13.20 **PI: new recommended optimization strategies**

Simona Di Giambenedetto, Roma

13.20 - 13.35 **PI: new approach without ritonavir**

Stefano Rusconi, Milano

13.40-15.10 AULA MAGNA

SYMPOSIUM HEPATITIS B: THE FUTURE

CHAIRS: **G.B. Gaeta** (Napoli), **M. Mondelli** (Pavia)

Novel short-term, highly effective and well tolerated therapies are needed for HBV infection because available drugs either have limited efficacy or require long-term administration. Present research efforts are directed to define strategies to improve protective immune responses and to block directly the different steps of the HBV life cycle. Thus, a deep understanding of protective immune responses and HBV biology is essential in the perspective of developing new anti-HBV treatments.

13.40-14.00	HBV-specific immunity: lessons from animal models	Luca Guidotti, Milano
14.00-14.20	Therapy: molecular targets	Massimo Levrero, Roma
14.20-14.40	Therapy: immunological targets	Carlo Ferrari, Parma
14.40-15.10	Discussion	

13.40-15.10 AULA U6 - 06

ORAL COMMUNICATIONS BASIC SCIENCE AND CLINICAL VIROLOGY

CHAIRS: **S. Buttò** (Roma), **L. Lopalco** (Milano)

OC59 13.40-13.50 Dynamics and phylogenetic relationships of HIV-1 transmitted drug-resistance according to subtype in Italy over the years 2000-2014

L. Fabeni¹, C. Alteri², D. Di Carlo², L. Carloti², A. Bertoli², C. Gori¹, F. Forbici¹, M.C. Bellocchi², F. Continenza¹, S. Cicalini¹, C. Pinnetti¹, R. Bellagamba¹, A. Ammassari¹, V. Borghi³, M. Giuliani⁴, G. De Carli¹, N. Orchi¹, P. Scognamiglio¹, A. Pennica⁵, C. Mastroianni⁶, F. Montella⁷, A. Cristaudo⁴, C. Mussini³, E. Girardi¹, M. Andreoni⁸, A. Antinori¹, F. Ceccherini-Silberstein², C.F. Perno¹, M.M. Santoro²

¹National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ²University of Rome Tor Vergata, Rome, Italy, ³Modena University Hospital, Modena, Italy, ⁴San Gallicano Dermatological Institute, IRCCS, Rome, Italy, ⁵S. Andrea Hospital, Rome, Italy, ⁶Sapienza University, Latina, Italy, ⁷S. Giovanni Addolorata Hospital, Rome, Italy, ⁸University Hospital Tor Vergata, Rome, Italy

OC60 13.52-14.02 PD-1 and CTLA-4-expressing cells are key contributors to viral persistence in ART-suppressed SIV-infected rhesus macaques

C.S. McGary¹, S. Paganini¹, C. Deleage², J. Harper¹, L. Micci¹, J.D. Estes², G. Silvestri^{1,3}, R.P. Sekaly⁴, M. Paiardini^{1,3}

¹Division of Microbiology and Immunology, Yerkes National Primate Research Center, Emory University, Atlanta, GA, ²AIDS Center Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, ³Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, ⁴Case Western Reserve University, Cleveland, OH

OC61 14.04-14.14 Pre-ART HIV-1 DNA correlates with viro-immunologic status and outcome in patients with 1st-line ART

F. Ceccherini-Silberstein¹, A. Cozzi Lepri², E. Merlini³, M. Surdo¹, G. Marchetti³, M.R. Capobianchi⁴, A. De Luca⁵, N. Gianotti⁶, G. Viale⁷, A. Antinori⁴, C.F. Perno⁴, A. D'Arminio Monforte³ for the ICONA Foundation

¹University of Rome Tor Vergata, Rome, Italy, ²University College London, UK, ³San Paolo Hospital, University of Milan, Milan, Italy, ⁴National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ⁵University Hospital of Siena, Siena, Italy, ⁶San Raffaele Scientific Institute, Milan, Italy, ⁷University of Bologna, Bologna, Italy

OC62 14.16-14.26 Defective proviruses accumulate early during HIV infection and show no decay during long-term cART

F.R. Simonetti¹, P. Cattaneo¹, A. Lai¹, S. Gioffrè¹, M. Franzetti¹, F. Binda¹, S. Rusconi¹, M. Tosiano², J.W. Mellors², E.M. Anderson³, F. Maldarelli³, M. Galli¹, C. Balotta¹

¹Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, Italy, ²University of Pittsburgh, Pittsburgh, PA, ³National Cancer Institute, Frederick MD

OC63 14.28-14.38 Analysis of the mRNA expression of DNA damage response genes in HIV infected patients

L. Mazzuti¹, F. Falasca¹, D. Di Carlo¹, G. Tranquilli¹, P. Maida¹, A. Fantauzzi², G. D'Ettore³, G. Antonelli¹, O. Turriziani¹

¹Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, ²Department of Clinical Medicine, Sapienza University of Rome, ³Department of Public Health and Infectious Diseases, Sapienza University of Rome

OC64 14.40-14.50 Intestinal dendritic cells and macrophages : what's their role in HIV infection?

M. Cavarelli^{1,2,3}, T. Schorr⁴, A. Cosma^{1,2,3}, N. Bosquet^{1,2,3}, U. Elmore⁴, G. Scarlati⁴, R. le Grand^{1,2,3}

¹Université Paris Sud, UMR 1184, France, ²CEA, DSV/iMETI, Division of Immuno-Virology, IDMIT, France, ³Insem, U1184, Center for immunology of viral infections and autoimmune diseases, France, ⁴San Raffaele Scientific Institute, Viral Evolution and transmission Unit, Milan, Italy

OC65 14.52-15.02 Probiotics supplementation modulates type I and II IFN response in treated HIV-1 positive patients with suppressed viremia
G. Corano Scheri¹, C. Selvaggi², N. Giustini¹, S. Serafino¹, I. Schietroma¹, M. Gentile², G. Ceccarelli¹, M. Andreotti³, G. Antonelli², V. Vullo¹, G. d'Etorre¹, C. Scagnolari²

¹Department of Public Health and Infectious Diseases, University of Rome "Sapienza", Rome, Italy, ²Pasteur Institute-Cenci Bolognetti Foundation, Rome, Italy, ³Department of Molecular Medicine, Laboratory of Virology, "Sapienza" University of Rome, Rome, Italy, ⁴Department of Therapeutic Research and Medicines Evaluation, Italian Institute of Health, Rome, Italy

13.40-15.10 AULA U6 - 07

ORAL COMMUNICATIONS COMMUNITY II

CHAIRS: **M. Cascio** (Palermo), **S. Marcotullio** (Roma)

OC66 13.40-13.50 Human dignity principle in the Italian Constitution: a value to be achieved in health care policies

M. Cappelletti¹, D. Badodi², F. Manfredi²

¹University of Parma, Department of Law - Public Comparative Law (Prof. Lucia Scaffardi), ²University of Parma, Department of Law - Criminal Law (Prof. A. Cadoppi)

OC67 13.52-14.02 HIV disclosure: how, when, to whom

G. Orofino, A. Perziano, P. Altini, S. Patrucco, C. Owen

Associazione Arcobaleno AIDS Torino, Ospedale Amedeo di Savoia

OC68 14.04-14.14 A budget impact analysis of the novel therapeutic regimens for the treatment of HCV infected patients in the Lombardy Region

E. Garagiola¹, L. Ferrario¹, D. Croce^{1,2}, B. Menzaghi³, T. Quirino³, G. Rizzardini^{4,5}, E. Foglia¹

¹Centre for Research on Health Economics, Social and Health Care Management, LIUC - Cattaneo University, Castellanza, Italy, ²School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³Infectious Diseases Department, Valle Olona ASST, Busto Arsizio, Italy, ⁴Department of Infectious Diseases, Fatebenefratelli Sacco Hospital, Milan, Italy, ⁵School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg

OC69 14.16-14.26 ChemSex: knowledge and behaviours among Italian MSM

G.M. Corbelli, S. Mattioli, C. Degli Esposti, C. Franchini, P. Gorgoni, P. Pieralli

Plus onlus

OC70 14.28-14.38 Psychiatric issues in treating HCV positive inmates with DAAs: a new challenge

R. Ranieri², M.L. Manzone¹, A. Foschi², M. Casana², A. Radice², C. Redaelli¹, A. Cospito³, C. Gala⁴, A. D'Arminio Monforte⁵

¹Mental Health Consultants-Opera, San Vittore, Bollate Correctional Houses, Santi Paolo and Carlo Hospital, University of Milan, ²Infectious Diseases Consultants-Opera, San Vittore, Bollate Correctional Houses, Santi Paolo and Carlo Hospital, University of Milan, ³Chief of Penitentiary Health Service-Regione Lombardia, ⁴Chief of Mental Health Department, Santi Paolo and Carlo Hospital, University of Milan, ⁵Chief of Infectious Diseases Unit, Santi Paolo and Carlo Hospital, University of Milan

OC71 14.40-14.50 The management of HIV+ patients suffering from neurocognitive impairment: determinants of cost

L. Ferrario¹, E. Foglia¹, E. Garagiola¹, E. Ricci², G. Rizzardini^{2,3}, P. Meraviglia², C. Atzori², M.V. Cossu², D. Croce^{1,4}

¹Centre for Research on Health Economics, Social and Health Care Management, LIUC - Cattaneo University, Castellanza, Italy, ²Department of Infectious Diseases, Fatebenefratelli Sacco Hospital, Milan, Italy, ³School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, ⁴School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

OC72 14.52-15.02 What recently infected people think about HIV? Results from a web survey for naïve patients

S. Marcotullio, D. Osorio, M. Martini, F. von Schloesser

Nadir Onlus, Rome, Italy

13.40 - 15.10 AULA U6 - 08

ORAL COMMUNICATIONS CLINICAL HIV IV

CHAIRS: **O. Armignacco** (Viterbo), **G. Madeddu** (Sassari)

0C73 13.40 - 13.50 A Multicenter Observational Study on the Efficacy and Metabolic Safety of Dolutegravir plus either TDF/FTC or ABC/3TC as a Simplification Strategy in HIV-1 Positive, Antiretroviral-experienced Patients

A. Borghetti¹, G. Baldin¹, A. Capetti², G. Sterrantino³, S. Rusconi⁴, A. Latini⁵, A. Giacometti⁶, G. Madeddu⁷, C. Picarelli⁸, M.V. Cossu², A. De Luca⁹, S. Di Giambenedetto¹ and the ODOACRE Study Group

¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, ²Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ³Division of Infectious Diseases, "Careggi" Hospital, Florence, Italy, ⁴Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy, ⁵Infectious Dermatology and Allergology Unit, IFO S. Galliciano Institute (IRCCS), Rome, Italy, ⁶Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy, ⁷Department of Clinical and Experimental Medicine, University of Sassari, Italy

0C74 13.52 - 14.02 Long term safety and tolerability of dual therapy with maraviroc (MVC) + darunavir/ritonavir (DRV/r) in virologically suppressed HIV infected patients with R5 viral tropism

B. Rossetti^{1,2}, R. Gagliardini², G. Meini³, G. Sterrantino⁴, F. Vignale⁵, V. Colanelli⁶, A. Latini⁷, M. Colafigli⁷, S. Rusconi⁸, G. Orofino⁹, V. Vullo¹⁰, A. Tosti¹¹, M. Trezzi¹², P. Grima¹³, A. Fantauzzi¹⁴, G. Marchetti¹⁵, A. Di Biagio¹⁶, M. Fabbiani², S. Lamonica², A. D'Avino², M. Zazzi², S. Di Giambenedetto², A. De Luca¹, on behalf of GUSTA group

¹University Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Infectious Diseases Unit, Catholic University of Sacred Heart, Rome, Italy, ³Department of Biotechnology, University of Siena, Siena, Italy, ⁴Infectious Diseases Unit, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy, ⁵Clinic of Infectious Diseases, University G. D'Annunzio, Chieti, Italy, ⁶Clinic of Infectious Diseases, Azienda Ospedaliera Universitaria S.Orsola Malpighi, Bologna, Italy, ⁷Infectious Dermatology and Allergology IRCCS IFO, Roma, Italy, ⁸Infectious Diseases Unit, DIBIC L. Sacco, Università di Milano, Milano, Italy, ⁹Infectious Diseases Division A, Amedeo di Savoia Hospital, Torino, Italy, ¹⁰Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, ¹¹Clinic of Infectious Diseases, University of Perugia, Perugia, Italy, ¹²Infectious Diseases, Pistoia Hospital, Pistoia, Italy, ¹³Infectious Diseases Unit, S. Caterina Novella Hospital, Galatina, Italy, ¹⁴Department of Clinic Medicine, Sapienza University, Rome, Italy, ¹⁵Infectious Diseases Unit, Azienda Ospedaliera San Paolo, Milano, Italy, ¹⁶Infectious Diseases Unit, IRCCS S. Martino-IST, Genova, Italy

0C75 14.04 - 14.14 Durability of rilpivirine- and integrase inhibitor-based simplification regimens in virologically suppressed HIV-Infected patients

N. Gianotti¹, A. Poli^{1,2}, S. Nozza¹, N. Galizzi^{1,2}, A. Carbone^{1,2}, M. Ripa^{1,2}, M. Merli^{1,2}, S. Salpietro¹, A. Lazzarin^{1,2}, A. Castagna^{1,2}

¹IRCCS Ospedale San Raffaele, Milano, Italy, ²Università Vita-Salute San Raffaele, Milano, Italy

0C76 14.16 - 14.26 A dual lamivudine + dolutegravir cART as maintenance strategy in patients with suppressed HIV-RNA

F. Maggiolo¹, R. Gulminetti², C. Mussini³, L. Pagnucco², M. Digaetano³, S. Benatti¹, D. Valentini¹, D. Ripamonti¹

¹Division of Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, ²Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, ³Division of Infectious Diseases, University of Modena, Modena, Italy

0C77 14.28 - 14.38 Efficacy and Safety of Lamivudine-Dolutegravir in a Multicenter Cohort of HIV-infected, Virologically Suppressed Patients and ODOACRE Study Group

G. Baldin¹, A. Borghetti¹, A. Capetti², V. Barocci³, G. Sterrantino⁴, A. Ciccullo¹, M.V. Cossu², A. Mondini¹, M. Fabbiani⁵, A. De Luca⁶, S. Di Giambenedetto¹

¹Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Policlinico Gemelli, Rome, ²Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy, ³Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy, ⁴Division of Infectious Diseases, "Careggi" Hospital, Florence, Italy, ⁵Division of Infectious Diseases, Department of Internal Medicine, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy, ⁶University Division of Infectious Diseases, Siena University Hospital, Siena, Italy

0C78 14.40 - 14.50 Durability of Dolutegravir (50 mg BID) including regimens in INI-resistant failing HIV-1 infected subjects in Italy: data from the PRESTIGIO National Database

A. Castagna^{1,2}, L. Galli¹, M. Ferrara³, M. Zaccarelli⁴, A. Di Biagio⁵, M. Menozzi⁶, A. Cericola⁷, E. Magistrelli⁸, A. Muscatello⁹, A. Rocadori¹⁰, G. Forastieri¹¹, P. Rizzini¹¹ on behalf of the PRESTIGIO National Database

¹Infectious Diseases Department, San Raffaele Scientific Institute, Milan, ²Vita Salute San Raffaele University, Milan, ³Dipartimento Scienze Mediche, Unità di Malattie Infettive, Università di Torino, ⁴Istituto Nazionale per le Malattie Infettive, Lazzaro Spallanzani, IRCCS, Roma, ⁵Infectious Diseases Unit, IRCCS AOU San Martino-IST, Genova, ⁶Clinic of Infectious Diseases, University of Modena, Modena, ⁷SC Farmacia Ospedaliera, EO Ospedali Galliera, Genova, ⁸Infectious Diseases Clinic, Policlinico Sant'Orsola Malpighi, Università degli studi di Bologna, Bologna, ⁹Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, ¹⁰Healthcare Systems Department, CINECA, Casalecchio di Reno, Bologna, ¹¹VitV Healthcare, Verona

14.55 - 15.10 **Minilecture: Has adherence a critical role nowadays?**

Adriana Ammassari, Roma

13.40 - 15.10 AULA U6 - 09

ORAL COMMUNICATIONS HIV EPIDEMIOLOGY

CHAIRS: **M. Lichtner** (Roma), **S. Lo Caputo** (Bari)

0C79 13.40 - 13.50 Determinants of 'HIV-risk unawareness' at the first diagnosis: analysis from National HIV Surveillance, 2010-2014

M. Dorrucchi¹, V. Regine¹, P. Pezzotti¹, A. Mammone², E. Girardi², B. Suligo¹

¹Istituto Superiore di Sanità, Rome, Italy, ²Istituto Nazionale per le Malattie Infettive "L. Spallanzani", Rome, Italy

0C80 13.52 - 14.02 Estimates of the number of people with undiagnosed HIV in need of antiretroviral therapy (ART) in Italy using the ECDC HIV modelling tool

V. Regine¹, M. Dorrucchi¹, P. Pezzotti¹, A. Mammone², B. Suligo¹

¹Istituto Superiore di Sanità, Rome, Italy, ²Istituto Nazionale per le Malattie Infettive "L. Spallanzani", Rome, Italy

0C81 14.04 - 14.14 Forecasting the Evolution of HIV Epidemics in Italy: Benefits of Early Treatment

M. Franzetti¹, F. Papa², A. Gandolfi³, C. Sinisgalli², F. Ceccherini-Silberstein³, S.G. Parisi⁴, S. Menzo⁵, M. Andreoni⁶, C. Balotta¹, G. Felici²

¹Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ²Institute for Systems Analysis and Computer Science "A. Ruberti", CNR, Roma, Italy, ³Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ⁴Department of Molecular Medicine, University of Padova, Padova, Italy, ⁵Department of Biomedical Sciences, Università Politecnica delle Marche, Ancona, Italy, ⁶Clinical Infectious Diseases, Tor Vergata University, Rome, Italy

0C82 14.16 - 14.26 Second national census among people diagnosed with HIV and in care in Italy in 2014

M. Raimondo¹, L. Camoni¹, R. Urcioli¹, S. Iacchini¹, B. Suligo¹, P. Pezzotti¹, Gruppo di studio CARPHA

Istituto Superiore di Sanità, Roma

0C83 14.28 - 14.38 An estimate of the continuum of HIV care in Italy in 2014 using surveillance and cohort data

A. Mammone¹, P. Pezzotti², L. Camoni², A. Tavelli³, M. Dorrucchi⁴, V. Regine⁵, M. Raimondo⁶, A. Gori⁷, A. Castagna⁸, C. Mussini⁹, A. d'Arminio Monforte³, B. Suligo², E. Girardi¹

¹National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ²Istituto Superiore di Sanità, Rome, Italy, ³Clinic of Infectious Diseases, San Paolo H, University of Milan, Italy, ⁴Division of Infectious Diseases, Department of Internal Medicine, "San Gerardo" Hospital, University of Milano-Bicocca, Monza, Italy, ⁵Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁶Università Vita-Salute San Raffaele, Milan, Italy, ⁷Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy

0C84 14.40 - 14.50 New HIV infections in Apulia from 2011 to 2015 : epidemiological aspects, management and retention in care

G. Bruno¹, A. Leone¹, M. Chironna², D. Loconsole², A. Tartaglia³, G. Buccoliero⁴, G. Brindicci⁵, P. Congedo⁶, S. Minniti⁷, M. Federica⁸, L. Monno¹, S. Lo Caputo¹, G. Angarano¹

¹Clinic of Infectious Diseases, University of Bari, ²Department of Biomedical Science and Human Oncology, University of Bari, ³Clinic of Infectious Diseases, University of Foggia, ⁴Infectious Diseases Unit, Taranto, ⁵Infectious Diseases Unit, Bisceglie, ⁶Infectious Diseases Unit, Lecce, ⁷Infectious Diseases Unit, Brindisi, ⁸Infectious Diseases Unit, Triggiano

0C85 14.52 - 15.02 Multimorbidity, Polypharmacy and Antiretrovirals' Prescription in The GEPP0 cohort (GERiatricPatients living with HIV/AIDS)

G. Guaraldi¹, A. Calcagno², A. Malagoli¹, C. Mussi³, B.M. Celesia⁴, F. Carli¹, S. Piconi⁵, G.V. De Socio⁶, A.M. Cattelan⁷, G. Orofino⁸, A. Riva⁹, E. Focà¹⁰, S. Nozza¹¹, G. Di Perri²

¹University of Modena and Reggio Emilia, Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Diseases Clinic, Modena, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, ³Centro di Valutazione e Ricerca Gerontologica, University of Modena and Reggio Emilia, Modena, ⁴Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, ARNA S Garibaldi, Catania, ⁵1st Division of Infectious Diseases Unit, University of Milano, Ospedale L. Sacco, Milano, ⁶Department of Infectious Diseases, Azienda Ospedaliera-Universitaria di Perugia, Perugia, ⁷Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliera-Universitaria di Padova, Padova, ⁸Unit of Infectious Diseases, "Divisione A", Ospedale Amedeo di Savoia, ASLTO2, Torino, ⁹3rd Division of Infectious Diseases, University of Milano, Ospedale L. Sacco, Milano, Italy, ¹⁰Department of Infectious and Tropical Diseases, University of Brescia, ¹¹Department of Infectious Diseases, San Raffaele Scientific Institute, Milano



15.15-16.55 AULA MAGNA

**SYMPOSIUM PRIORITIES AND SUSTAINABILITY OF THE HEALTHCARE SYSTEM:
THE STAKEHOLDERS' VIEW**

CHAIRS: **A. Chirianni** (Napoli), **M.R. Iardino** (Milano)

Health systems can be very different in the future. It will be important to be aware of this when reflecting on future strategies. It will be necessary to rethink the structure of the existing national healthcare systems, as well as role of stakeholders in the pursuit of sustainable health systems. Sustainability is a key implementation outcome and must be a priority in stakeholders view.

15.15-15.35 **Overview**

Giovanni Fattore, Milano

15.35-15.55 **The economic scenario**

Emanuela Foglia, Castellanza VA

15.55-16.15 **The real HCV scenario**

Ivan Gardini, Vimercate MB

16.15-16.35 **People living with HIV proactive role**

Ophelia Haanyama, Stockholm S

16.35-16.55 Discussion

16.55-17.05 AULA MAGNA

ICAR 2016 AWARDS

CHAIRS: **A. Gori** (Monza), **A. Lazzarin** (Milano), **F. Maggiolo** (Bergamo)

ICAR - SIMIT

5 Awards for the best abstracts accepted as Oral Communication, presented by young investigators

Antonio Chirianni, Napoli

ICAR - SIVIM

1 Award for the best abstract of Basic Virology and Clinical

Adriano Lazzarin, Milano

17.05-17.15 AULA MAGNA

CLOSING REMARKS

A. Gori (Monza), **A. Lazzarin** (Milano), **F. Maggiolo** (Bergamo)

Poster

CLINICAL DIAGNOSTICS HEPATITIS

P1 **Real life experience of hcv ns3/ns5a/ns5b sequencing allows the most accurate genotype and subtype assignment: a clinical relevance in the era of new direct acting antivirals**

M. Aragri¹, V.C. Di Maio¹, V. Cento¹, P. Rossi², C. Masetti², L. Gianserra³, M. Tontodonati⁴, V. Micheli⁵, S. Landonio⁶, A. Manunta⁷, A. Bertoli⁸, M. Ciotti⁹, F.P. Antonucci¹, I. Lenci², S. Francioso², P. Cacciatore⁴, A. Pieri⁴, E. Polillo⁴, D. Di Paolo², L. Baiocchi², L.A. Nicolini⁹, S. Marengo⁹, E. Teti¹⁰, L. Lambiase³, M. Milana², I. Maida⁷, A. Di Biagio⁹, L. Sarmati¹⁰, A. Pellicelli¹¹, L. Nosotti¹², S. Grieco¹³, E. Biliotti¹³, F. Sozio⁴, D. Romagnoli¹⁴, M. Siciliano¹⁵, G. D'Et-torre¹³, S. Babudieri⁷, M. Lichtner¹⁶, U. Vespasiani-Gentilucci¹⁷, M. Romano¹⁸, L. Fondacaro¹¹, C. D'Ambrosio¹¹, C. Sarrecchia¹⁰, A. Grieco¹⁵, F. Morisco¹⁹, C. Mastroianni¹⁶, J. Vecchiet²⁰, M. Puoti²¹, V.P. Palitti²², N. Caporaso¹⁹, A. Gasbarrini¹⁵, S. Bruno²³, M. Paoloni²⁴, V. Calvaruso²⁵, A. Craxi²⁵, P. Tarquini²⁶, C. Magni⁶, M.S. Mura⁷, G. Taliani¹³, V. Vullo¹³, P. Andreone²⁷, A. Picciotto⁹, G. Rizzardini⁶, M. Andreoni¹⁰, C. Pasquazzi³, G. Parruti⁴, M. Angelico², C.F. Perno^{1,8}, F. Ceccherini-Silberstein¹

¹Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ²Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ³Infectious Diseases, Sant'Andrea Hospital – "La Sapienza" University, Rome, Italy, ⁴Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ⁵Unit of Microbiology, Hospital Sacco of Milan, Milan, Italy, ⁶Division of Infectious Disease, Hospital Sacco of Milan, Milan, Italy, ⁷Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ⁸Molecular Virology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, ⁹S. Martino Hospital, Genova, Italy, ¹⁰Infectious Disease, University Hospital of Rome "Tor Vergata", Rome, Italy, ¹¹Hepatology Unit, San Camillo Forlanini Hospital, Rome, Italy, ¹²Hepatology Unit, National Institute of Health, Migration and Poverty, Rome, Italy, ¹³"La Sapienza" University, Rome, Italy, ¹⁴Department of Biomedical, Metabolic and Neural Sciences, NOCSAE Baggiovara, ¹⁵Gastroenterology, Catholic University of Rome, Rome, Italy, ¹⁶Infectious Diseases, "La Sapienza" University, Latina, Italy, ¹⁷Campus Biomedico, Rome, Italy, ¹⁸S. Pertini Hospital, Rome, Italy, ¹⁹Università «Federico II», Napoli, Italy, ²⁰Infectious Disease Clinic, Hospital Ss. Annunziata, Chieti, Italy, ²¹Hospital Niguarda Ca' Granda, Milan, Italy, ²²Hepatology Unit, Ospedale San Massimo, Penne, Italy, ²³Internal Medicine, Humanitas University, Rozzano, Milan, Italy, ²⁴Infectious Disease Unit, Avezzano General Hospital, Avezzano, Italy, ²⁵Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ²⁶Infectious Disease, Hospital of Teramo, ²⁷University of Bologna, Bologna, Italy

P2 **Pre-emptive post-transplant HCV treatment with IFN-free DAA: preliminary results from a pilot study**

L. Pasulo¹, C. Iegri¹, C. Mazzarelli², M. Colpani¹, G. Perricone², R. Viganò², M. Colledan¹, De Carlis², A. Corti², E. Mazza², A. De Gasperi², M. Marchesi¹, F. Donato³, S. Fagioli¹, L. Belli²

¹USC di Gastroenterologia, ASST Papa Giovanni XXIII, Bergamo, Italia, ²Ospedale Niguarda Ca' Granda, Milano, ³I.R.C.C.S. Ospedale Maggiore di Milano, Policlinico, Italia

P3 **CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection**

N. Capoluongo¹, R. Zampino², G. Bellini³, M. Stanzione⁴, A. Marrone², M. Macera¹, L.E. Adinolfi², E. Miraglia Del Giudice⁵, I. Gentile⁶, E. Sagnelli¹, F. Rossi⁵, N. Coppola¹

¹Department of Mental Health and Public Medicine, Second University of Naples, ITALY, ²Internal Medicine and Hepatology, Second University of Naples, ³Department of Experimental Medicine, Second University of Naples, ⁴Department of Clinical and Experimental Medicine and Surgery, Second University of Naples, Naples, Italy, ⁵Department of Woman, Child and of General and Specialized Surgery, Second University of Naples, ⁶Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy

P4 **HCV genotype: comparison of LiPA 1.0, LiPA 2.0 and NS5B phylogenetic analysis**

E. Rappazzo¹, C. Arcuri¹, P. Canepa¹, S. Delucis¹, G. De Rosa², L. Sticchi^{1,2}, B. Bruzzone²

¹Igiene Unit, Department of Health Sciences, University of Genoa, IRCCS AOU San Martino - IST, Genoa, Italy, ²Igiene Unit, IRCCS AOU San Martino - IST, Genoa, Italy

P5 **DAA Resistance Associated Mutations in Patient Failing Treatment before and after therapy**

S. Paolucci¹, M. Premoli¹, R. Gulminetti², S. Novati², R. Maserati², G. Barbarini³, P. Sacchi³, A. Girello³, S. Ludovisi², S. Cima³, F. Baldanti¹

¹Molecular Virology Unit, Virology and Microbiology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ²Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ³Division of Infectious and Tropical Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

P6 **DxN VERIS System for HCV viral load monitoring in the era of second wave DAAs (Direct-Acting Antiviral Agents)**

A. Mancon¹, A. Lombardi¹, D. Mileto¹, C.F. Magni², L. Milazzo², N. Zanchetta¹, E. Angeli², G. Gubertini², M. Galli², M.R. Gismondo¹, V. Micheli¹

¹Laboratory of Clinical Microbiology, Virology and Bioemergencies - ASST FBF Sacco, Milan, ²Infectious Diseases Department - ASST FBF Sacco, Milan

P7 **Platelet to lymphocyte ratio (PLR) and Neutrophil to lymphocyte ratio (NLR) are strictly related with FIB 4 score in HIV/HCVRNA positive co-infected patients starting Highly active antiretroviral therapy (HAART) – a Master Cohort study**

P. Nasta¹, M. Giralda², C. Pezzoli¹, I. Izzo¹, F. Maggiolo³, E. de Filippo³, N. Ladisa⁴, R. Gagliardini⁵, A. Gori⁶, F. Baragli⁷, L. Sighinolfi⁸, F. Zacchi⁹, F. Castelli¹⁰

¹Clinic of Infectious and Tropical Diseases, Spedali Civili General Hospital, Brescia, Italy, ²Infectious Diseases and International Health Foundation, Brescia, Italy, ³Clinic of Infectious Diseases, Ospedale Giovanni XXIII, Bergamo, Italy, ⁴Clinic of Infectious Diseases, Ospedale Policlinico, Bari, Italy, ⁵Clinic of Infectious Diseases, "Sacro Cuore" Catholic University of Rome, Rome, Italy, ⁶Clinic of Infectious Diseases, San Gerardo Hospital, Monza, Italy, ⁷Clinic of Infectious Diseases, Ospedale S.M. Annunziata, Florence, Italy, ⁸Clinic of Infectious Diseases, Ospedale Sant'Anna, Ferrara, Italy, ⁹Clinic of Infectious Diseases, Istituti Ospitalieri, Cremona, Italy, ¹⁰University Division of Infectious and Tropical Diseases, University of Brescia-Spedali Civili General Hospital, Brescia, Italy

P8 **Rapid Screening for HCV infection in Dental Clinic: San Raffaele Pilot Study**

M.R. Parisi¹, S. Tecco², G. Gastaldi², E. Polizzi², S. D'Amicantonio², S. Negri³, I. Gardini⁴, K. Schlusnus⁵, E. Gherlone², P. Cappare², A. Lazzarin¹

¹Department of Infectious Diseases, Vita-Salute University, IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Unit of Dentistry - Dental School, IRCCS San Raffaele Scientific Institute, Milan, Italy, ³ANLAIDS Sezione Lombarda, Milan, Italy, ⁴EpaC Onlus, Milan, Italy, ⁵AIRON Communication, Milan, Italy

- P9 HBV Reactivation in antiviral prophylaxis in patients under immunosuppressive treatment for haematological diseases**
N. Capoluongo¹, M. Macera¹, S. De Pascalis¹, S. Guastafierro², A. Sica², M. Ferrara², M. Pisaturo¹, L. Onorato¹, N. Coppola¹
¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy, ²Hematology Unit, Second University of Naples, Naples, Italy
- P10 Baseline HCV NS3 variants are frequently harbored by HIV/HCV coinfected naïve patients: single centre experience**
T. Ruggiero¹, A. Proietti¹, E. Burdino¹, G. Gregori¹, T. Alice¹, M.G. Milia¹, L. Bogleione², L. Trentini², C. Alcantarin², S. Bonora², G. Di Perri², V. Ghisetti²
¹Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Torino, Italy, ²Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
- P11 Virological characteristics of HBsAg-negative patients with acute hepatitis B**
G. Di Caprio^{1,2}, M. Starace¹, L. Alessio^{1,2}, C. Minichini¹, V. Messina², M. Pisaturo², E. Sagnelli¹, P. Filippini^{1,2}, N. Coppola¹
¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy, ²Infectious diseases Unit, A.O. Caserta, Italy
- P12 Recovery of the Irritative Basic EEG Rhythm in Patients with Chronic Hepatitis C After New DAAs Treatment**
E. Teti¹, P. Onorati², L. Sarmati¹, A. Ricciardi¹, C. Sarrecchia¹, G. Toma², A. Pennica³, C. Babiloni², G. Noce², M. Andreoni¹
¹Clinical Infectious Diseases, Tor Vergata University, Rome, Italy, ²Department of Physiology, Sapienza University of Rome, Italy, ³Clinical Infectious Diseases, Sant'Andrea Hospital, Sapienza University of Rome, Italy
- P13 HCV-RNA monitoring in HIV/HCV co-infected patients starting a DAA containing regimen**
A. Callegaro, M. Arosio, G. Cologni, D. Guarneri, G.P. Gregis, G.P. Quinzan, F. Maggiolo
ASST Papa Giovanni XXIII, Bergamo

CLINICAL DIAGNOSTICS HIV

- P14 Pre-existent NRTI and NNRTI resistance and pre-therapy viremia >500,000 cps/mL are associated with a higher risk to lose virological suppression in HIV-1 infected patients switching to a tenofovir/emtricitabine/rilpivirine single-tablet regimen**
D. Di Carlo¹, D. Armenia¹, A. Calcagno², G. Vendemiati², F. Forbici³, A. Bertoli¹, G. Berno³, S. Carta³, F. Continenza³, L. Fabeni³, R. Bellagamba⁴, S. Cicalini⁴, A. Ammassari⁴, R. Libertone⁴, M. Zaccarelli⁴, V. Ghisetti², M. Andreoni⁵, F. Ceccherini-Silberstein¹, S. Bonora², G. Di Perri², A. Antinori⁴, C.F. Perno³, M.M. Santoro¹
¹University of Rome Tor Vergata, Experimental Medicine and Surgery, Rome, Italy, ²University of Turin, Division of Infectious Diseases, Turin, Italy, ³National Institute for Infectious Diseases L. Spallanzani, IRCCS, Antiretroviral Drugs Monitoring Unit, Rome, Italy, ⁴National Institute for Infectious Diseases L. Spallanzani, IRCCS, Infectious Diseases Division, Rome, Italy, ⁵University of Rome Tor Vergata, Systems Medicine, Rome, Italy
- P15 Liver transplantation in HIV-positive patients: the initial experience of two northern Italy transplant centers**
C. Di Benedetto¹, C. Iegri¹, L. Pasulo¹, G. Travi², C. Moiol², M. Colledan¹, A. De Carlis², C. Mazzarelli², G. Cologni¹, A. Corti², E. Mazza², M. Marchesi¹, A. De Gasperi¹, L. Belli¹, S. Fagioli¹, M. Puoti²
¹USC di Gastroenterologia, ASST Papa Giovanni XXIII, Bergamo, Italia, ²USC di Malattie Infettive, ASST Niguarda Ca' Granda, Milano, Italia
- P16 Is it still worthwhile perform quarterly CD4+ T lymphocyte cell count in HIV-1 infected patients with stable HIV-RNA <50 copies/ml?**
M. Montefiori¹, D. Sirello², M. Ameri¹, G. Cenderello³, E. Di Bella¹, L. Taramasso², B. Giannini⁴, M. Giacomini⁴, C. Viscoli⁵, G. Cassola², A. Di Biagio²
¹Department of Economics, University of Genoa, Genoa, Italy, ²Infectious Disease Clinic, IRCCS San Martino – IST Hospital, Genoa, Italy, ³EO Galliera Hospital, Genoa, Italy, ⁴Department of Informatics, Bioengineering, Robotics and System Engineering, University of Genoa, Genoa, Italy
- P17 Determinants of HIV residual viremia patterns during successful first-line cART**
A. Amendola, G. Bibbolino, A. Ammassari, A. Navarra, G. Rozera, I. Abbate, C. Pinnetti, E. Girardi and M.R. Capobianchi
Laboratory of Virology, INMI "L. Spallanzani", Rome; Clinical Department, INMI "L. Spallanzani" Rome, Epidemiology Department, INMI "L. Spallanzani" Rome, Italy
- P18 TM6SF2 E167E variant is associated with a higher serum cholesterol values and carotid intima-media thickness in patients with HIV infection**
S. Martini¹, G. Di Caprio¹, A. Cascone¹, G. De Stefano², M. Starace³, N. Farella², C. Minichini³, G. Cirillo⁴, L. Alessio¹, V. Iodice², E. Miraglia De Giudice⁴, N. Coppola^{1,3}
¹HIV Unit, Second University of Naples, Naples Italy, ²IX Interventional Ultrasound Unit for Infectious Diseases- AORN dei Colli-P.O. Cotugno- Naples, Naples Italy, ³Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples Italy, ⁴Pediatric Unit, Second University of Naples, Naples Italy
- P19 Development of an in-house phenotypic HIV-1 coreceptor tropism assay**
A. Giannini¹, F. Saladini¹, V. Micheli², B. Bruzzone³, M. Zazzi¹, I. Vicenti¹
¹Dipartimento di Biotecnologie Mediche, Università di Siena, ²U.O. Microbiologia e Virologia, Ospedale L. Sacco, Milano, ³U.O. Igiene, IRCCS AOU San Martino-IST, Genova

- P20 Evaluation of integrase inhibitor genotyping tests for clinical detection of integrase resistance mutations in raltegravir-experienced patients**
T. Alice¹, M.G. Milia¹, E. Burdino¹, G. Gregori¹, T. Ruggiero¹, A. Proietti¹, B. Simoncelli¹, L. Marinaro², A. Calcagno², G. Orofino², S. Bonora² and V. Ghisetti¹
¹Laboratory of Microbiology and Virology, Amedeo di Savoia Hospital, Torino, Italy, ²Department of Infectious Disease, Amedeo di Savoia Hospital, Torino
- P21 A difficult to diagnose pneumonia in HIV late presenter**
F. Bulla, F. Zoboli, S. Sica, T.A. Santantonio
Department of Infectious Diseases, University of Foggia
- P22 Different biochemical lipid profiles in HIV+ and HIV-atherosclerotic plaques**
A. D'Abramo¹, G. d'Ettore¹, M.A. Zingaropoli¹, A. Macone², A. Oliva¹, C. D'Agostino¹, M. Iannetta¹, C.M. Mastroianni¹, V. Vullo¹
¹Department of Public Health and Infectious Diseases "Sapienza" University of Rome, ²Department of Biochemical Science "A. Rossi Fanelli", "Sapienza", University of Rome

CLINICAL HEPATITIS

- P23 Treating HCV positive Italian inmates with DAAs: a clinical experience in three major Correctional Houses of Milan**
R. Ranieri¹, A. Foschi¹, M. Casana¹, A. Radice¹, C. D'Angelo², A. De Bona³, F. Bai³, C. Lari⁴, A. d'Arminio Monforte³
¹Infectious Diseases Consultants Milano Opera, Milano San Vittore, and Milano Bollate Correctional Houses, Santi Paolo e Carlo Hospital, University of Milan, ²Pharmacy Unit, Santi Paolo e Carlo Hospital, University of Milan, ³Clinic of Infectious Diseases, Santi Paolo e Carlo Hospital, University of Milan, ⁴Health Department, Santi Paolo e Carlo Hospital, University of Milan
- P24 High rates of tolerability and efficacy of second generation Direct Acting Antivirals (DAA) regimens in a real life population of HCV/HIV co-infected patients with cirrhosis or advanced fibrosis from a large regional database in Tuscany**
E. Salomoni¹, B. Valoriani², M. Pozzi¹, S. Sani³, R. Cinelli³, F. Menichetti⁴, R. Iapace⁴, B. Rossetti⁵, C. Nencioni⁶, D. Tacconi⁶, A. Nerli⁷, P. Blanc⁸, D. Bartolozzi¹ and A. De Luca^{2,9} on behalf of SIMIT Toscana and Epatologi Toscani
¹Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, Firenze, ²UDC Malattie Infettive Universitarie, AOU Senese, Siena, ³Malattie Infettive, Spedali Riuniti di Livorno, Livorno, ⁴Malattie Infettive, Azienda Ospedaliero-Universitaria pisana, Pisa, ⁵Malattie Infettive, Ospedale Misericordia, Grosseto, ⁶Malattie Infettive, Ospedale S. Donato, Arezzo, ⁷Malattie Infettive, Ospedale di Prato, Prato, ⁸Malattie Infettive e Tropicali, Ospedale Santa Maria Annunziata, Firenze, ⁹Dip Biotecnologie Mediche, Università di Siena, Siena
- P25 Challenges of treating HIV-HCV co-infected patients with Directly Acting Agents (DAAs) - a real life multicenter study cohort**
L.A. Nicolini¹, E. Pontali², M. Setti³, R. Prinapori⁴, V. Bartolacci⁵, P. De Leo⁶, A. Di Biagio¹, G. Cenderello², C. Dentone⁷, L. Ferrari¹, M. Izzo⁷, G. Ferrea⁷, S. Artoli⁴, M. Anselmo⁶, G. Riccio⁷, G. Cassola², C. Viscoli¹
¹IRCCS AOU San Martino-IST, University of Genoa, ²Infectious Diseases Unit, Galliera Hospital, Genoa, ³Internal Medicine and Clinical Immunology Unit, IRCCS AOU SAN MARTINO-IST, Genoa, ⁴Infectious Diseases Unit, Sant'Andrea Hospital, La Spezia, ⁵Infectious Diseases Unit, S. M. Misericordia Hospital, Albenga, ⁶Infectious Diseases Unit, S. Paolo Hospital, Savona, ⁷Infectious Diseases Unit, S. Remo Hospital, San Remo
- P26 Early serum HBsAg decline is a strong predictor of sustained response to pegylated interferon alfa-2a in patients with chronic hepatitis B HBeAg-negative and E genotype**
L. Bogleione, J. Cusato, G. Cariti, G. Di Perri, A. D'Avolio
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital
- P27 The new direct acting-antiviral agents rapidly clean up the reservoir of hepatitis C virus**
F. Calò¹, S. De Pascalis¹, S. Martini², M. Macera¹, M. Starace¹, L. Onorato¹, A. Cascone², G. Di Caprio¹, C. Minichini¹, N. Coppola^{1,2}
¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy, ²HIV Unit, Second University of Naples, Naples, Italy
- P28 Real practice experience in a referral site during 2015 in treating chronic HCV patients**
C. Magni, E. Angeli, M. Bolis, M. Colaneri, R. Giorgi, G. Gubertini, S. Landonio, A. Mainini, F. Niero, M. Schiavini and G. Rizzardini
¹Divisione Malattie Infettive ASST Fatebenefratelli-Sacco, Milano
- P29 Clinical impact of vaccine-escape HBsAg mutants circulating among HBV-infected patients: high rate of atypical serological profiles and increased level of viremia and transaminases**
R. Salpini¹, L. Fabeni², A. Battisti¹, L. Colagrossi¹, C. Alteri¹, A. Bertoli¹, D. Di Carlo¹, M. Pollicita¹, D. Armenia¹, L. Carioti¹, M.C. Bellocchi¹, F. Continenza², R. Sbrocchi¹, F. Di Santo¹, C. Sarrecchia³, M. Lichtner⁴, C. Mastroianni⁴, G. De Sanctis⁵, M. Paoloni⁶, M. Marignani⁷, C. Pasquazzi⁷, D. Di Paolo⁸, N. Iapadre⁹, T. Mari¹⁰, C. Puoti¹¹, G. Parruti¹², S. Romano¹³, M. Visca¹³, I. Vecchie¹⁴, M. Andreoni³, G. Cappiello¹³, A. Spanò¹³, M. Angelico⁸, C.F. Perno¹, V. Svischer¹
¹Tor Vergata University, Department of Experimental Medicine and Surgery, Rome, Italy, ²INMI L. Spallanzani, Antiretroviral Drug Monitoring Unit, Rome, Italy, ³Tor Vergata University Hospital, Infectious Diseases Unit, Rome, Italy, ⁴"Sapienza" University, Department of Public Health and Infectious Disease, Rome, Italy, ⁵"Umberto I" University Hospital, Rome, Italy, ⁶"S.S. Filippo e Nicola" Hospital, Infectious Disease Unit, Avezzano, Italy, ⁷"S. Andrea Hospital", Department of Gastroenterology, Rome, Italy, ⁸Tor Vergata University Hospital, Hepatology Unit, Rome, Italy, ⁹"San Salvatore Hospital", L'Aquila, Italy, ¹⁰"Nuovo Regina Margherita" Hospital, Rome, Italy, ¹¹Department of Internal Medicine and Liver Unit, Marino Hospital, Rome, Italy, ¹²Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ¹³Microbiology and Virology Unit, "S. Pertini" Hospital, Rome, Italy, ¹⁴Clinic of Infectious Diseases, Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy

- P30 Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir in HCV infected patients with or without HIV infection: a multicenter observational study**
G. Bruno¹, C. Fabrizio¹, E. Milano¹, R. Dell'Acqua¹, M. Fasano², G. Buccoliero³, A. Tartaglia², A. Giammarino², M. Milella¹, A. Saracino¹, G. Angarano¹
¹Clinic of Infectious Diseases, University of Bari, ²Clinic of Infectious Diseases, University of Foggia, ³Oncohaematologic Department, Infectious Diseases, "San G. Moscati" Hospital, ASL Taranto
- P31 Cannabinoid Receptor 2-63-RR variant is associated with a more severe liver damage in CH patients with HIV/HCV coinfection and may favor the acquisition of HIV infection**
C. Sagnelli¹, M. Merli², C. Uberti-Foppa², H. Hasson², G. Bellini³, M. Starace⁴, C. Minichini⁴, S. Salpietro², E. Messina², M. Parisi², N. Capoluongo⁴, N. Coppola⁴, A. Lazzarin², E. Sagnelli⁴, F. Rossi³
¹Department Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples, Italy, ²Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy, ³Department of Pediatrics, Second University of Naples, Naples, Italy, ⁴Department Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy
- P32 DAA treatment in HCV-HIV co-infected patients on waiting list for liver transplant**
G. Guaraldi¹, S. Zona¹, G. Dolci¹, A. Santoro¹, M. Menozzi¹, E. Franceschini¹, B. Beghetto¹, A.R. Silva², F. Carli¹, C. Mussini¹
¹Infectious Diseases Unit, University Policlinico Hospital, Modena, Italy, ²Infectious Diseases Unit at the Royal Liverpool University Hospital, Liverpool, UK
- P33 Assessment of liver fibrosis in patients receiving DAAs: the experience of the SCOLTA project**
L.A. Nicolini¹, E. Ricci², B. Menzaghi³, V. Fiore⁴, P. Bonfanti⁵, F. Benanti⁶, F. Vichi⁷, R. Gulminetti⁸, G.V. De Socio⁹, C. Magni², V.C. Martinelli¹⁰, M. Fabbiani¹¹, C. Grosso¹², K. Falasca¹³, A. Di Biagio¹, T. Quirino³ on behalf of CISA group
¹Infectious Diseases Unit, Department of Social Health (DISSAL), University of Genoa-IRCCS San Martino IST, Genoa, ²Infectious Diseases Unit, ASST Fatebenefratelli Sacco, Milan, ³Infectious Diseases Unit, ASST Valle Olona - Busto Arsizio, Busto Arsizio, ⁴Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ⁵Infectious Diseases, A. Manzoni Hospital, Lecco, ⁶Infectious Diseases, Garibaldi Hospital, Catania, Italy, ⁷Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, ⁸Infectious Diseases Unit, San Matteo Hospital, Pavia, ⁹Infectious Diseases Unit, Santa Maria Hospital, Perugia, ¹⁰Infectious Diseases Unit, Careggi Hospital, Firenze, ¹¹Infectious Diseases Unit, San Gerardo Hospital, Monza, ¹²Infectious Diseases Unit, M. Bufalini Hospital, Cesena, ¹³Infectious Diseases Unit, University of Chieti
- P34 Treatment rate for HCV in the DAA's era in HIV co-infected patients: data from an Italian cohort**
G. Cuomo, C. Puzzolante, C. Mussini, V. Borghi
Clinic of Infectious diseases, AOU Policlinico di Modena, Italy
- P35 DAAs therapy in HIV/HCV co-infected and HCV-monoinfected cirrhotic patients**
G. Chieffo, L. Pagnucco, R. Gulminetti, S. Novati, D. Zanaboni, R. Maserati, L. Minoli
Infectious Diseases Department, Fondazione IRCCS Policlinico San Matteo, Pavia
- P36 Efficacy of the new DAAs: one year of HCV treatment in Italy. Experience of the HCV-SCOLTA project**
B. Menzaghi¹, E. Ricci², F. Peruzzo³, L. Nicolini⁴, P. Bonfanti⁵, S. Passerini⁶, M. Gussio⁶, C. Martinelli⁷, F. Vichi⁸, A. Patacca⁹, R. Gulminetti¹⁰, A. Soria¹¹, S. Coladonato¹², M. Farinazzo¹ e T. Quirino³ per il Gruppo C.I.S.A.I.
¹Unit of Infectious Diseases, ASST Valle Olona - Busto Arsizio, ²Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, ³Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ⁴Infectious Diseases, San Martino Hospital Genoa, University of Genoa, ⁵Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, ⁶Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, ⁷Unit of Infectious Diseases, Careggi Hospital, Firenze, ⁸Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Firenze, ⁹Unit of Infectious Diseases, Santa Maria Hospital, Perugia, ¹⁰Unit of Infectious Diseases, San Matteo Hospital, Pavia, ¹¹Unit of Infectious Diseases, San Gerardo Hospital, Monza, ¹²Unit of Infectious Diseases, University of Chieti
- P37 Access to new generation DAA treatment in HIV-negative and HIV-positive individuals with F3-F4 stage of liver disease: results from PITER and Icona/HepalCONA cohorts**
A. Cozzi Lepri on behalf of PITER and ICONA/HepalCONA Studies
<https://www.dropbox.com/s/zuijny7mnbj2ff/Icona%2C%20Hepalcona%20and%20Piter%20Study%20Groups.docx?dl=0>
University College London
- P38 Is DAA treatment for HCV a risk factor for developing bacterial infective complications? A single-centre case series experience**
F. Sabbatini, S. Costarelli, A. Soria, S. Trovati, A. Cappelletti, L. Alagna, L. Bisi, M. Fabbiani, G. Lapadula, A. Bandera, A. Gori
Ospedale San Gerardo Malattie Infettive, Monza
- P39 Kidney and bone toxicity among patients long-term treated with third generation Nucleotide Analogues for Chronic B Hepatitis**
V. Guardigni, R. Pascale, L. Badia, P. Viale, G. Verucchi
Policlinico S.Orsola-Malpighi, University of Bologna
- P40 Failing to achieve full HCV suppression during first month of treatment or at end of treatment is associated with decreased probability of SVR in HIV/HCV co-infected patients treated with DAA**
G. Fabbri¹, A. Ammassari¹, A. Garbuglia², F. Lupi¹, A. Amendola², R. Bellagamba¹, B. Bartolini², S. Mosti¹, I. Abbate², M. Capobianchi², A. Antinori¹, M. Zaccarelli¹
¹Clinical Department, National Institute for Infectious Diseases "L. Spallanzani", Rome, ²Virological Department, National Institute for Infectious Diseases "L. Spallanzani", Rome

- P41 Efficacy and safety of Directly Acting Antivirals in HIV-HCV coinfecting patients**
M. Schiavini¹, F. Niero¹, C. Magni¹, S. Landonio¹, E. Angeli¹, C. Gulisano¹, N. Astuti¹, L. Carenzi¹, A. Capetti¹, P. Meraviglia¹, A. Mainini¹, R. Giorgi¹, V. Micheli², G. Gubertini¹, G. Rizzardini¹
¹Department Infectious Disease, ASST-FBF-SACCO, Milan, Italy, ²Clinical Microbiology, Virology and Bioemergencies, Clinical Microbiology, Virology and Bioemergencies, ASST-FBF-SACCO, Milan, Italy
- P42 Aspartate-to-Platelet Ratio Index evaluation in a cohort of HIV/HCV infected patients treated with raltegravir**
L. Taramasso¹, E. Ricci², B. Menzaghi³, P. Vitello³, G. Orofino⁴, G. Rizzardini⁵, G. Parruti⁶, G.V. De Socio⁷, P. Bonfanti⁸, P. Bagella⁹, M. Franzetti⁵, C. Bel-lacosa¹⁰, C. Dentone¹¹, C. Martinelli¹², C. Pinnetti¹³, A. Antinori¹³, G. Penca¹⁴, B.M. Celesia¹⁵, A. Di Biagio¹ on behalf of the CISA Study Group
¹Unit of Infectious Diseases, San Martino Hospital, University of Genoa, Italy, ²Epi2004, Milan, Italy, ³Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy, ⁴Department of Infectious Diseases, Amedeo di Savoia Hospital, Turin, Italy, ⁵Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy, ⁶Department of Infectious Diseases, Pescara Hospital, Italy, ⁷Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ⁸Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, ⁹Unit of Infectious Diseases, University of Sassari, Italy, ¹⁰Unit of Infectious Diseases, University of Bari, Italy, ¹¹Unit of Infectious Diseases, Sanremo Hospital, Sanremo, Italy, ¹²Unit of Infectious Diseases, Careggi Hospital, Firenze, Italy, ¹³Clinical Department, National Institute of Infectious Disease L. Spallanzani, Roma, Italy, ¹⁴Unit of Infectious Diseases, Galliera Hospital, Genoa, Italy, ¹⁵Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy
- P43 Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg negative subjects: a meta-analysis**
L. Onorato¹, C. Sagnelli², E. Sagnelli¹, I.F. Angelillo³, N. Coppola¹
¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy, ²Department of Clinical and Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples, Italy, ³Department of Experimental Medicine, Second University of Naples, Naples, Italy
- P44 Marked Reduction of Adiponectin Plasma Levels in HCV Diabetic and HIV coinfecting Patients Receiving Interferon(IFN)-containing and IFN-free Treatments**
P. Pavone¹, S. Serafino¹, N. Giustini¹, I. Schietroma¹, G. Corano-Scheri¹, C. Mascia^{1,2}, T. Tieghi^{1,2}, G. d'Ettore¹, M. Lichtner^{1,2}, G. Passavanti¹, C.M. Mastroianni^{1,2}, V. Vullo¹
¹Public Health and Infectious Diseases Department, Sapienza University of Rome, ²Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina
- P45 DAAs safety and role in hepatic necrosis improvement: do HCV mono-infected and HIV/HCV co-infected patients differ?**
M. Chiamenti, M. Cerrone, A. De Bona, F. Bai, A. Raimondi, G. Marchetti, A. d'Arminio Monforte
Clinic of Infectious Diseases, "San Paolo" Hospital, University of Milan
- P46 Primary biliary cholangitis–autoimmune hepatitis overlap syndrome in a patient affected by HCV-related hepatic cyrrsis in DAA era**
E. Ciraci¹, J. Valerio², F. Camilli³, S. Semeraro⁴, M. Criscuolo⁵, P. Gatti⁶
¹UO Medicina Interna, Ospedale di Ostuni, ASL BR, ²Servizio di Anatomia e Istologia Patologica, Ospedale Perrino, ASL BR, ³UOS Biologia Molecolare, Ospedale Perrino, ASL BR, ⁴UO Medicina Interna, Ospedale di Ostuni, ASL BR, ⁵Servizio di Anatomia e Istologia Patologica, Ospedale Perrino, ASL BR, ⁶UO Medicina Interna, Ospedale di Ostuni, ASL BR
- P47 Safe and Well Tolerated Standard Dose Sofosbuvir in an HIV/HCV coinfecting patient with HIVAN and Pre-End-Stage Renal Disease**
L. Foroghi, E. Teti, A. Ricciardi, C. Stingone, C. Cerva, G. Maffongelli, E. Gentilotti, C. Sarrechia, L. Sarmati, M. Andreoni
Infectious Diseases Unit, Tor Vergata University, Rome, Italy
- P48 Absence of correlation between drug plasma levels and virological failure in Sofosbuvir + Daclatasvir therapy**
S. Ianniruberto¹, L. Badia¹, A. Prezzavento², C. Assirelli¹, V. Guardigni¹, M. Conti³, P. Viale¹, G. Verucchi¹
¹Infectious Diseases Unit, Department of Medical and Surgical Sciences, Sant'Orsola-Malpighi Hospital, Alma Mater University of Bologna, Italy, ²Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Messina, Italy, ³Centralized Analysis Laboratory, S. Orsola-Malpighi University Hospital, Bologna, Italy
- P49 Early changes in non invasive assessment of liver fibrosis in hepatitis C virus-infected patients treated with DAAs: preliminary reports**
C. Iegri, L. Pasulo, M. Colpani, A. Baldan, G. Magini, M. De Giorgio, G. Gaffuri, L. Sangiovanni, M.G. Lucà, G. Gibiino, S. Fagioli
Department of Gastroenterology and Liver Transplant Unit, ASST Papa Giovanni XXIII, Bergamo
- P50 Effects on bone metabolism of long term antiviral therapy for the treatment of chronic hepatitis B: monocentric experience between 2007 and 2015**
F. Barbaro¹, E.M. Erne¹, V. Camozzi², A. Cattelan¹
¹Unità Operativa Complessa Malattie Infettive, Azienda Ospedaliera Universitaria, Padova, Italy, ²Unità Operativa Complessa Endocrinologia, Azienda Ospedaliera Universitaria, Padova, Italy
- P51 Changes in quality of life during treatment of HCV infection with directly acting antivirals (DAAS)**
A. Venturini, E. Pontali, M.P. Crisalli, G. Cenderello, G. Cassola
Department of Infectious Diseases - Galliera Hospital - Genova - Italy

- P52 Use of new direct-acting antiviral agents (DAA) for treatment of hepatitis C virus in myasthenia gravis: a case report**
P. Lanza, I. Izzo, S. Casari, A. Spinetti, S. Zalron, L. Urbinati, S. Odolini, P. Nasta, L. Praticò, A. Vavassori, A. Apostoli, E. Chiari, C. Grecchi, E. Festa, F. Castelli
University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
- P53 Efficacy of new Direct Acting Antivirals in PI-experienced HCV positive patients**
C. Magni¹, E. Angeli¹, N. Astuti¹, M. Bolis¹, M. Colaneri¹, R. Giorgi¹, G. Gubertini¹, C. Gulisano¹, S. Landonio¹, A. Mancon², A. Mainini¹, D. Mileto², V. Micheli², F. Niero¹, M. Schiavini¹, G. Rizzardini¹
¹ Department of Infectious Diseases ASST FBF SACCO, Milano, ² Clinical Microbiology, Virology and Bioemergencies ASST FBF SACCO, Milano
- P54 Real-life data: efficacy and safety of long term tenofovir in the prevention and treatment of hepatitis B virus (HBV) reactivation in patients with haematological malignancies**
G. Gentile, A. Salaroli, F. De Angelis, A. Di Rocco, A. Micozzi, A. Pulsoni, M. Martelli, F. Mauro, M.T. Petrucci, W. Barberi, S. Chiaretti, M.A. Lozzi, D. Rivanera, G. Antonelli, R. Foà
Sapienza University Hospital Rome
- P55 Adverse events of the new DAAs: cardiac toxicity**
K. Falasca, C. Ucciferri, G. Ruggieri, M. Di Carlo, F. Ricci, S. Coladonato, F. Vignale, E. Di Ilio, J. Vecchiet
Clinic of Infectious Diseases – Department of Medicine and Science of Aging, University “G. d’Annunzio” Chieti-Pescara, Italy
- P56 The importance of recommending antiviral prophylaxis: a case report about HBV-reactivation during immunosuppressive drug therapy**
C. Monari¹, L. Onorato¹, G. Di Caprio¹, M. Macera¹, S. De Pascalis¹, S. Guastafierro², M. Starace¹, N. Coppola¹
¹ Department of Mental Health and Public Medicine, Infectious Diseases Unit, Second University of Naples, Naples, Italy, ² Hematology Unit, Second University of Naples, Naples, Italy
- P57 Early Virologic Response and adherence of DAAs in the treatment of Hepatitis C Virus infection in "Mater Domini" University Hospital - Catanzaro (Italy)**
M. De Fina¹, A.E. De Francesco¹, B. Caroleo², M.C. Zito¹, M.D. Naturale³, F. Perticone⁴
¹ "Mater Domini" University Hospital, Pharmacy, Catanzaro, Italy, ² Internal Medicine Clinics, Cardiovascular Geriatric Diseases Unit, "Mater Domini" University Hospital, Catanzaro, Italy, ³ ALTEMS Università Cattolica del Sacro Cuore Roma, ⁴ Director of Internal Medicine Residency Program, "Mater Domini" University Hospital, Catanzaro, Italy

CLINICAL HIV

- P58 Alexithymia Predicts Increased IMT and Vascular Events in a Multicentric HIV Cohort**
F. Socio¹, F. Vadini¹, G. Nunnari², G. Madeddu³, G. De Socio⁴, F. Vichi⁵, M. Pinzone⁶, P. Bonfanti⁷, P. Maggi⁷ and G. Parruti¹ for the CISA study group
¹ Infectious Diseases Unit, Pescara General Hospital, Italy, ² Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases at the University of Catania, Catania, Italy, ³ Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ⁴ Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, ⁵ S. Maria Annunziata Hospital, Florence, Italy, ⁶ Alessandro Manzoni Hospital Authority, Lecco, Italy, ⁷ Infectious Diseases Clinic, University Hospital Policlinico, Bari, Italy, for the CISA study Group
- P59 Metabolic impact, efficacy and durability of switching from a PI/r- to an INI-containing regimen in a monocentric cohort of drug-experienced HIV-positive subjects**
S. Rusconi, L. Oreni, T. Formenti, E. Colella, V. Di Cristo, M. Franzetti, A. Giacomelli, A. Lupo, A.L. Ridolfo and M. Galli
Infectious Diseases Unit, DIBIC "Luigi Sacco", University of Milan
- P60 Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients**
N. Gianotti¹, A. Poli^{1,2}, M. Franzini³, P. Tadini³, N. Galizzi^{1,2}, A. Carbone^{1,2}, M. Merli^{1,2}, M. Ripa^{1,2}, S. Chiappetta^{1,2}, C. Otolini^{1,2}, A. Andolina^{1,2}, A. Lazzarin^{1,2}, A. Castagna^{1,2}
¹ Infectious Diseases, IRCCS San Raffaele, Milano, Milano, Italy, ² Università Vita-Salute San Raffaele, Milano, Milano, Italy, ³ Pharmacy, IRCCS San Raffaele, Milano, Milano, Italy
- P61 Impact of polypharmacy on antiretroviral prescription in people living with HIV**
M. Menozzi¹, A.R. Silva², S. Zona¹, C. Stentarelli¹, A. Malagoli¹, C. Mussi³, C. Mussini¹, S. Khoo⁴, M. Cesari⁵, G. Guaraldi¹
¹ Metabolic Clinic, Infectious Diseases Unit, University Policlinico Hospital, Modena, Italy, ² Infectious Diseases Unit at the Royal Liverpool University Hospital, Liverpool, UK, ³ Geriatrics Division, University of Modena and Reggio Emilia, Modena, Italy, ⁴ Infectious Diseases Unit at the Royal Liverpool University Hospital, Liverpool, UK, ⁵ Gèrontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- P62 Neurocognitive performance and psychological symptoms improve in HIV-positive patients switching from an efavirenz- to a rilpivirine-based cART**
M. Ricotini, C. Pinnetti, P. Balestra, P. Lorenzini, R. Libertone, V. Mazzotta, M.M. Plazzi, R. Bellagamba, M. Zaccarelli, A. Antinori and A. Ammassari
National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, Rome, Italy

- P63 Health transitions across liver transplantation in HIV-positive patients**
G. Dolci¹, S. Zona¹, T. Brothers², F. Di Benedetto³, V. Serra³, G. Tarantino³, E. Franceschini¹, C. Mussini¹, K. Rockwood⁴ and G. Guaraldi¹
¹ Clinica di Malattie Infettive, A.O.U. Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ² Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada, ³ Chirurgia Oncologica Epato-bilio-pancreatica e dei Trapianti di Fegato, A.O.U. Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ⁴ Department of Medicine (Geriatric Medicine and Neurology), Dalhousie University, Halifax, Nova Scotia, Canada
- P64 Heel quantitative ultrasound (QUS) changes in patients at higher risk for cardiovascular, renal comorbidity and premature aging**
A. Leone, P. Maggi, C.R. Santoro, T. Tancon, F. Di Gennaro, G. Angarano
Institute of Infectious Diseases, Policlinico, Bari
- P65 Factors associated with virological efficacy of cART in a large single-center clinical cohort**
E. Di Filippo¹, L. Comi¹, A. Callegaro², S. Di Matteo³, M.C. Valentino³, G.M. Bruno³, D. Valenti¹, M. Rizzi¹, F. Maggiolo¹
¹ USC of Infectious Diseases, ² Laboratory of Microbiology and Virology, ASST Papa Giovanni XXIII, Bergamo, ³ S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy
- P66 Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load (TMC278HTX4002 Study)**
N. Galizzi^{1,2}, L. Galli¹, A. Poli², N. Gianotti¹, E. Carini¹, A. Bigoloni¹, G. Tambussi¹, S. Nozza¹, A. Lazzarin^{1,2}, A. Castagna^{1,2}, D. Mancusi³, R. Termini³
¹ Infectious Diseases, IRCCS San Raffaele, Milano, Milano, Italy, ² Università Vita-Salute San Raffaele, Milano, Milano, Italy, ³ Janssen-Cilag SpA, Medical Affairs, Cologno Monzese - Milano, Italy
- P67 Epidemiology and Outcomes of Antibiotic Resistant patterns of Bloodstream Infections in HIV-Patients; a 11-year Single Center Study**
E. Franceschini¹, S. Zona¹, C. Lazzaretti¹, C. Venturelli², F. Ferrari², A. Bedini¹, C. Puzolante¹, M. Meschiarì¹, G. Orlando¹, M. Codeluppi¹, F. Rumpianesi², C. Mussini¹
¹ Infectious Disease Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy, ² Unit of Microbiology and Virology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy
- P68 Pitfalls of HBV vaccination in the HIV setting: acceptance rate and grounds for refusal**
L.A. Nicolini¹, R. Pincino¹, F. Magné¹, L. Taramasso¹, L.V. Faccio², Sticchi², G. Mazzarello¹, M. Mikulska¹
¹ Infectious Diseases Unit, Department of Social Health (DISSAL), IRCCS AOU San Martino-IST, University of Genoa, Genoa, ² Section of Hygiene and Preventive Medicine, Department of Social Health (DISSAL), IRCCS AOU San Martino-IST, University of Genoa, Genoa
- P69 Integrase inhibitors with lamivudine, as maintenance-dual therapy, in a real-life clinical setting**
G. Cucchetto, M. Lanzafame, S. Nicolè, P. Del Bravo, F. Rigo, E. Lattuada, E. Concia
Unità Operativa di Malattie Infettive, Ospedale Policlinico "G.B. Rossi", Verona
- P70 PROJECT STOP Smoking in HIV patients, STOPS HIV. A multi center prospective study**
G.V. De Socio¹, M. Dell'Omo², P. Maggi³, E. Schiaroli¹, C.R. Santoro³, G. Angeli¹, C. Pallotto¹, B. Tiri⁴, C. Abeli⁵, P. Bagella⁶, F. Magné⁷, C. Molteni⁸, N. Squillace⁹, D. Francisca⁴, F. Baldelli¹, on behalf of CISA group
¹ Malattie Infettive di Perugia, ² Centro anti fumo di Medicina del Lavoro di Perugia, ³ Malattie Infettive di Bari, ⁴ Malattie Infettive di Terni, ⁵ Malattie Infettive di Busto Arsizio, ⁶ Malattie Infettive di Sassari, ⁷ Malattie Infettive di Genova, ⁸ Malattie Infettive di Lecco, ⁹ Malattie Infettive di Monza
- P71 Discordant couples with HIV infection: how is changed the behavior over the years? (DisCo cohort)**
A. Poggi¹, S. Lo Caputo², A. Degli Esposti¹, P. Pierotti¹, F. Vichi¹, F. Mazzotta¹
¹ Infectious Disease Unit, Santa Maria Annunziata Hospital, Florence, Italy, ² Clinic of Infectious Diseases, University of Bari
- P72 Health Outcomes and Cost Analysis of darunavir/ritonavir + raltegravir versus tenofovir DF/emtricitabine + darunavir/ritonavir in HIV-infected naïve adults: preliminary results from the NEAT 001/ANRS 143 Italian Pharmacoeconomics Substudy**
E. Focà¹, A. Tramarin², M. Braggion^{3,4}, A. Antinori⁵, G. Di Perri⁶, A. Castagna⁷, L. Palmisano⁸, S. Vella⁹, R. Bellagamba⁵, M. Galli⁹, A. D'Arminio Monforte¹⁰, V. Vullo¹¹, F. Castelli¹ and the NEAT 001/ANRS 143 Trial Study Group
¹ University Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, ² USSL 6, Vicenza, Italy, ³ Department of Economics, Ca' Foscari University Venice, ⁴ Veneto Institute of Oncology (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy, ⁵ INMI L. Spallanzani, Rome, Italy, ⁶ Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ⁷ Division of Infectious Diseases, San Raffaele Hospital, Vita-Salute University, Milano, ⁸ Istituto Superiore di Sanità, Rome, ⁹ Division of Infectious Diseases, DIBIC Luigi Sacco Hospital, University of Milano, ¹⁰ Division of Infectious Diseases, San Paolo Hospital, University of Milano, ¹¹ Umberto I Hospital – La Sapienza University, Rome
- P73 The effects of rosuvastatin on albuminuria and renal function in HIV-infected patients with non-end stage chronic kidney disease**
L. Calza, E. Magistrelli, V. Colangeli, I. Contadini, R. Manfredi, M.A. Di Bari, G. Legnani, P. Viale
Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, S.Orsola-Malpighi Hospital, University of Bologna

- P74 Generic antiretroviral for the treatment of HIV: a novel challenge for western countries**
M. Andreoni¹, G. Carosi², D. Cattaneo³, R. Cauda⁴, A. Lazzarin⁵ and G. Rizzardini^{6,7}
¹Infectious Disease Unit, Tor Vergata University Hospital, Rome, Italy, ²Professor Emeritus, University of Brescia, Italy, ³Unit of Clinical Pharmacology, Luigi Sacco Hospital, Milan, Italy, ⁴Department of Infectious Diseases, Catholic University of the Sacred Heart, Rome, ⁵Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy, ⁶Department of Infectious Diseases, Luigi Sacco Hospital, Milan, Italy, ⁷School of Clinical Medicine, University of the Witwatersrand, Johannesburg
- P75 Denosumab for the treatment of osteoporosis in a premenopausal HIV-positive woman: a case report**
G. Contardi¹, F. De Nard², M. Romano², L. Bogliolo², R. Maserati¹
¹Infectious Disease Dept. and ²Rheumatology Unit, Foundation I.R.C.C.S. Policlinico "San Matteo", Pavia
- P76 Reaching an HCV-free generation in HIV transplant setting**
E. Franceschini¹, S. Zona¹, G. Nardini¹, A. Santoro¹, Y. Neeman², A. Malagoli¹, E. Roncaglia¹, M. Codeluppi¹, C. Mussini¹, G. Giovanni¹
¹Infectious Disease Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy, ²Sackler Faculty of Medicine, Tel Aviv, Israel
- P77 NRTI sparing regimen including Atazanavir/r +Maraviroc versus Vitamin E add-on therapy for the treatment of non alcoholic fatty liver disease in patients with HIV infection**
C. Stentarelli, M. Menozzi, S. Zona, A. Santoro, I. Franconi, N. Riva, F. Carli, G. Dolci, C. Mussini, G. Guaraldi
Infectious Diseases Unit, University Policlinico Hospital, Modena, Italy
- P78 Clinical evolution in patients treated with atazanavir not boosted by ritonavir: focus on non-AIDS morbidity and deaths over a long-term follow-up**
M.C. Postorino¹, M. Proserpio², E. Focà³, E. Quiros-Roldan³, E. Di Filippo⁴, F. Maggiolo⁴, A. Borghetti⁵, N. Ladisa⁶, M. Di Pietro⁷, A. Gori⁸, L. Sighinolfi⁹, A. Pan¹⁰, N. Mazzini¹¹, C. Torti¹
¹Infectious Diseases Unit, University "Magna Graecia" Catanzaro, Italy, ²Department of Epidemiology, College of Public Health and Health Professions & College of Medicine, University of Florida, USA, ³University Department of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, Brescia, Italy, ⁴Clinic of Infectious Diseases of "Papa Giovanni XXIII" Hospital of Bergamo, Italy, ⁵Institute of Clinical Infectious Diseases of Catholic University of Sacred Heart, Rome, Italy, ⁶Clinic of Infectious Diseases, University of Bari, Bari, Italy, ⁷Clinic of Infectious Diseases of "Azienda Ospedaliera S.M. Annunziata" of Firenze, Italy, ⁸Clinic of Infectious Diseases, San Gerardo de' Tintori Hospital, Monza, Italy, ⁹Clinic of Infectious Diseases of "Azienda Ospedaliera S. Anna" of Ferrara, Italy, ¹⁰Clinic of Infectious Diseases of "Istituti Ospitalieri" of Cremona, Italy, ¹¹MISI Foundation
- P79 Usefulness of calcaneal quantitative ultrasound stiffness for the evaluation of bone health in HIV-1 infected subjects: comparison with dual X-ray absorptiometry**
A. Fantauzzi¹, M. Florida², F. Ceci³, D. Pastori⁴, S. Angelini⁵, V. Vullo⁵, I. Mezzaroma¹
¹Department of Clinical Medicine, Sapienza - University of Rome, ²Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità (ISS), Rome, ³Department of Experimental Medicine, Sapienza - University of Rome, ⁴Department of Internal Medicine and Medicine Specialties, Sapienza-University of Rome, ⁵Department of Public Health and Infectious Diseases, Sapienza - University of Rome
- P80 Oral cholecalciferol supplementation restores bone quality in HIV-1 infected subjects**
A. Fantauzzi¹, M. Florida², F. Ceci³, S. Angelini⁵, D. Pastori⁴, V. Vullo⁵, I. Mezzaroma¹
¹Department of Clinical Medicine, Sapienza - University of Rome, ²Department of Therapeutic Research and Medicines Evaluation, ISS, Rome, ³Department of Experimental Medicine, Sapienza - University of Rome, ⁴Department of Internal Medicine and Medical Specialties, Sapienza - University of Rome, ⁵Department of Public Health and Infectious Diseases, Sapienza - University of Rome
- P81 Effectiveness and safety of atazanavir/ritonavir+lamivudine dual therapy regimen in a real life cohort of HIV infected patients: 48 week follow-up**
S.M. Ferrara¹, A. Tartaglia², S. Sica¹, T.A. Santantonio¹
¹SC Malattie Infettive-Ospedali Riuniti di Foggia, ²Malattie Infettive-ASL Foggia
- P82 Factors associated with cART discontinuation in a large single-center clinical cohort**
E. Di Filippo¹, L. Comi¹, A. Callegaro², M.C. Valentino³, G.M. Bruno³, S. Di Matteo³, D. Valenti¹, G. Gregis¹, F. Maggiolo¹
¹USC of Infectious Diseases, ²Laboratory of Microbiology and Virology, ASST Papa Giovanni XXIII, Bergamo, ³S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy
- P83 Renal Safety during Treatment with Darunavir-based Regimens in an Italian Observational Study**
A. Antinori¹, N. Gianotti², A. Gori³, S. Rusconi⁴, R. Maserati⁵, D. Spicola⁶, G. Airoidi⁷, D. Mancus⁸, R. Termini⁹
¹Clinical Department, National Institute for Infectious Diseases "L. Spallanzani" - Rome, Italy, ²Infectious Diseases, San Raffaele Scientific Institute - Milan, Italy, ³Clinic of Infectious Diseases, San Gerardo Hospital, University of Milano-Bicocca - Monza, Italy, ⁴Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan - Milan, Italy, ⁵Clinic of Infectious Diseases, Fondazione IRCCS Policlinico "San Matteo" - Pavia, Italy, ⁶Infectious Diseases Division, Policlinico Universitario "P.Giaccone" - Palermo, Italy, ⁷Studio Associato Airoidi, Cicogna, Ghirri - Milan, Italy, ⁸Janssen-Cilag SpA, Medical Affairs, Cologno Monzese - Milan, Italy
- P84 Retention in Care of Naïve Infected Migrants**
C. Gabrielli, C. Pallotto, A. Patacca, G. Angeli, E. Schiaroli, C. Sfara, R. Papili, M.B. Pasticcini, D. Francisci, F. Baldelli
Infectious Disease Clinic, University Hospital of Perugia

- P85 Kinetics of HIV-RNA decay in paired blood and semen samples after initiation of the first antiretroviral regimen in HIV-1 infected men**
C. Fabrizio¹, A. Saracino¹, A. Volpe¹, K. Falasca², N. Ladisa¹, N. de Gennaro¹, G. Bruno¹, F. Di Gennaro¹, L. Monno¹, G. Angarano¹
¹Clinica Malattie Infettive, Università di Bari, ²Clinica Malattie Infettive, Dipartimento Medicina e Scienze dell'Invecchiamento, Università degli Studi "G. D'Annunzio" Chieti-Pescara
- P86 Efficacy of Dolutegravir-based combination antiretroviral therapy in clinical practice in Italy and Wales: results from a multicenter, international study**
G. Madeddu¹, G. Caruana¹, P. Bagella¹, F. Clark², G. Nunnari³, G. Pellicanò³, G. Angioni⁴, M. Sedda⁵, M.S. Mura⁶, A. Freedman⁶
¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ²University Hospital of Wales Pharmacy, Cardiff, UK, ³Unit of Infectious Diseases, G. Martino University Hospital, University of Messina, Italy, ⁴Department of Infectious Diseases, Santissima Trinità Hospital, ASL Cagliari, Italy, ⁵University of Cagliari, Cagliari, Italy, ⁶Department of Infectious Diseases, University Hospital of Wales, Cardiff, UK
- P87 FIB-4 values and neurocognitive function in HIV-infected patients without hepatic coinfections**
G. Madeddu¹, V. Lai¹, B. Zizi¹, F. Vadini², G.M. Calia¹, C. Lovigu¹, I. Maida¹, M. Mannazzu¹, P. Bagella¹, V. Fiore¹, F. Peruzzo¹, G. Caruana¹, S. Babudieri¹, M.S. Mura¹
¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ²Unit of Infectious Diseases, Pescara Hospital, Pescara, Italy
- P88 Cardiovascular Risk in HIV-positive Patients: Is it Time to Include Additional Biomarkers of Subclinical Disease?**
C. Montrucchio¹, A. Calcagna¹, F. D'Ascenzo², M.C. Tettoni¹, F. Ballocca², G. Orofino³, L. Trentini¹, W. Grosso Marra³, D. Penoncellì³, G. Di Perri¹ and S. Bonora¹
¹Unit of Infectious Diseases and ²Unit of Cardiology, Department of Medical Sciences, University of Torino, ³Unit of Infectious Diseases, "Divisione A", Ospedale Amedeo di Savoia, ASLTO2, Torino, Italy
- P89 Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians?**
P. Maggi¹, G.V. De Socio², S. Cicalini³, M. D'Abbraccio⁴, G. d'Ettore⁵, A. Di Biagio⁶, C. Martinelli⁷, G. Nunnari⁸, S. Rusconi⁹, L. Sighinolfi¹⁰, V. Spagnuolo¹¹, N. Squillace¹²
¹Clinica Malattie Infettive Policlinico, Bari, ²Clinica Malattie Infettive Policlinico S. Maria della Misericordia, Perugia, ³INMI L. Spallanzani, Roma, ⁴UOC. di Immunodeficienze e Malattie Infettive di Genere, P.O. "D. Cotugno" - AORN Dei Colli, Napoli, ⁵Clinica Malattie Infettive. Policlinico Umberto I, Roma, ⁶Clinica Malattie Infettive IRCCS AOU San Martino-IST, Genova, ⁷SOD Malattie Infettive e Tropicali AOU Careggi, Firenze, ⁸Clinica Malattie Infettive Policlinico, Messina, ⁹Divisione Clinizzata AOU L. Sacco, Milano, ¹⁰U.O.Malattie Infettive AOU Ferrara, ¹¹Clinica Malattie Infettive Ospedale S. Raffaele, Milano, ¹²Divisione Malattie Infettive AO S. Gerardo, Monza
- P90 Efficacy and tolerability of EVG/COBI/FTC/TDF in HIV-positive experienced-patients with detectable and undetectable baseline viremia**
G. Sterrantino¹, F. Lagi¹, S. Tekle Kiroso², I. Campolmi¹, C. Pallotto³, B. Tiri³, L.M. Saraca³, A. Patacca³, M.G. Lai⁴, D. Francisci³, A. Bartoloni^{1,2}
¹Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Careggi, Firenze, ²Dipartimento di Medicina Clinica e Sperimentale, Università di Firenze, Firenze, ³Clinica di Malattie Infettive, Università di Perugia, Perugia, ⁴Dipartimento Farmaceutico, AOU Careggi, Firenze
- P91 Impact of a diet at low fat and gluten intake in a group of HIV infected patients with high BMI**
N. Squillace, G. Cuccarese, M. Fabbiani, A. Bandera, A. Muscatello, I. Beretta, A. Soria, G. Lapadula, S. Costarelli and A. Gori
Infectious Diseases Unit, San Gerardo Hospital/University of Milano-Bicocca, Monza
- P92 Safety, efficacy and durability of INSTI (Integrase strand transfer inhibitors) in treatment naïve patients in real life**
R. Gagliardini¹, A. Bandera⁴, G. Sterrantino³, M. Colafigli², A. Mondì¹, E. Visconti¹, A. Gori⁴, R. Cauda¹, A. De Luca⁵, S. Di Giambenedetto¹, M. Fabbiani⁴
¹Catholic University of Sacred Heart, Institute of Infectious Diseases, Rome, Italy, ²Infectious Dermatology and Allergology IRCCS IFO, Roma, Italy, ³Clinic of Infectious Diseases, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy, ⁴San Gerardo Hospital, University of Milano-Bicocca, Division of Infectious Diseases, Department of Internal Medicine, Monza, Italy, ⁵Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
- P93 Determinants of frailty in HIV a viremic subjects: disability and Inflammatory Milieu**
S. Vita¹, M. Lichtner², C. Tosato¹, R. Rossi¹, R. Marocco², C. Mascia¹, V. Belvisi², C. Ajassa¹, G. d'Ettore¹, C.M. Mastroianni² and V. Vullo¹
¹Sapienza University of Rome, ²Sapienza University of Rome, Polo Pontino
- P94 Simplification to dual antiretroviral therapy in treatment-experienced HIV-1-infected patients**
A. Mastroianni¹, E. Briganti¹, F. Allegrini¹, C. Grosso¹, S. Brighi¹, C. Antonini¹, S. Di Cesare¹, L. Bonvegna¹, M. Magni¹, G.F. Ravaglia², F. Pieraccini², C. Cancellieri¹
¹U.O. Malattie Infettive, P.O. "G.B. Morgagni - L.Pierantoni Forlì & P.O. "M.Bufalini" Cesena, ²Farmacia, P.O. "G.B. Morgagni - L.Pierantoni, Forlì, Azienda USL della Romagna
- P95 Rilpivirine association with abacavir/lamivudine or tenofovir/emtricitabine: changes in renal function in the clinical practice**
G. Cucchetto, M. Lanzafame, S. Nicolè, P. Del Bravo, F. Rigo, E. Lattuada, E. Concia
Unità Operativa di Malattie Infettive, Ospedale Policlinico "G.B. Rossi", Verona
- P96 Efficacy and safety of switching from branded to generic efavirenz: one year experience**
D. Segala, M. Libanore, L. Sighinolfi
Infectious Diseases Unit, Azienda Ospedaliero Universitaria, Ferrara

- P97 Circulating ANGPTL2 Is Associated with Age and Decreased CKD-EPI in Subjects on cART**
M.R. Pinzone¹, M. Maresca¹, B.M. Celesia¹, B. Cacopardo¹, G. Nunnari²
¹Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Catania, Italy, ²Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Messina, Italy
- P98 Antiretroviral therapy for HTLV-1-related tropical spastic paraparesis: a case report**
F. Calò¹, S. De Pascalis¹, L. Onorato¹, S. Esposito², G. Tedeschi², N. Capoluongo¹, N. Coppola¹
¹Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy, ²Neurology Unit, Second University of Naples, Naples, Italy
- P99 Effectiveness of a Dolutegravir (DTG), Atazanavir/r (ATV/r) and Maraviroc (MVC)-based therapy in a HIV1/HIV2 infected experienced patient: a case report**
G. Di Filippo, G. Palmiero, A.E. Maraolo, O. Tambaro, G. Bonadies, R. Orlando
Unity of Viral Diseases including AIDS Day Hospital, AOU Federico II, Naples
- P100 Dual regimen NRTI-sparing with Maraviroc plus a ritonavir boosted PI in proactive switch for experienced HIV/HCV coinfecting patients of a multicentric cohort: data of 96 weeks of follow-up**
S. Martini¹, N. Coppola¹, G. Di Caprio¹, A. Cascone¹, A. Tartaglia², S. Ferrara², L. Alessio¹, M. Macera¹, P. Filippini¹
¹UOS Diagnosi e Terapia Immunodeficienza Acquisita della Seconda Università degli Studi di Napoli, ²UOC di Malattie Infettive della AOU Ospedali Riuniti di Foggia
- P101 Spontaneous HBV reactivation leading to liver transplantation in a HIV co-infected patient**
D. Motta¹, M.C. Moiola¹, A.M. Pazzi¹, G. Travi¹, B. Menzaghi², T. Quirino², M. Puoti¹
¹S.C. Malattie Infettive, ASST Grande Ospedale Metropolitano Niguarda, Milano, ²S.C. Malattie Infettive, ASST Valle Olona, Presidio Ospedaliero Ospedale di Circolo di Busto Arsizio
- P102 Significant association between statin-associated myalgia and vitamin D deficiency among HIV-infected patients on combination antiretroviral therapy**
L. Calza¹, E. Magistrelli¹, V. Colangeli¹, M. Borderi¹, I. Contadini¹, I. Bon², M.C. Re², P. Viale¹
¹Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, and ²Unit of Microbiology, S.Orsola-Malpighi Hospital, University of Bologna
- P103 Dolutegravir monotherapy in a small cohort of HIV-infected naive patients with <100.000 copies/ml HIV RNA load**
M. Lanzafame¹, E. Lattuada², R. Mazzi², F. Rigo², S. Nicolè², G. Cucchetto², D. Gibellini², E. Concia², S. Vento⁴
¹"Diagnosis and Therapy of HIV Infection" Unit, G.B. Rossi University Hospital, Verona, Italy, ²Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy, ³Microbiology Unit, G.B. Rossi University Hospital, Verona, Italy, ⁴Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan
- P104 Better and faster immunological recovery in early treated primary HIV infection**
D. Motta^{1,2}, E. Quiros-Roldan¹, N. Brianese¹, A. Ferraresi¹, A. Bonito¹, E. Domenighini¹, S. Casari¹, M.C. Pezzoli¹, F. Castelli¹, E. Focà¹
¹Department of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, ²SC of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milano
- P105 A multidisciplinary approach to HIV lipodystrophic syndrome in Regione Piemonte: final results of the pilot project**
G.C. Orofino¹, D. Penoncelli¹, M. Guastavigna¹, M. Farenga¹, S. Carosella¹, F. Tomassetti¹, D. Demarie¹, S. Lupo¹, F. Busso¹, M.C. Tettoni¹, M. Zignin², P. Caramello¹
¹Ambulatorio per il trattamento dei dismetabolismi e della sindrome lipodistrofica HIV correlata, ASLTO2, Torino, ²SUISM, Torino
- P106 Efficacy and safety of dolutegravir + NRTI as first line regimen in HIV/1 infected naïve patients in a real life setting**
L. Pagnucco, R. Gulminetti, G. Chieffo, S. Novati, D. Zanaboni, R. Maserati and L. Minoli
Fondazione IRCCS Policlinico San Matteo, Dipartimento di Malattie Infettive / Università degli Studi di Pavia
- P107 Recovery of renal function after emtricitabine/tenofovir (FTC/TDF) discontinuation in a large Italian cohort of HIV positive subject – Master Cohort Study**
M. Giralda¹, P. Nasta², I. Izzo², C. Pezzoli², F. Maggiolo³, E. De Filippo³, N. Ladisa⁴, S. Di Giambenedetto⁵, A. Gori⁶, B. Del Pin⁷, L. Sighinolfi⁸, S. Lorenzotti⁹, F. Castelli², G. Carosi¹
¹Infectious Diseases and International Health Foundation, Brescia, Italy, ²University Division of Infectious and Tropical Diseases University of Brescia and Spedali Civili General Hospital, Brescia Italy, ³Clinic of Infectious Diseases, Ospedale Giovanni XXIII, Bergamo, Italy, ⁴Clinic of Infectious Diseases, Ospedale Policlinico, Bari, Italy, ⁵Clinic of Infectious Diseases, "Sacro Cuore" Catholic University of Rome, Roma, Italy, ⁶Clinic of Infectious Diseases, San Gerardo Hospital, Monza, Italy, ⁷Clinic of Infectious Diseases, Ospedale S.M. Annunziata, Firenze, Italy, ⁸Clinic of Infectious Diseases, Ospedale Sant'Anna, Ferrara, Italy, ⁹Clinic of Infectious Diseases, Istituti Ospitalieri, Cremona, Italy
- P108 A CD4/CD8 ratio <0.3 is associated with low vitamin D levels in a cohort of HIV-positive subjects on cART**
M.R. Pinzone¹, M. Maresca¹, B. Celesia¹, B. Cacopardo¹, G. Nunnari²
¹Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Catania, Italy, ²Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Messina, Italy

- P109 Incidence of renal toxicity after a 24-month follow-up in naive patients starting tenofovir/emtricitabine or abacavir/lamivudine associated with darunavir/ritonavir**
L. Calza¹, E. Magistrelli¹, V. Colangeli¹, I. Contadini¹, I. Bon², M.C. Re², P. Viale¹
¹Department of Medical and Surgical Sciences, Clinics of Infectious Diseases, and ²Unit of Microbiology, S.Orsola-Malpighi Hospital, University of Bologna
- P110 Reasons for switching ART in a cohort of HIV patients: comparison among data collected in 2012-13 and 2014-15**
M.C. Burla¹, F.M. Fusco², L. Rabatti¹, F. Vichi², F. Mazzotta²
¹UO Farmacia Ospedaliera, Ospedale Santa Maria Annunziata, ASL Toscana Centro, ²UO Malattie Infettive, Ospedale Santa Maria Annunziata, ASL Toscana Centro
- P111 Impact of Antiretroviral Therapy on Prevalence of low Bone Mineral Density in HIV-Infected Persons Cohort**
F. Rigo, E. Lattuada, M. Lanzafame, S. Nicolè, G. Cucchetto, E. Concia
Infectious Disease Unit, G.B. Rossi Hospital, Verona, Italy
- P112 Psychodiagnostic investigation through MMPI-2 of males at HIV diagnosis: evaluation and identification of an individualized psychological intervention**
A. Borysowicz, T. Speranza, A. Del Maestro, A. Palummieri, A. Ammassari
Istituto Nazionale di Malattie Infettive Lazzaro Spallanzani, Roma
- P113 Respiratory symptoms to improve early detection of lung disease in HIV patients**
A. Santoro, A. Malagoli, S. Neri, M. Menozzi, F. Carli, I. Franconi, C. Stentarelli, N. Riva, C. Mussini, G. Guaraldi
Clinica di Malattie Infettive, A.O.U. Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy
- P114 HIV Low Level Viremia (LLV) is not associated to recent and historical HAART adherence**
L. Vinci, S. Sofia, L. La Ferla, M.E. Locatelli, M. Maresca, M. Gussio, R. Bruno, B. Cacopardo, F. Palermo, B.M. Celesia
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, ARNAS Garibaldi Catania
- P115 Ligurian Vaccination in HIV program: a local experience**
P. De Leo¹, V. Frumento², L. Sticchi³, T. Bruzzone¹, M. Marturano¹, A. Beltrame¹, E.N. Malfatto¹, M. Anselmo¹
¹Infectious Diseases Department San Paolo Hospital ASL2 Savona, ²Hygiene Department ASL 2 Savona, ³Hygiene Department University of Genoa
- P116 Risk factors for febrile neutropenia during chemotherapy for AIDS and non-AIDS-related lymphoma**
A. Cascavilla, M. Bartoletti, S. Tedeschi, E. Razzaboni, L. Bussini, P. Viale
Infectious Disease Unit, S. Orsola-Malpighi Hospital, University of Bologna
- P117 AIDS and lymphoma: a single center experience**
A. Leone¹, R. Dell'Acqua¹, F. Di Gennaro¹, L. Lepore¹, N. De Gennaro¹, M. Delia², L. Monna¹, G. Angarano¹
¹Institute of Infectious Diseases, Policlinico Bari, ²Division of Hematology, Policlinico Bari
- P118 Fungal Infections (IFI) in HIV/AIDS. Clinical characteristic and outcomes in 114 patients, observational study**
E.A. Piga¹, O. Pilia², A. Bolliri², M. Motzo², S. Piga¹
¹Department of Infectious Disease Hospital SS. Trinità, Cagliari, ²Infectious Diseases University of Sassari
- P119 HAART and 5HT2-inhibitors Use in HIV-positive Patients with Detectable Cerebrospinal Fluid JCV DNA**
S. Mornese Pinna¹, V. Ghisetti², R. Bertucci¹, C. Costa¹, D. Imperiale³, A. Lucchini¹, G. Di Perri¹, S. Bonora¹ and A. Calcagno¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, ²Laboratory of Microbiology and Molecular Biology, Ospedale Amedeo di Savoia, ASL TO2 and ³Unit of Neurology, Ospedale Maria Vittoria, ASLTO2, Torino, Italy
- P120 Monotherapy versus Combined ART: Impact on HIV Reservoir, Immune Activation and EBV load**
M.R. Petrarà^{1,2}, A.M. Cattelan³, L. Sasseti⁴, R. Freguja¹, F. Carmona⁵, M. Zanchetta⁵, A. De Rossi^{1,5}
¹Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, AIDS Reference Centre, University of Padova, Padova, ²Epidemiology and Biostatistics Unit, Centro di Riferimento Oncologico (CRO)–IRCCS, National Cancer Institute, Aviano (PN), ³Division of Infectious and Tropical Disease, Hospital of Padova, Padova, ⁴Division of Infectious Disease, Hospital of Rovigo, Rovigo, ⁵Istituto Oncologico Veneto-IRCCS, Padova
- P121 Virological suppression and cART discontinuation and the role of baseline genotypic resistance and tropism on in HIV-positive subjects with primary HIV infection (PHI)**
P. Tau¹, M. Fabbiani², M. Ripa³, E. Focà⁴, S. Nozza³, A. Bandera², A. Muscatello² and S. Rusconi¹ on behalf of the INACTION study group
¹Divisione Malattie Infettive, DIBIC Luigi Sacco, Università degli Studi di Milano, ²Divisione Malattie Infettive, Ospedale San Gerardo, Università degli Studi di Milano – Bicocca, ³Divisione Malattie Infettive, Ospedale San Raffaele, Università Vita-Salute, Milano, ⁴Divisione Malattie Infettive, Spedali Civili, Università degli Studi di Brescia, Italy

P122 The BOOSTER-FREE project: a potential role of unboosted-atazanavir (ubATV) plus dolutegravir (DTG) in virologically suppressed HIV-positive subjects with a long-term exposure to antiretrovirals

A. Riva¹, A. Poli², S. Rusconi¹, S. Bonora³, M. Ferrara³, R. Gulminetti⁴, L. Pagnucco⁴, A.M. Cattelan⁵, S. Cavinato⁵, V. Spagnuolo², E. Quiros Roldan⁶, A. Castagna²

¹Infectious Diseases Unit, DIBIC "Luigi Sacco", Università degli Studi di Milano, ²Infectious Diseases Unit, San Raffaele Scientific Institute, Milano, ³Infectious Diseases Unit, Ospedale Amedeo di Savoia, Università degli Studi di Torino, ⁴Infectious Diseases Unit, Fondazione IRCCS Policlinico S. Matteo, Pavia, ⁵Infectious Diseases Unit, Azienda Ospedaliera Università di Padova, ⁶Infectious Diseases Unit, Spedali Civili, Università degli Studi di Brescia

P123 Moving closer to gender medicine: simplification to a STR containing rilpivirine maintains the efficacy and minimizes the adverse effects

N. Riccardi¹, L. Taramasso¹, A. Capetti², G. Cenderello³, A. Signori⁴, P. Vitello⁵, M. Guerra⁶, G.V. De Socio⁷, G. Cassola³, T. Quirino⁵, C. Viscoli⁸, A. Di Biagio⁸

¹Department of Health Science, Infectious Diseases, University of Genoa, Italy, ²Infectious Disease, Ospedale Luigi Sacco, Milan-Italy, ³Infectious Disease, Ospedali Galliera-Genoa-Italy, ⁴Department of Health Science, Biostatistics, University of Genoa, Italy, ⁵Infectious Disease, Ospedali di Busto Arsizio, Varese, Italy, ⁶Infectious Disease, Ospedale di Spezia, Italy, ⁷Infectious Disease, Ospedale Santa Maria della Misericordia, University of Perugia-Italy, ⁸Infectious Disease, IRCCS AOU San Martino-IST, National Institute for Cancer Research, Genoa-Italy

COINFECTIONS AND SEXUALLY TRANSMITTED INFECTIONS

P124 HIV and Syphilis prevalence in pregnant women in Beira, Mozambique

F. Di Gennaro^{1,2}, D. Pizzo², G. Guilandé², L. Monno¹, C. Boscardin³, G. Putoto⁴, A. Saracino¹

¹Clinic of Infectious Diseases, University of Bari, Bari, Italy, ²Operational Research Unit, Doctors with Africa CUAMM; Beira – Mozambique, ³Department of Woman's and Child's Health, University of Padua; Padua - Italy, ⁴Operational Research Unit, Doctors with Africa CUAMM; Padova – Italy

P125 Anal cytologic abnormalities among HIV-infected men who have sex with men: prevalence and predictors

M.G. Donà¹, M. Benevolo², A. Latini¹, M. Colafigli¹, F. Rollo², V. Laquintana², A. Giglio³, D. Moretto³, A. Cristaudo¹, M. Giuliani¹

¹HIV/STI UNIT, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy, ²Pathology Department, Regina Elena National Cancer Institute, Rome, Italy, ³Clinical Pathology and Microbiology Department, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy

P126 Neurosyphilis and HIV infection: clinical validation of a literature-based How-to

S. Giuliano, S. Savinelli, A. Lazzaro, G. Di Girolamo, G. Ceccarelli, G. d'Ettore, V. Vullo

Department of Public Health and Infectious Diseases Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy

P127 Early regression of liver fibrosis in HCV infected patients with or without HIV infection after treatment with DAAs

G. Bruno, R. Dell'Acqua, E. Milano, C. Fabrizio, M. Milella, A. Saracino, G. Angarano

Clinic of Infectious Diseases, University of Bari

P128 Predictors of liver fibrosis progression and clinical events in HIV/HCV co-infected patients: role of CD4 T cell count and NRTI exposure

E. Focà¹, M. Fabbiani², M. Prosperi³, E. Quiros Roldan¹, F. Castelli¹, F. Maggiolo⁴, E. Di Filippo⁴, S. Di Giambenedetto⁵, R. Gagliardini⁵, A. Saracino⁶, M. Di Pietro⁷, A. Gori², L. Sighinolfi⁸, A. Pan⁹, M.C. Postorino¹⁰, C. Torti¹⁰ for the MASTER cohort

¹University Department of Infectious and Tropical Diseases, University of Brescia and Brescia Spedali Civili General Hospital, Brescia, Italy, ²Clinic of Infectious Diseases, San Gerardo de' Tintori Hospital, Monza, Italy, ³Department of Epidemiology, College of Public Health and Health Professions & College of Medicine, University of Florida, USA, ⁴Clinic of Infectious Diseases of "Papa Giovanni XXIII" Hospital of Bergamo, Italy, ⁵Institute of Clinical Infectious Diseases of Catholic University of Sacred Heart, Rome, Italy, ⁶Clinic of Infectious Diseases, University of Bari, Bari, Italy, ⁷Clinic of Infectious Diseases of "Azienda Ospedaliera S.M. Annunziata" of Firenze, Italy, ⁸Clinic of Infectious Diseases of "Azienda Ospedaliera S. Anna" of Ferrara, Italy, ⁹Clinic of Infectious Diseases of "Istituti Ospitalieri" of Cremona, Italy, ¹⁰Infectious Diseases Unit, University "Magna Graecia" Catanzaro, Italy

P129 Tenofovir exposure is related with a lower risk of death in HIV/HCV-RNA positive co-infected patients starting highly active antiretroviral therapy – a MASTER cohort study

P. Nasta¹, M. Giralda², G. Parainfo¹, F. Maggiolo³, E. De Filippo³, A. Saracino⁴, R. Gagliardini⁵, A. Gori⁶, M. Di Pietro⁷, L. Sighinolfi⁸, C. Fornabai⁹, G. Carosi², F. Castelli¹⁰

¹University Division of Infectious and Tropical Diseases University of Brescia and Spedali Civili General Hospital, Brescia Italy, ²Infectious Diseases and International Health Foundation, Brescia, Italy, ³Clinic of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy, ⁴Clinic of Infectious Diseases, Ospedale Policlinico, Bari, Italy, ⁵Clinic of Infectious Diseases, "Sacro Cuore" Catholic University of Rome, Rome, Italy, ⁶Clinic of Infectious Diseases, San Gerardo Hospital, Monza, Italy, ⁷Clinic of Infectious Diseases, Ospedale S.M. Annunziata, Florence, Italy, ⁸Clinic of Infectious Diseases, Ospedale Sant'Anna, Ferrara, Italy, ⁹Clinic of Infectious Diseases, Istituti Ospitalieri, Cremona, Italy, ¹⁰University Division of Infectious and Tropical Diseases, University of Brescia-Spedali Civili General Hospital, Brescia, Italy

P130 Prevalence and determinants of high risk (HR) HPV genotypes and cervical displasia in a cohort of HIV-infected and HIVuninfected women in Maputo, Mozambique

G. Guidotti¹, C. Malcontenti², B. Rossetti^{2,10}, U. Rovigatti³, M. Magnano San Lio⁴, A.G. Naccarato³, I. Marchetti³, E. Wale⁵, C. Carrilho⁶, I. Zimba⁷, S. Mancinelli⁸, M.C. Marazzi⁹, L. Palombi⁴, A. De Luca^{2,9}

¹Dream Program, Rome, Italy, ²UOC Malattie Infettive Universitarie, AOU Senese, Siena, Italy, ³Dipartimento di Oncologia, Trapianti e Nuove Tecnologie in Medicina Università di Pisa, Italy, ⁴Università di Roma Tor Vergata, Dipartimento di Biomedicina e Prevenzione, ⁵Departamento de Ginecologia e Obstetricia HCM, Maputo, Mozambique, ⁶Departamento de Anatomia Patologica HCM, Maputo, Mozambique, ⁷Dream Program, Maputo, Mozambique, ⁸LUMSA University of Rome, Italy, ⁹Dipartimento di Biotechnologie Mediche, Università di Siena, Siena, Italy, ¹⁰UOC Malattie Infettive, Università del Sacro Cuore, Roma, Italy

P131 An economic analysis of the complications and comorbidities in HIV+ and HIV/HCV setting: a pilot observational study

E. Foglia¹, L. Ferrario¹, E. Garagiola¹, G. Rizzardini^{2,3}, P. Meraviglia², D. Croce^{1,4}

¹Centre for Research on Health Economics, Social and Health Care Management – Carlo Cattaneo – LIUC University, Castellanza, Italy, ²Fatebenefratelli Sacco Hospital, Milan, Italy, ³School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, ⁴School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

P132 HPV detection in anal swabs of a cohort of HIV infected patients

N. Squillace¹, S. Malandrini², A. Brenna³, M. Polese⁴, S. Cuttin³, A. Bandera¹, E. Cappelletti¹, S. Costarelli¹, A. Muscatello¹, F. Sabbatini¹, V. Giardini¹ and A. Gori¹

¹Infectious Diseases "San Gerardo" Hospital, University of Milano-Bicocca Monza, Italy, ²Microbiology and Virology Laboratories, "San Gerardo" Hospital, Monza, Italy, ³Division of Pathology, "San Gerardo" Hospital, University of Milano-Bicocca Monza, Italy, ⁴Department of Surgery, "San Gerardo" Hospital, Monza, Italy

P133 Development of multiple carcinomas in an HIV-HBV-HPV coinfecting woman, a case record

F. Sabbatini, N. Squillace, A. Bandera and A. Gori

Infectious Diseases Unit, San Gerardo Hospital-University of Milano-Bicocca, Monza

P134 FIB 4 to evaluate risk of liver related events and liver related death in HIV-HCV-RNA positive co-infected patients starting Highly active antiretroviral therapy (HAART) – A Master Cohort study

M. Giralda¹, P. Nasta², S. Casari², E. Focà², F. Maggiolo³, E. De Filippo³, A. Saracino⁴, R. Gagliardini⁵, A. Gori⁶, B. Del Pin⁷, L. Sighinolfi⁸, A. Zoncada⁹, F. Castelli², G. Carosi¹

¹Infectious Diseases and International Health Foundation, Brescia, Italy, ²University Division of Infectious and Tropical Diseases University of Brescia and Spedali Civili General Hospital, Brescia, Italy, ³Clinic of Infectious Diseases, Ospedale Giovanni XXIII, Bergamo, Italy, ⁴Clinic of Infectious Diseases, Ospedale Policlinico, Bari, Italy, ⁵Clinic of Infectious Diseases, "Sacro Cuore" Catholic University of Rome, Rome, Italy, ⁶Clinic of Infectious Diseases, San Gerardo Hospital, Monza, Italy, ⁷Clinic of Infectious Diseases, Ospedale S.M. Annunziata, Firenze, Italy, ⁸Clinic of Infectious Diseases, Ospedale Sant'Anna, Ferrara, Italy, ⁹Clinic of Infectious Diseases, Istituti Ospitalieri, Cremona, Italy

P135 Assessing HCV infections among HIV infected MSM outpatients admitted in the Infectious Diseases Clinic of Modena

M. Digaetano¹, M. Menozzi¹, G. Cuomo¹, S. Tagliacuzzi², V. Borghi¹, C. Mussini¹

¹Infectious Disease Clinic, AOU Policlinico di Modena, Modena, Italy, ²Department of Diagnostic Medicine, Clinical and Public Health, AOU Policlinico di Modena, Modena, Italy

P136 Possible impact of DAA treatment on HIV reservoir in HCV/HIV co-infected patients treated with cART

I. Abbate¹, M. Zaccarelli², G. Fabbri², P. Lorenzini², A. Amendola¹, G. Rozera¹, S. Cicalini², A. Antinori², M.R. Capobianchi¹, A. Ammassari²

¹Laboratory of Virology and ²Clinical Department, INMI L.Spallanzani, Rome, Italy

P137 Prevalence, concordance and risk factors of oral and anal Human Papillomavirus infection in HIV-infected men who have sex with men

M.G. Donà¹, A. Latini¹, F. Rollo², V. Laquintana², A. Giglio³, D. Moretto³, M. Colafigli¹, B. Pichi⁴, M. Benevolo², A. Cristaudo¹, M. Giuliani¹

¹STI/HIV Unit, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy, ²Pathology Department, Regina Elena National Cancer Institute, IRCCS, Rome, Italy, ³Microbiology and Pathology Department, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy, ⁴Otolaryngology Head Neck Surgery Department, Regina Elena National Cancer Institute, IRCCS, Rome, Italy

P138 Syphilis and HIV coinfection: the trend in Sicily from 2004 to 2015

A. Dimartino², L. La Ferla¹, M.E. Locatelli¹, S. Piacenti¹, M. Maresca¹, M. Gussio¹, B. Cacopardo¹, M. Cuccia², B.M. Celesia¹

¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, ARNAS Garibaldi Catania, ²Unit of Epidemiology ASP 3 Catania

P139 Use of the new direct-acting antivirals (DAAs) in a cohort of HIV/HCV co-infected patients: a real life experience

O. Tambaro, G. Palmiero, A.E. Maraolo, F. Lanzieri Pignataro, G. Bonadies, F. Borrelli, R. Orlando

Unity of Viral Diseases including AIDS Day Hospital, AOU Federico II, Naples

EPIDEMIOLOGY HEPATITIS

P140 Naturally occurring NS3, NS5A and NS5B resistance associated variants in treatment-naïve patients with chronic hepatitis C

L. Sticchi^{1,2}, E. Rappazzo¹, P. Canepa¹, B. D'Ambrosio¹, S. Delucis¹, L.A. Nicolini^{1,3}, L. Taramasso³, B. Bruzzone², G. Icardi^{1,2}

¹Department of Health Sciences (DiSSal), University of Genoa, Italy, ²Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ³Infectious Diseases, IRCCS AOU San Martino-IST, Genoa, Italy

- P141 Differences in epidemiological, clinical and treatment characteristics between HCV-monoinfected and HCV/HIV coinfecting patients enrolled in the SCOLTA project**
C. Molteni¹, E. Ricci², B. Menzaghi³, B.M. Ceslasia⁴, S. Costarelli⁵, C. Grosso⁶, E. Salomoni⁷, F. Vichi⁸, R. Gulminetti⁹, C. Magni², K. Falasca¹⁰, A. Patacca¹¹, C.R. Santoro¹², V. Fiore¹³, L. Nicolini¹⁴, P. Bonfanti¹ on behalf of CISAI group
¹ASST di Lecco - Ospedale A.Manzoni, ²ASST Fatebenefratelli Sacco - I Divisione Malattie Infettive, ³ASST Valle Olona - Ospedale di Busto Arsizio, ⁴Malattie Infettive Catania, ⁵ASST di Monza - Ospedale San Gerardo, ⁶Malattie Infettive Cesena, ⁷Ospedale Careggi Firenze, ⁸Ospedale S. Annunziata Firenze, ⁹ASST di Pavia - Clinica Malattie Infettive, ¹⁰Malattie Infettive Chieti, ¹¹Malattie Infettive Perugia, ¹²Clinica Malattie Infettive di Bari, ¹³Clinica Malattie Infettive di Sassari, ¹⁴Ospedale S.Martino Genova
- P142 Clinical and virological characteristics of HIV neg. and HIV pos. individuals infected by HCV genotype 4: data from an Italian Center**
A. Andolina^{1,2}, M. Merli^{1,2}, S. Bagaglio¹, H. Hasson¹, E. Messina¹, C. Uberti-Foppa¹ and G. Morsica¹
¹Infectious Diseases Department, Scientific Institute Ospedale San Raffaele, Milan, Italy, ²Vita-Salute University, Milan, Italy
- P143 Prevalence and outcomes of patients with Hepatocellular Carcinoma associated with HBV or HCV infection**
I. Maida¹, V. De Murtas¹, C. Pisano¹, G. Garrucciu², G. Vidili¹, F. Bandiera³, S. Babudieri¹, M.S. Mura¹
¹Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, ²Unit of General Medicine 1, Medical Pathology, AOU Sassari, Sassari, Italy, ³Unit of Internal Medicine 2, ASL 1 Sassari, Sassari, Italy

EPIDEMIOLOGY HIV

- P144 Epidemiological survey of the use of ARV drugs in a large single-center clinical cohort**
E. Di Filippo¹, L. Comi¹, D. Valsecchi², S. Di Matteo³, G.M. Bruno³, D. Valenti¹, M. Rizzi¹, F. Maggiolo¹
¹USC of Infectious Diseases, ²USC of Pharmacy, ASST Papa Giovanni XXIII, Bergamo, ³S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy
- P145 Cost of rapid HIV testing in non clinical settings**
C. Angeletti¹, P. Piselli¹, G. Chiaradia¹, P. Scognamiglio¹, L. Scappaticci¹, M. Oldrini², E. Albertini³, A. Camposeragna⁴, M. Farinella⁵, D. Lorenzetti⁶, L. Rancilio⁷, G. Ippolito¹, E. Girardi¹
¹Istituto Nazionale Malattie Infettive "L. Spallanzani", IRCCS, Roma, ²LILA, ³Arcigay, ⁴CNCA, ⁵Circolo Mario Mieli, ⁶ANLAIDS, ⁷Caritas
- P146 Transgender sex workers contribute to the complexity and transmission dynamics of the HIV-1 epidemic in Italy**
A. Lai¹, S. Giuffrè¹, F.R. Simonetti¹, M. Franzetti¹, A. Bergna¹, P. Cattaneo¹, V. Micheli², F. Binda¹, C. Aztori³, M. Galli¹, C. Balotta¹
¹Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy, ²Clinical Microbiology Virology and Diagnosis of Bioemergency, L.Sacco University Hospital, Milan, Italy, ³1st Division of Infectious Diseases, L. Sacco University Hospital, Milan, Italy
- P147 Outreach program of HIV rapid testing among people at higher risk of HIV living in Italy: final results**
P. Scognamiglio¹, G. Chiaradia¹, P. Piselli¹, L. Scappaticci¹, C. Bianchi¹, M. Oldrini², M. Breveglieri³, E. Albertini³, A. Camposeragna⁴, M. Farinella⁵, D. Lorenzetti⁶, L. Rancilio⁷, M.G. Pompa⁸, E. Girardi¹, G. Ippolito¹
¹Istituto Nazionale Malattie Infettive "L. Spallanzani", IRCCS, Roma, ²LILA, ³Arcigay, ⁴CNCA, ⁵Circolo Mario Mieli, ⁶ANLAIDS, ⁷Caritas, ⁸Ministero della Salute
- P148 The evolution of HIV epidemic in the Brescia Local Health Authority (LHA), a population based-study from 2003 to 2014**
N. Brianese¹, E. Quiros-Roldan¹, M. Magoni², E. Raffetti³, M.C. Pezzoli¹, E. Focà¹, A. Bonito¹, A. Ferraresi¹, P. Lanza¹, F. Castelli¹
¹University Department of Infectious and Tropical Diseases, University of Brescia, ²Local Health Agency of the Brescia Province, Brescia, ³Brescia University, Unit of Hygiene
- P149 Time from infection with HIV to diagnosis in Italy: an estimate using surveillance data**
A. Mammoni¹, P. Pezzotti², L. Camoni², V. Regine², M. Raimondo², M. Dorrucchi², B. Suligoj², E. Girardi¹
¹National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy, ²Istituto Superiore di Sanità, Rome, Italy
- P150 The cascade of care in HIV-infected patients in a Clinic of Northern Italy: a twenty-year experience**
P. Rodari¹, E. Focà¹, M.C. Pezzoli², S. Casari², N. Brianese¹, F. Castelnuovo², G. Parainfo², F. Castelli¹, E. Quiros-Roldan¹
¹University of Brescia, Italy, ²Department of Infectious and Tropical Diseases, Spedali Civili General Hospital, Brescia, Italy
- P151 Development of a data-driven epidemic model for HIV infection in the region of Bologna, Italy**
I. Rigoni¹, L. Badia², P. Viale², L. Badia¹
¹Dept. of Information Engineering, University of Padova, ²Infectious Diseases Unit, Department of Medical and Surgical Sciences, Sant'Orsola Hospital, Alma Mater University of Bologna
- P152 Characteristics and trend of new HIV diagnoses among men who have sex with men in Italy, from 2010 to 2014**
V. Regine, M. Raimondo, B. Suligoj and the Italian HIV surveillance network
 Centro Operativo AIDS, Istituto Superiore di Sanità, Rome, Italy

- P153 Loss to follow up and re-engagement among HIV-infected individuals into HIV medical care**
P. Rodari¹, E. Focà¹, A. Bonito¹, A. Ferraresi¹, P. Lanza¹, M.C. Pezzoli², F. Castelnuovo², G. Parainfo², F. Castelli¹, E. Quiros-Roldan¹
¹University of Brescia, Italy, ²Department of Infectious and Tropical Diseases, Spedali Civili General Hospital, Brescia, Italy
- P154 The cost of cART in a large single-center clinical cohort**
E. Di Filippo¹, L. Comi¹, D. Valsecchi², G.L. Colombo^{3,4}, S. Di Matteo⁴, G.M. Bruno⁴, M.C. Valentino⁴, D. Valenti¹, F. Maggiolo¹
¹USC of Infectious Diseases, ²USC of Pharmacy, ASST Papa Giovanni XXIII, Bergamo, ³Department of Drug Sciences, University of Pavia, ⁴S.A.V.E. Studi - Health Economics & Outcomes Research, Milan, Italy
- P155 Prevalence of Chronic Obstructive Pulmonary Disease (COPD) among HIV-positive and HIV-negative population of Brescia province (Northern Italy)**
V. Barbera, A. Bonito, A. Ferraresi, N. Brianese, M.C. Pezzoli, E. Focà, P. Rodari, F. Castelli, E. Quiros-Roldan
 University Division of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
- P156 Replicative capacity of HIV isolates bearing resistance mutations in recently infected patients**
S. Caucchi¹, P. Bagnarelli¹, M. Franzetti², M. Andreoni³, C. Balotta², S. Menzo¹
¹Dipartimento di Scienze Biomediche e Sanità Pubblica, Università Politecnica delle Marche, Ancona, ²Dipartimento di Scienze Biomediche e Cliniche "L. Sacco", Milano, ³Clinica di Malattie Infettive, Università di Tor Vergata, Roma
- P157 Anonymous unlinked testing for estimating occult HIV seroprevalence in Pavia province, Italy**
F. Genco¹, V. Meroni¹, A. Corcione¹, G. Albonico², M. Prestia³, F. Baldanti¹, G. Comolli¹, L. Scudeller³
¹Microbiology and Virology Unit, ²Clinical Chemistry Laboratory, ³Clinical Epidemiology and Biostatistics Unit IRCCS Polyclinic San Matteo Foundation Pavia, Italy
- P158 Epidemiology of newly diagnosed HIV infections: two years compared**
N. Zanchetta¹, A. Di Gregorio¹, P. Meraviglia², A. Capetti², C. Galli³, C. Bossi¹, G. Rizzardini², M. Galli², S. Rusconi², M.R. Gismondo¹
¹Clinical Microbiology, Virology and Bioemergency, University of Milan, ASST FBF-Sacco Hospital, ²Department of Infectious Diseases, University of Milan, ASST FBF Sacco Hospital, ³Scientific Affairs, Abbott Diagnostic, Abbott
- P159 HIV, HBV and HCV infection in people who voluntarily undergo to anti HIV test at "Caserta S. Anna S. Sebastiano Hospital" from 1999 to 2014**
M. Pisaturo¹, V. Messina¹, F. Simeone¹, A. Iodice¹, V. Selva¹, L. Alessio¹, G. Massaro², P. Filippini^{1,2}
¹Division of Infectious Diseases, AORN Sant'Anna e San Sebastiano di Caserta, Caserta, Italy, ²Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples, Naples, Italy
- P160 The health costs and resource allocation of HIV cases living in the Brescia Local Health Authority (LHA), a population based-study from 2003 to 2014**
N. Brianese¹, E. Quiros-Roldan¹, M. Magoni², E. Raffetti³, E. Focà¹, G. Parainfo¹, A. Bonito¹, A. Ferraresi¹, P. Rodari¹, F. Castelli¹
¹University Department of Infectious and Tropical Diseases, University of Brescia, ²Local Health Agency of the Brescia Province, Brescia, ³Brescia University, Unit of Hygiene
- P161 Prevalence and characteristics of new HIV diagnoses in the Calabria Region (CalabrHIV Cohort) and in one nearby centre in Messina: lessons learned and call for collaboration**
M.C. Postorino¹, F. Luciani², G. Pellicano³, C. Mangano⁴, M.S. Carpentieri⁴, P. Scerbo⁵, A. Priamo⁵, G. Berardelli⁶, R. Marino⁷, A. Vallone⁷, J. Caglioti⁸, N. Serrao⁹, V. Pisani¹, C. Costa¹, A. Terremoto², G. Foti⁴, L. Cosco⁵, D. Corigliano⁷, M. Mazzitelli¹, A. Strazzulla¹, G. Nunnari³ and C. Torti¹
¹Infectious Diseases Unit, "Magna Graecia" University, Catanzaro, ²Infectious Diseases Unit, "Annunziata" Hospital, Cosenza, ³Infectious Diseases Unit, University of Messina, ⁴Infectious Diseases Unit, "Bianchi-Melacrino-Morelli" Hospital, Reggio Calabria, ⁵Infectious Diseases Unit, "Pugliese-Ciaccio" Hospital, Catanzaro, ⁶Infectious Diseases Unit, "Giovanni Paolo II" Hospital, Lamezia Terme, Catanzaro, ⁷Infectious Diseases Unit, "Jazzolino" Hospital, Vibo Valentia, ⁸Infectious Diseases Unit, "San Giovanni di Dio" Hospital, Crotone

HIV PREVENTION

- P162 The dyadic adjustment in HIV-serodiscordant couples during Peri-conception antiretroviral Pre-Exposure Prophylaxis (PrEP-C)**
A. Palummieri, G. De Carli, V. Puro
 Centro di Riferimento AIDS-National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Roma
- P163 Anlaids and Re. Te. - New tools to create a successful supportive relationship**
R. Galipò, P. Ferri, P. Narciso, M. Ghenzer
 Anlaids Lazio
- P164 Renal safety of coformulated TDF/FTC/EVG/COB (Stribild®) in the Post-Exposure Prophylaxis to HIV: our experience**
A. Franco¹, L. Aprea², E. Manzillo³, A. Marocco¹, N. Maturo², T. Pizzella³, F. Simioli³, M. Gargiulo³
¹AORN "Ospedale dei Colli", ²UOSD di "Sorveglianza e profilassi post-esposizione", ³UOSD di "Pronto Soccorso Infettivologico ed accettazione", ⁴UOC di "Immunodeficienza e malattie dell'emigrazione"

IMMUNOLOGY

- P165 Intermediate inflammatory monocytes predict the time to HIV-1 viral load reduction under 50 copies/ml, after first line ART initiation**
M. Iannetta, R. Rossi, S. Savinelli, S. Vita, C. Mascia, P. Zuccalà, F. Schiavone, G. d'Ettore, C.M. Mastroianni, M. Lichtner and V. Vullo
Department of Public Health and Infectious Diseases, Sapienza University, Rome
- P166 The role of Presepsin (sCD14-ST) as an indirect marker of microbial translocation and immune activation in HIV and HIV/HCV coinfected patients**
V. Zuccaro¹, P. Sacchi¹, S. Cima¹, Columpsi¹, S. Toppino¹, S. Paolucci², G. Comolli², F. Baldanti², M. Mariconti¹, R. Bruno¹
¹Dipartimento di Malattie Infettive, Fondazione IRCCS Policlinico San Matteo, Pavia, ²Unità di Virologia Molecolare, S.C. di Microbiologia e Virologia, Fondazione IRCCS Policlinico San Matteo, Pavia
- P167 Conserved response to IL-12/IL-15 and Natural Cytotoxicity receptor Inducibility of NK cells are a hallmark of efficient control of circulating HIV DNA reservoir in HIV infected patients**
F. Marras¹, F. Bozzano², A. Di Biagio³, L. Nicolini³, L. Taramasso³, C. Viscoli³, C. Dentone⁴, E. Pontali⁵, S. Boni⁶, M. Setti^{3,7}, G. Orofino⁸, E. Mantia⁹, L. Moretta¹, C. Orlandi¹⁰, A. Casabianca¹⁰, M. Magnani¹⁰, A. De Maria^{2,11}
¹Istituto Giannina Gaslini, Genoa, Italy, ²Department of Experimental Medicine, DIMES, University of Genova, Genoa, Italy, ³Department of International Medicine and infectious Disease IRCCS A.O.U. SanMartino-IST Genova, Italy, ⁴Unità di Malattie Infettive, Ospedale Sanremo, Sanremo, Italy, ⁵Unità di Malattie Infettive, Ospedale Galliera, Genoa, Italy, ⁶Unità di Malattie Infettive, Ospedale Sant'Andrea, La Spezia, Italy, ⁷Department of Internal Medicine, University of Genova, Genova, Italy, ⁸Unità di Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy, ⁹Unità di Malattie Infettive, Az. Osp. Santi A.B.C. Arrigo, Alessandria, Italy, ¹⁰Department of Biomolecular Science University of Urbino "Carlo Bo", Urbino (PU), Italy, ¹¹Center of Excellence in Biomedical Research, University of Genova, Genoa, Italy
- P168 Bone-marrow-resident CD34+DNAM-1brightCXCR4+ committed lymphoid precursors during chronic infection and inflammation supports innate and adaptive immune responses**
F. Bozzano^{1,2}, F. Marras³, M.L. Ascierto^{4,5}, C. Canton^{1,2,3}, G. Cenderello⁶, C. Dentone⁷, A. Di Biagio⁸, G. Orofino⁹, E. Mantia¹⁰, S. Boni¹¹, P. De Leo¹², A. Piccotto^{1,3}, F. Braido¹⁴, F. Antonini³, E. Wang^{4,15}, F. Marincola¹⁵, L. Moretta³, A. De Maria^{2,8,16}
¹Department of Experimental Medicine, University of Genova, Italy, ²Center for Excellence in Biomedical Research, University of Genova, Italy, ³Istituto Giannina Gaslini, Genoa, Italy, ⁴Department of Transfusion Medicine, Clinical Center and Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA, ⁵Department of Oncology, Johns Hopkins University, Baltimore, MD, USA, ⁶U.O.C. Malattie Infettive, Ospedale Galliera, Genova, Italy, ⁷U.O.C. Malattie Infettive, Ospedale Sanremo, Sanremo (IM), Italy, ⁸Clinica Malattie Infettive, IRCCS AOU San Martino-IST Genova, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, ⁹SOC Malattie Infettive ASO S.S. Antonio e Biagio e C. Arrigo Alessandria, ¹⁰U.O.C. Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy, ¹¹U.O.C. Malattie Infettive, Ospedale Sant'Andrea, La Spezia, Italy, ¹²U.O.C. Malattie Infettive, Azienda Sanitaria Locale n.2, Savona, Italy, ¹³Allergy and Respiratory Unit, Department of Internal Medicine, University of Genova, Italy, ¹⁴Hepatology Unit, Department of Internal Medicine, University of Genova, Italy, ¹⁵Sidra Medical and Research Centre, Doha, Qatar, ¹⁶Department of Health Sciences, DISSAL, University of Genova, Genova, Italy
- P169 End-of-treatment HCV negativization following direct-acting antivirals (DAAs) leads to the expansion of CD127+ CD8 and CD4 T cells in a cohort of HIV/HCV patients**
M. Cerrone, M. Chiamenti, A. De Bona, F. Bai, A. Raimondi, G. Marchetti, A. d'Arminio Monforte
Clinic of Infectious Diseases, Department of Health Sciences, San Paolo University Hospital, University of Milan
- P170 NCR expression/inducibility on NK cells is associated to different levels of control of HIV infection in Virologically discordant non progressor (VDNP) and in HIV controller (HC) patients**
F. Marras¹, F. Bozzano², A. Di Biagio³, L. Nicolini³, L. Taramasso³, C. Dentone⁴, E. Pontali⁵, S. Boni⁶, M. Setti^{3,7}, G. Orofino⁸, E. Mantia⁹, L. Moretta¹, C. Orlandi¹⁰, A. Casabianca¹⁰, M. Magnani¹⁰, A. De Maria^{2,11}
¹Istituto Giannina Gaslini, Genoa, Italy, ²Department of Experimental Medicine, DIMES, University of Genova, Genoa, Italy, ³Department of International Medicine and infectious Disease IRCCS A.O.U. San Martino-IST Genova, Italy, ⁴Unità di Malattie Infettive, Ospedale Sanremo, Sanremo, Italy, ⁵Unità di Malattie Infettive, Ospedale Galliera, Genoa, Italy, ⁶Unità di Malattie Infettive, Ospedale Sant'Andrea, La Spezia, Italy, ⁷Department of Internal Medicine, University of Genova, Genova, Italy, ⁸Unità di Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy, ⁹Unità di Malattie Infettive, Az. Osp. Santi A.B.C. Arrigo, Alessandria, Italy, ¹⁰Department of Biomolecular Science University of Urbino "Carlo Bo", Urbino (PU), Italy, ¹¹Center of Excellence in Biomedical Research, University of Genova, Genoa, Italy
- P171 Study of the innate and adaptive immunity in HIV/HCV co-infected and HCV mono-infected patients undergoing IFN free therapy**
P. Zuccalà¹, M. Lichtner¹, S. Vita¹, R. Marocco², C. Mascia¹, S. Savinelli¹, M. Campagna¹, F. Mengoni¹, T. Tieghi², F. Schiavone¹, G. D'Ettore¹, F. Paoletti¹, C.M. Mastroianni¹, V. Vullo¹
¹Sapienza University of Rome, ²Sapienza University of Rome, Polo Pontino, Latina, Italy

NEUROPATHOGENESIS AND NEUROLOGIC COMPLICATIONS

- P172 Molecular mechanisms of cell toxicity and Matrix Metalloproteinase-9 inhibition by Antiretroviral Drugs in Cultured Primary Astrocytes**
I. Pati¹, T. Latronico¹, A. Fasano¹, F. Mengoni², M. Lichtner^{2,3}, C.M. Mastroianni^{2,3}, G.M. Liuzzi¹
¹Department of Biosciences, Biotechnologies and Biopharmaceutics, Aldo Moro University, Bari, Italy, ²Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy, ³Infectious Diseases Unit, Sapienza University, Polo Pontino, Latina, Italy

- P173 Correlation between neurocognitive disorders and pattern cytokines in HIV+ patients**
S. Coladonato¹, K. Falasca¹, C. Ucciferri¹, M. Di Nicola², G. Di Martino², F.M. Reale³, Vignale¹, J. Vecchiet¹
¹Clinic of Infectious Diseases – Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara– Italy, ²Laboratory of Biostatistics, Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio", Chieti-Pescara, Italy, ³Unit of Immunodiagnostic and Molecular Pathology, Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio", Chieti-Pescara, Italy
- P174 Predictors of neurocognitive impairment in a cohort of Italian HIV+ patients: the CARE HIV Study**
P. Meraviglia¹, D. Croce^{2,3}, L. Ferrario², E. Foglia², E. Garagiola², E. Ricci¹, C. Atzori¹, G. Rizzardini^{1,4}
¹Department of Infectious Diseases, Fatebenefratelli Sacco Hospital, Milan, Italy, ²Centre for Research on Health Economics, Social and Health Care Management, LIUC - Cattaneo University, Castellanza, Italy, ³School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg
- P175 Factors influencing the HIV+ treatments performances in patients with neurocognitive impairments**
L. Ferrario¹, E. Foglia¹, E. Garagiola¹, E. Ricci², G. Rizzardini^{2,3}, P. Meraviglia², C. Atzori², M.V. Cossu², D. Croce^{1,4}
¹Centre for Research on Health Economics, Social and Health Care Management, LIUC - Cattaneo University, Castellanza, Italy, ²Department of Infectious Diseases, Fatebenefratelli Sacco Hospital, Milan, Italy, ³School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa, ⁴School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- PEDIATRICS, ADOLESCENT, MATERNAL, FETAL**
- P176 HIV-1 of children with slow disease progression escapes autologous neutralization and triggers development of cross-neutralizing responses**
S. Dispinseri¹, M. Cavarelli¹, A.M. Plebani², M. Jansson^{3,4}, G. Scarlati¹
¹San Raffaele Scientific Institute, Milan, Italy, ²Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico Milan, Milan, Italy, ³Lund University, Lund, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
- P177 HIV and adolescents in Mozambique: the friendly health services for young and adolescents (SAAs) experience**
T. Serena¹, D. Pizzol², G. Marquez³, G. Pita⁴, F. Di Gennaro⁵, A. George², M. Romanelli², G. Putoto⁶
¹Department of Woman's and Child's Health, University of Padua, Padua - Italy, ²Doctors with Africa CUAMM, Beira - Mozambique, ³Unicef Mozambique, ⁴District Health Department (DDS) Beira - Mozambique, ⁵Department of Infectious Diseases, Università di Bari, Italy, ⁶Doctors with Africa CUAMM, Padova - Italy
- P178 Retention in care of HIV adolescents and young adults in a pediatric center: virological, immunological and social implications**
V. Giacometti¹, C. Madia¹, P. Nannini¹, M. Della Negra², D. Peluzo Pacola², A.R. Benincaso¹, P. Erba¹, L. Pogliani³, G.V. Zuccotti⁴
¹Pediatric Infectious Disease Unit, Department of Pediatrics, Luigi Sacco Hospital, University of Milan, ²Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil, ³Department of Pediatrics, Luigi Sacco Hospital, University of Milan, ⁴Department of Pediatrics, Vittore Buzzi Children's Hospital, University of Milan
- P179 Pregnancy among HIV-infected women in Genoa over three decades, 1985-2014**
S. Grignolo¹, R. Agnello², D. Gerbaldo², C. Gotta³, C. Alicino⁴, B. Bruzzone⁴, A. Di Biagio¹, G. Mazzarello¹, A.I. Alessandrini¹, C. Gustavino², S. Trasino³, C. Viscoli¹
¹Infectious Diseases Unit, IRCCS AOU San Martino-IST, University of Genova, Genoa, Italy, ²Department of Obstetrics and Gynecology, IRCCS AOU San Martino-IST, University of Genova, Genoa, Italy, ³Neonatal Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ⁴Hygiene Unit, IRCCS AOU San Martino-IST, Genoa, Italy

PHARMACOLOGY, PHARMACOGENOMICS AND DRUG INTERACTIONS

- P180 Intensive pharmacokinetics (PK) of dolutegravir 50 mg associated with atazanavir 400 mg once daily in the clinical setting**
M. Ferrara¹, L. Marinaro¹, S. Rusconi², A. Crippa², A. Riva², A. Ariaudo¹, M. Simiele¹, A. D'Avolio¹, M.C. Tettoni¹, A. Castagna³, M. Galli², G. Di Perri¹, and S. Bonora¹
¹Infectious Diseases Unit, Department of Medical Sciences, University of Torino, ²Infectious Diseases Unit, DIBIC "Luigi Sacco", Università degli Studi di Milano, ³Infectious Diseases Unit, San Raffaele Scientific Institute, Milano
- P181 Co-treatment with sofosbuvir increases simeprevir plasma exposure, leading to higher risk of dermatological toxicity**
A. De Nicolò, L. Bogleione, F. Favata, A. Ariaudo, J. Cusato, C.S. Cardellino, C. Carcieri, G. Di Perri and A. D'Avolio
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
- P182 Role of vitamin D and BSEP gene polymorphisms in simeprevir plasma concentrations, HCV-RNA drop and dermatological toxicity prediction**
J. Cusato, A. De Nicolò, L. Bogleione, A. Ariaudo, F. Favata, C.S. Cardellino, C. Carcieri, G. Cariti, G. Di Perri, A. D'Avolio
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
- P183 Determinants of bone diseases in HIV patients**
C. Gervasoni¹, D. Minisci¹, P. Meraviglia¹, S. Baldelli², E. Clementi², G. Rizzardini¹, D. Cattaneo²
¹Department of Infectious Diseases, L. Sacco University Hospital, Milan, Italy, ²Unit of Clinical Pharmacology, L. Sacco University Hospital, Milan, Italy

- P184 Plasma and Intracellular Atazanavir Concentrations During Pregnancy in HIV-positive Patients according to ABCB1, SLCO1B1 and PXR genetic polymorphisms**
E. Focà¹, A. Calcagno², A. Bonito¹, M. Simiele², E. Domenighini¹, A. D'Avolio², E. Quiros-Roldan¹, G. Di Perri², F. Castelli¹, S. Bonora²
¹Department of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy, ²Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
- P185 A possible role of pharmacogenetics in lipid toxicity prediction in patients treated with lopinavir**
J. Cusato, S. Allegra, A. Calcagno, A. Arduino, L. Marinaro, S. Battisti, S. Bonora, G. Di Perri, A. D'Avolio
Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy
- P186 Pharmacogenetics of Antiretrovirals' Penetration into the Cerebrospinal Fluid**
M. Scarvaglieri, J. Cusato, S. Audagnotto, F. Lipani, C. Cardellino, C. Costa, A. D'Avolio, S. Bonora, G. Di Perri and A. Calcagno
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
- P187 Preliminary pharmacokinetic and clinical overview of anti-HCV therapies with DAAs in a "real-life" setting: the "KINETI-C" study**
A. De Nicolò, L. Boglione, A. Ariaudo, F. Favata, V. Avataneo, L. Paglietti, J. Cusato, C. Carcieri, G. Di Perri and A. D'Avolio
University of Turin, Department of Medical Sciences, "Amedeo di Savoia" Hospital
- P188 Markers of Tenofovir Tubular Toxicity in Naïve HIV-positive Patients: a Pilot Randomized Study**
L. Marinaro, A. Calcagno, J. Cusato, C. Montrucchio, M.E. Scarvaglieri, M.C. Tettoni, L. Trentini, C. Alcantarini, M. Simiele, M. Milesi, A. D'Avolio, G. Di Perri and S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy
- P189 CD4/CD8 ratio slope after switching from triple- to double combinations or PI-monotherapy**
C. Mussini¹, P. Lorenzini², A. Cozzi-Lepri³, G. Marchetti⁴, S. Rusconi⁵, A. Gori⁶, N. Gianotti⁷, C. Pinnetti⁸, A. Antinori⁹, A. d'Arminio Monforte⁴
¹University of Modena and Reggio Emilia, Modena, Italy, ²National Institute for Infectious Disease, Roma, Italy, ³University College London, London, UK, ⁴University of Milan, San Paolo Hospital, Milan, ⁵L. Sacco Hospital, University of Milan, Milan, Italy, ⁶S. Gerardo Hospital, University of Milan Bicocca, Monza, Italy, ⁷Infectious disease department, San Raffaele Scientific Institute, Milano, Italy
- P190 In the real world plasma trough levels of antiretrovirals do not change before and during DAA treatments in HIV/HCV co-infected persons**
M. Tempestilli, M. Zaccarelli, L. Timelli, G. Fabbri, S. Mosti, S. Cicalini, F. Lupi, A.L. Gallo, A. Antinori, L.P. Pucillo, A. Ammassari
National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome
- P191 Maraviroc reduces the ritonavir induced endothelial damage in cultured Human Aortic Endothelial Cells**
S. Cipriani¹, B. Renga², E. Schiaroli¹, P. Blas³, B. Albertini⁴, M. Simonetti², C. Pallotto¹, D. Francisci¹, S. Fiorucci², and F. Baldelli¹
¹Infectious Disease Clinic, University of Perugia, ²Department of Surgical and Biomedical Sciences, University of Perugia, ³School of Pharmacy, University of Camerino, ⁴Department of Pharmaceutical Sciences, University of Perugia
- P192 Pharmacokinetics of Simeprevir and Risk of Skin Reactions in Patients with Co-infection HIV/HCV with or without a Protease Inhibitor Containing**
A. Barco¹, L. Marinaro¹, G. Vendemiati¹, M. Merli², C. Alcantarini¹, F. Patti¹, A. Ariaudo¹, F. Favata¹, M. Milesi¹, J. Cusato¹, M.C. Tettoni¹, L. Trentini¹, H. Hasson², C. Uberti Foppa², A. D'Avolio¹, G. Di Perri¹ and S. Bonora¹
¹Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, ²Infectious Diseases Clinic, IRCCS, San Raffaele Hospital, Milan, Italy
- P193 Drug-Drug Interactions (DDIs) With New anti HCV Oral Interferon-Free drugs (DAA) in a polycentric cohort of HCV mono-infected and HIV co-infected patients (DAADD study)**
M. Gussio¹, A. Saracino², L. Larocca³, G. Madeddu⁴, F. Luciani⁵, M. Maresca¹, V. Fiore⁴, B. Cacopardo¹, F. Benanti¹, B.M. Ceslesia¹
¹Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Catania, ARNAS Garibaldi Catania, ²Unit of Infectious Diseases University of Bari, ³Unit of Infectious Diseases AO OVE Policlinico Catania, ⁴Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, ⁵Unit of Infectious Diseases Cosenza
- P194 Pharmacokinetics and Tubular Safety of Tenofovir/Emtricitabine/Rilpivirine**
L. Marinaro, G. Vendemiati, A. Calcagno, C. Montrucchio, M. Ferrara, M. Fiumanò, J. Cusato, C. Alcantarini, M. Simiele, S. Raviolo, M.C. Tettoni, L. Trentini, A. D'Avolio, G. Di Perri and S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino
- P195 Effectiveness and durability of DRV/r monotherapy as a maintenance strategy of routine care in Modena Clinic, an observational study**
A. Santoro, S. Zona, V. Borghi, C. Puzzolante, F. Carli, B. Beghetto, E. Roncaglia, G. Nardini, M. Menozzi, C. Mussini
Clinica di Malattie Infettive, A.O.U. Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy

- P196 Pharmaceutical care for hospital discharging HIV patients**
C. Carcieri, M. Chiarle, A. Lovera, S. Bertini, D. Piccioni, G. Cinnirella
Amedeo di Savoia Hospital, Pharmacy Department, Turin (Italy)
- P197 Hyperbilirubinemia during co-administration of daclatasvir and atazanavir/ritonavir in HIV/HCV coinfected patients: monocentric preliminary data**
P. Lanza, S. Odolini, I. Izzo, A. Spinetti, S. Casari, L. Urbinati, S. Zalron, P. Nasta, L. Praticò, A. Vavassori, A. Apostoli, C. Grecchi, F. Castelli
Clinic of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital, Brescia, Italy
- P198 Acute Renal Tubular Dysfunction in two HIV/HCV-coinfected Patients Treated with ledipasvir/sofosbuvir and Tenofovir-containing HAART**
C. Alcantarini, L. Marinaro, M. Ferrara, A. Barco, M. Milesi, F. Patti, L. Trentini, M.C. Tettoni, J. Cusato, A. De Nicolò, F. Favata, A. Ariaudo, A. D'Avolio, G. Di Perri and S. Bonora
Unit of Infectious Diseases, Department of Medical Sciences, University of Turin

SOCIAL AND BEHAVIOURAL SCIENCE, COMMUNITY ASPECTS AND COMMUNITY SURVEYS

- P199 Impact on the budget of the Italian National Health Service of the simplification to ATV+r+3TC of ATV+r+2NRTI therapy based on ATLAS-M Trial**
U. Restelli^{1,2}, M. Fabbiani³, S. Di Giambenedetto³, C. Nappi⁴, D. Croce^{1,2}
¹Centre for Research on Health Economics, Social and Health Care Management (CREMS), LIUC – Università Cattaneo, Castellanza (VA), ²School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, ³Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, ⁴Health Economics, Bristol Myers Squibb S.r.l., Rome
- P200 The European HIV Testing Week 2015 in Italy: characteristics of organizations and users**
G.M. Corbelli¹, E. Albertini², V. Brescia³, M. Breveglieri⁴, M. Cascio⁵, N. Catucci⁶, A.M. Covi⁷, D. Deserti⁸, F. Donini⁹, M. Farinella¹⁰, A. Ferrarotto¹¹, M. Galdiolo¹², S. Giudici¹³, M. Lichtner¹⁴, M. Maffeo¹⁵, L. Mastropietro¹⁶, L. Nigro¹⁷, N. Orchi¹⁸, M. Pace¹⁹, S. Patrucco²⁰, T. Prestileo²¹, G. Sartori²², F. Sorbara²³, E. Teti²⁴
¹Plus onlus, ²Arcigay Perugia, ³Arcigay Torino, ⁴Arcigay Verona, ⁵NPS Sicilia, ⁶LILA di Bari, ⁷Lila Trentino Onlus, ⁸Arcigay Milano, ⁹Arcigay Modena, ¹⁰Circolo di cultura omosessuale "Mario Mieli" Roma, ¹¹Arcigay Catania, ¹²Arcigay Padova, ¹³Fondazione LILA Milano Onlus, ¹⁴Sapienza Università di Roma Ospedale SM Goretti Latina, ¹⁵Arcigay Siena, ¹⁶Lila Piemonte onlus, ¹⁷Lila Catania, ¹⁸Istituto Nazionale Malattie Infettive L. Spallanzani Roma, ¹⁹Arcigay Palermo, ²⁰Arcobaleno Aids, ²¹Anlaids Sicilia Sezione "Felicia Impastato" Palermo, ²²Circolo Tondelli Lgbti, ²³Arcigay Napoli, ²⁴Fondazione Villa Maraini onlus
- P201 Using a grid as a reference point for HIV + patients counselling**
A. Bianchi¹, A. Antonino², G. Ardenghi², M. Drusiani², V. Meneghin², G. Fracca², A. Castagna¹, M. Cernuschi^{1,2}
¹Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy, ²ASA Associazione Solidarietà AIDS Onlus, Milan, Italy
- P202 "Uni-versità Uni-te contro l'HIV": a project to improve knowledge of HIV and STIs among undergraduates in Milan**
S. Penon¹, S. Giudici¹, G. Vidoni², A. Barilaro², L. Brignolo², A. Savio³, L. Bagnoli⁴, M. Di Maio⁵
¹Fondazione LILA Milano ONLUS, ²CRH-MTS – ATS Città Metropolitana di Milano, ³Università degli Studi di Milano, ⁴Collettivo universitario-GayStatale Milano, ⁵Associazione B.E.St. - Bocconi Equal Students
- P203 What could Italian People Think of PrEP? A Network Analysis Approach to Social Representations**
A. Toscano¹, A. Santoro², A. Bignardi³, C. Mussini²
¹Polo Universitario di Milano - Università degli Studi eCampus, 1 Centro Studi Airone, Taranto - Ita, ²Dept. of Medical and Surgical Sciences for Children & Adults (Infectious Disease Clinic), University of Modena and Reggio Emilia, ³Arcigay "Matthew Shepard", Modena, Ita
- P204 Proficiency in condom use among male migrants evaluated by a Condom Use Skills score**
F. Zoboli¹, D. Martinelli², M. Di Stefano¹, M. Fasano¹, R. Prato², T.A. Santantonio¹, J.R. Fiore¹
¹Clinic of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, ²Sector of Hygiene, Department of Medical and Surgical Sciences, University of Foggia
- P205 Correlates of infection and molecular characterization of blood-borne HIV, HCV and HBV in HIV-1 infected inmates in Italy**
N. Sanarico¹, S. D'Amato², R. Bruni¹, E. Salvi¹, P. Di Zeo¹, C. Rovetto¹, P. Chionne¹, E. Madonna¹, G. Pisani¹, A. Costantino¹, M. Equestre¹, M.E. Tosti¹, A. Cenci¹, E. Pontali³, A. Pansera⁴, S. Carbonara⁵, L. Surace⁶, G. Federzoni⁷, G. Starnini⁸, S. Babudieri⁹, M. Rapicetta¹, M.G. Pomba², A. Caraglia², B. Ensoli¹, A. Ciccaglione¹ and S. Buttò¹
¹Istituto Superiore di Sanità, Roma, ²Ministry of Health, ³ASL 3, Genova, ⁴Spedali Civili, Brescia, ⁵Clinica Malattie Infettive AOU, Bari, ⁶Presidio Ospedaliero di Lamezia Terme, ⁷Dip. Cure Primarie AUSL Modena, ⁸Ospedale Belcolle, ASL Viterbo, ⁹Malattie Infettive e Tropicali, AOU Sassari
- P206 HIV actually: action research focusing on stigma and false beliefs through social networks**
M.M. Ratti^{1,2}, F. Bertin², S. Sara², G. Delli Zotti¹, L. Sarno^{1,2}
¹Health and Clinical Psychology Service, IRCCS San Raffaele Hospital, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy

- P207 CON-TATTO: usage of Family Shiatsu in Lombardy HIV/AIDS Family Homes**
L. Rancilio¹, G. Gaiera¹, E. Lamperti², R. Palasciano² e CRCA Lombardia¹
¹Coordinamento Regionale Case Alloggio per persone con HIV/AIDS della Lombardia, ²shiatsu practitioner, Shiatsu International School, Milan
- P208 Activities to support Retention in Care (RiC) conducted by associations and NGO involved in HIV: a survey**
G. Chiaradia¹, P. Piselli¹, L. Scappaticci¹, C. Cimaglia¹, M. Oldrini², M. Breveglieri³, A. Camposeragna⁴, M. Farinella⁵, C. Falanga⁶, L. Rancilio⁷, S. Marcotullio⁸, M. Stagnitta⁴, G. Gaiera⁹, M. Errico¹⁰, P. Scognamiglio¹, G. Ippolito¹, E. Girardi¹
¹Istituto Nazionale Malattie Infettive "L. Spallanzani", IRCCS, Roma, ²Lila, ³Arcigay, ⁴CNCA, ⁵Circolo Mario Mieli, ⁶ANLAIDS, ⁷Caritas, ⁸NADIR, ⁹CICA, ¹⁰NPS
- P209 Relationship between Burnout, coping strategies and self-perceived health in healthcare providers working with HIV/AIDS patients**
M.M. Ratti^{1,2}, S. Sofisti², G. Delli Zotti¹, B. Vai^{3,4}, M.S. Spada⁵, M. Rizzi⁵, L. Sarno^{1,2}
¹Health and Clinical Psychology Service, IRCCS San Raffaele Hospital, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³Department of Clinical Neurosciences, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ⁴Department of Human Studies, Libera Università Maria Ss. Assunta, Roma, Italy, ⁵ASST Papa Giovanni XXIII, Bergamo, Italy
- P210 Impact of a Patient Support Program in HCV treatment: tailored interventions and HealthCare system optimization**
V. Sangiovanni, V. Penta, G. Di Flumeri, A. Marocco, A. Chirianni
A.O. Dei Colli - Plesso Cotugno - III Div. U.O.C. Infezioni Sistemiche e dell'Immunodepresso, Napoli
- P211 Complementary Medicine Techniques for HIV-Infected Subjects on Stable Combination Antiretroviral Therapy: a Pilot Study**
R. Silva¹, M.S. Pillitteri^{1,2}, C. Tincati¹, G. Cirafici¹, T. Bini¹, G. Marchetti¹, A. d'Arminio Monforte¹
¹Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, ²Dermatology Unit, ASST Santi Paolo e Carlo, Milan
- P212 Fixed associations of nucleoside-nucleotide analogues in antiretroviral therapy: a virtuous use during years 2014-2015, among efficacy, safety, adherence, governance, and costs**
L. Appolloni¹, R. Manfredi², G. Pensalfine¹, L. Cantoro¹, M. Morotti¹, C. Puggioli¹
¹Hospital Pharmacy, ²Infectious Disease, S. Orsola-Malpighi Hospital, Bologna, Italy
- P213 The Clinical Governance of Hepatitis C Virus in Calabria Region (Italy): DAAS and AIFA Monitoring Register**
M. De Fina¹, A.E. De Francesco¹, S. Esposito¹, G. Brancati², R. Fatarella³
¹"Mater Domini" University Hospital, Pharmacy, Catanzaro, Italy, ²Basic Levels of Care (LEA) Department, Regione Calabria, Italy, ³Basic Levels of Care (LEA), Director of Health Protection Department, Regione Calabria
- P214 The Test Days in Modena: Contributions from Psychology of Prevention to Enhance HIV Counselling and Testing Impact**
A. Toscano¹, A. Santoro², A. Bignardi³, C. Mussini²
¹Polo Universitario di Milano - Università degli Studi eCampus, 1 Centro Studi Airone, Taranto - Ita, ²Dept. of Medical and Surgical Sciences for Children & Adults (Infectious Disease Clinic), University of Modena and Reggio Emilia, ³Arcigay "Matthew Shepard", Modena, Ita

VIROLOGY

- P215 Local epidemics gone viral: follow-up study reveals the evolution and nation-wide spread of the Italian recombinant form CRF60**
A. Lai¹, F.R. Simonetti¹, G. Brindicci², S. Gioffrè¹, A. Bergna¹, S. Di Gianbenedetto³, K. Sterrantino⁴, C. Mussini⁵, S. Menzo⁶, M. Zazzi⁷, G. Angarano², L. Monno², C. Balotta¹
¹Department of Biomedical and Clinical Sciences L. Sacco, University of Milan, Milan, ²Clinic of Infectious Diseases, University of Bari, Bari, ³Institute of Infectious Diseases, Catholic University of Sacred Heart, Rome, ⁴Division of Tropical and Infectious Diseases, Careggi Hospital, Florence, ⁵Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, ⁶Unit of Virology, Azienda Ospedaliero-Universitaria "Ospedali Riuniti", Torrette Ancona, ⁷Department of Medical Biotechnologies, University of Siena, Siena
- P216 Impact of occult HBV infection in HCC presentation in HCV-related cirrhosis**
M. Starace¹, V. Iodice^{1,2}, C. Minichini¹, N. Farella², L. Onorato¹, G. Liorre², E. Sagnelli¹, G. de Stefano², N. Coppola¹
¹Department of Mental Health and Public Medicine, Second University of Naples, ²IX Interventional Ultrasound Unit for Infectious Diseases-AORN dei Colli-P.O. Cotugno-Naples
- P217 Prevalence of Transmitted Resistance Mutations to Integrase Inhibitors using Ultra-Deep Pyrosequencing assays: preliminary data from a single centre (Northern Italy)**
G. Lapadula¹, S. Malandrini², N. Squillace¹, A. Soria¹, A. Muscatello¹, M. Fabbiani¹, S. Costarelli¹, A. Bandera¹, A. Cavallero², A. Gori¹
¹Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, ²Microbiology Unit, San Gerardo Hospital, Monza, Italy

- P218 Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) in HCC/cirrhotic transplanted patients**
M.C. Sorbo¹, F.P. Antonucci¹, L. Carioti¹, M. Manuelli², I. Lenci³, M.C. Bellocchi¹, F. Continenza¹, V. Cento¹, D. Sforza², F. De Leonardis³, M. Milana³, T. Manzia², G. Tisone², M. Angelico³, C.F. Perno¹, F. Ceccherini-Silberstein¹
¹Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ²Liver Transplant Centre, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy, ³Hepatology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy
- P219 Role of HCV genotype on inflammation and neuronal damage in HIV/HCV co-infected patients**
S. Carta¹, V. Fedele¹, P. Lorenzini¹, C. Pinnetti¹, A.R. Garbuglia¹, F. Forbici¹, A. Ammassari¹, F. Ceccherini-Silberstein², M.R. Capobianchi¹, A. Antinori¹, C.F. Perno¹
¹National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ²University of Rome Tor Vergata, Rome, Italy
- P220 Simultaneous quantification of total, unintegrated and integrated HIV-1 DNA as a marker to monitor therapeutic efficacy and to predict viral rebound**
A. Casabianca¹, C. Orlandi¹, B. Canovari², M. Rocchi¹, D. Libetti¹, M. Acetoso², M. Valentini² and M. Magnani¹
¹Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino Italy, ²Azienda Ospedaliera Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore, Pesaro, Italy
- P221 A multi-mutate genotype 1a and 1b dual HCV infection with HIV co-infection and porphyria**
P. Canepa¹, E. Rappazzo¹, O. Magnani², L. Sticchi^{1,3}, G. De Rosa², M. Setti², B. Bruzzone²
¹Hygiene Unit, Department of Health Sciences, University of Genoa, IRCCS AOU San Martino - IST, Genoa, Italy, ²Internal Medicine and Clinical Immunology Unit, IRCCS AOU San Martino-IST, Genoa, Italy, ³Hygiene Unit, IRCCS AOU San Martino - IST, Genoa, Italy
- P222 Integrated study of HCV and ALT kinetics in cirrhotic patients treated with direct-acting antiviral agents differentiate the effect of interferon and DAA inhibitors**
V. Cento¹, T.H.T. Nguyen², D. Di Carlo¹, E. Biliotti³, L. Gianserra⁴, I. Lenci⁵, D. Di Paolo⁵, V. Calvaruso⁶, E. Teti⁷, M. Cerrone⁸, D. Romagnoli⁹, M. Melis¹⁰, E. Danieli¹¹, B. Menzaghi¹², E. Polilli¹³, M. Siciliano¹⁴, L.A. Nicolini¹⁵, A. Di Biagio¹⁵, C. Magni¹⁶, M. Bolis¹⁶, F.P. Antonucci¹, V.C. Di Maio¹, R. Alfieri¹⁷, L. Sarmati⁷, P. Casalino¹⁸, S. Bernardini¹⁸, V. Micheli¹⁹, G. Rizzardini¹⁶, G. Parruti¹³, T. Quirino¹², M. Puoti¹¹, S. Babudieri¹⁰, A. D'Arminio Monforte⁸, M. Andreoni⁷, A. Craxi⁸, M. Angelico⁵, C. Pasquazzi⁴, G. Taliani³, J. Guedj², F. Ceccherini-Silberstein¹, C.F. Perno¹
¹Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, ²Infection. Antimicrobials. Modelling. Evolution (IAME) UMR 1137, Inserm and Université Paris Diderot, Paris, France, ³Tropical Diseases, Policlinic "Umberto I", Rome, Italy, ⁴Infectious Diseases, Sant'Andrea Hospital - "La Sapienza" University, Rome, Italy, ⁵Hepatology Unit, Policlinico of Rome Tor Vergata, Rome, Italy, ⁶Gastroenterology, "P. Giaccone" University Hospital, Palermo, Italy, ⁷Infectious Diseases, Policlinico of Rome Tor Vergata, Rome, Italy, ⁸Clinic of Infectious Disease, Department of Health Sciences, San Paolo University Hospital, University of Milan, Milan, Italy, ⁹Department of Biomedical, Metabolic and Neural Sciences, NOCSAE Baggiovara, ¹⁰Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Italy, ¹¹S.C. Malattie Infettive/Infectious Diseases Dept., AO Ospedale Niguarda Cà Granda, Milan, Italy, ¹²Infectious Diseases, Ospedale di circolo di Busto Arsizio, Busto Arsizio, Varese, Italy, ¹³Infectious Disease Unit, Pescara General Hospital, Pescara, Italy, ¹⁴Gastroenterology, Catholic University of Rome, Rome, Italy, ¹⁵University of Genoa (DISSAL) Infectious Diseases Unit/AOU IRCCS San Martino-IST Genoa, Italy, ¹⁶Division of Infectious Disease, Hospital Sacco di Milan, Milan, Italy, ¹⁷Istituto Nazionale di Genetica Molecolare (INGM) "Romeo ed Enrica Invernizzi", Milan, Italy, ¹⁸Laboratory Medicine, Policlinico Tor Vergata, Rome, Italy, ¹⁹Unit of Microbiology, Hospital Sacco di Milan, Milan, Italy
- P223 Preliminary evaluation of antiviral activity of candidate HIV inhibitors targeting human DDX3 protein**
A. Boccuto¹, A. Brai², A. Giannini¹, C. Tintori², A. Garbelli³, G. Maga³, M. Botta², M. Zazzi¹, F. Saladini¹
¹Dipartimento di Biotecnologie Mediche, Università di Siena, ²Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, ³Istituto di Genetica Molecolare, CNR, Pavia
- P224 Molecular diversity in illegal or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples**
C. Minichini¹, C. Sagnelli^{2,3}, M. Ciccozzi^{4,5}, A. Lo Presti⁴, M. Starace¹, L. Alessio^{1,3}, M. Macera^{1,3}, E. Celli^{4,6}, L. Gualdieri⁷, N. Caprio^{1,8}, G. Pasquale¹, E. Sagnelli¹, N. Coppola^{1,3}
¹Department of Mental Health and Public Medicine, Second University of Naples, Italy, ²Department of Clinical and Experimental Medicine and Surgery, Second University of Naples, Naples, Italy, ³Medical Center, Centro Sociale ex Canapificio, Caserta, Italy, ⁴Epidemiology Unit, Department of Infectious, Parasite and Immune-Mediated Diseases, Italian Institute of Health, Rome, Italy, ⁵University of Biomedical Campus, Rome, Italy, ⁶Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, ⁷Medical Center, Centro per la Tutela della Salute degli Immigrati, Naples, Italy, ⁸Medical center, Centro Suore Missionarie della Carità, Naples, Italy
- P225 HIV-RNA quantification: performance evaluation of a new rapid assay Xpert® HIV-1 Viral Load**
N. Nigro¹, P. Caligiuri², B. D'Ambrosio², R. Barresi¹, R. Cerruti¹, G. Icardi^{1,2}, B. Bruzzone¹
¹Hygiene Unit, IRCCS AOU San Martino - IST, Genoa, Italy, ²Hygiene Unit, Department of Health Sciences, University of Genoa, IRCCS AOU San Martino - IST, Genoa, Italy
- P226 Regular update of HIV-1 subtyping is highly needed, mainly for newly emerging strains in western countries**
L. Fabeni¹, G. Bero¹, J. Fokam², C. Alteri³, L. Carioti³, A. Bertoli³, C. Gori¹, F. Forbici¹, S. Carta¹, V. Fedele¹, S. Cicalini¹, C. Pinnetti¹, R. Bellagamba¹, A. Ammassari¹, V. Borghi¹, M. Giuliani⁵, G. De Carli¹, N. Orchi¹, P. Scognamiglio¹, A. Pennica⁶, C. Mastroianni⁷, F. Montella⁸, A. Cristaudo⁵, C. Mussini⁴, E. Girardi¹, M. Andreoni⁷, A. Antinori¹, F. Ceccherini-Silberstein³, C.F. Perno¹ and M.M. Santoro³
¹National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome, Italy, ²Chantal Biya International Reference for research on HIV/AIDS prevention and management, Yaoundé, Cameroon, ³University of Rome Tor Vergata, Rome, Italy, ⁴Modena University Hospital, Modena, Italy, ⁵San Gallicano Dermatological Institute, IRCCS, Rome, Italy, ⁶S. Andrea Hospital, Rome, Italy, ⁷Sapienza University, Latina, Italy, ⁸S. Giovanni Addolorata Hospital, Rome, Italy, ⁹University Hospital Tor Vergata, Rome, Italy



Oggi, il mondo di domani

Oggi il mondo di domani è l'impegno ad agire per un presente responsabile ed un futuro sostenibile. Per Bristol-Myers Squibb significa scoprire, sviluppare e offrire terapie innovative per aiutare i pazienti a sconfiggere malattie gravi. Ma significa anche avere la piena consapevolezza degli obblighi verso la comunità locale e globale, trasformandoli in impegno concreto. Il nostro impegno guarda al futuro e alle realtà più lontane ma inizia nel presente e dai luoghi a noi più vicini. **Oggi per il domani.**



abbvie
care

IT/ADI/1215/0961a

AbbVie Care

LA PIATTAFORMA DI SOLUZIONI PER LE PERSONE CON ESPERIENZA DI MALATTIA

AbbVie Care è frutto della sensibilità e attenzione di AbbVie verso i bisogni delle Persone che vivono quotidianamente l'esperienza di malattia.

AbbVie Care è stato sviluppato per offrire soluzioni personalizzate per i Pazienti ed i Caregivers.

AbbVie Care offre continuità alle indicazioni del Medico specialista, contribuendo alla corretta gestione dei suoi Pazienti, anche al di fuori dell'ambiente sanitario, a vantaggio dei livelli assistenziali.

AbbVie Care permette al Medico specialista di accedere a dati di qualità di vita e di aderenza dei propri Pazienti, contribuendo a massimizzare il rapporto Medico-Paziente.

AbbVie Care si diversifica in Programmi di supporto al Paziente specifici per diverse patologie totalmente gratuiti per il SSN ed il Paziente.

Per maggiori informazioni sul progetto AbbVie Care inviare un'email al seguente indirizzo: abbviecare.it@abbvie.com



PROGRAMMA di supporto al **PAZIENTE** in trattamento con farmaci antivirali ad azione diretta



PROGRAMMA di supporto al **PAZIENTE** in trattamento con farmaco biologico



PROGRAMMA di supporto per il **BAMBINO** e la **FAMIGLIA** nel percorso di prevenzione delle gravi affezioni da VRS



Italian
Conference on
AIDS and **Antiviral**
Research



Presidenza del Congresso
Andrea Gori, Monza
Adriano Lazzarin, Milano
Franco Maggiolo, Bergamo



il PROGRAMMA di supporto al PAZIENTE in trattamento con farmaci antivirali ad azione diretta ha ottenuto il patrocinio di



68 giugno 2016
MIANO
Università Milano-Bicocca

Conference Venue

Università Milano-Bicocca

Piazza dell'Ateneo Nuovo, 1 – 20126 Milano – www.unimib.it**How to reach the Conference Venue****Public transports**Tram n. 7 stop Arcimboldi Ateneo Nuovo and Bus n. 87
Underground line "Lilla" stop Ponale**Railway station**

5 Km from the Central Station

**Airport**17 km from Milano Linate
50 Km from Milano Malpensa**Car**

Wide pay parking available near the Congress Venue

**Official languages**

Italian and English. No simultaneous translation provided.

Pre-conference advanced courses and Congress dates

Pre-conference advanced courses: Monday, June 6 from 13.30 to 16.00

Conference: from Monday, June 6 at 13.00 to Wednesday, June 8 at 17.15

Conference Secretariat opening times

Monday, June 6 from 10.00 to 20.00

Tuesday, June 7 from 08.00 to 18.00

Wednesday, June 8 from 08.00 to 17.15

Exhibition Area opening times

Monday, June 6 from 13.00 to 20.00

Tuesday, June 7 from 08.00 to 18.00

Wednesday, June 8 from 08.00 to 17.15

ICAR official events**Monday, June 6**

Opening Session: Conference venue, from 17.00 in Aula Magna

ICAR-CROI Awards: Conference venue, from 18.20 to 18.40 in Aula Magna

ICAR 2016 Welcome Reception: Transfer at 20.00 from Bicocca University

Wednesday, June 8

ICAR 2016 Awards from SIMIT and SIVIM: Conference venue, from 16.55 in Aula Magna

Instructions for Speakers

It is not possible to bring presentations directly to the lecture hall. All presentations have to be handed over at the Slide Center Room at least 2 hours before the session. At the Slide Center Room, Speakers will have the possibility of:

- Reviewing power-point presentations
- Last minute changes of power-point presentations
- Being supported by technical staff
- Uploading power-point presentation in the dedicated session conference room

All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide. For more information:

<http://www.icar2016.it/pages/en/speakersInstructions/>**Oral Communication Sessions**

Selected abstract will be presented in Oral Communication Sessions. The Authors of the selected abstract are requested to attend those sessions and provide max 12 (Microsoft Power Point) slides resuming their poster. Time allowed for presentation: 10 minutes followed by 2 minutes for discussion. All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

Poster Discussion Sessions

Selected abstract will be presented in Oral Discussion Sessions. Presentations will be held in the Poster Area through interactive touch screen stations. The Authors of the selected abstract are requested to attend those sessions and provide max 3/4 (Microsoft Power Point) slides resuming their poster. Time allowed for presentation: 5 minutes followed by 2 minutes for discussion. All Speakers are requested to start their presentations with a Disclosure of Potential Conflicts of Interest slide.

Authors can set up their posters according to the number received from the Organizing Secretariat on June 6, 2016 from h. 9.30 and remove them on June 8, 2016 at the end of the Congress.

Poster Exhibition

ICAR Poster exhibition will take place within a dedicated area of the Congress Center. Dimensions should not exceed 70x100 cm. Authors can set up their posters according to the number received from the Organizing Secretariat on June 6, 2016 from h. 9.30 and remove them on June 8, 2016 at the end of the Congress.

**RaccontART**

The art competition launched by ICAR to students who are invited to present their views on HIV/AIDS through various forms of expression. During the Conference Opening Session (*Aula Magna, Bicocca University, Monday June 6, from 13.00 to 16.00*) the finalists will present their artistic works and the winners will be awarded by the Jury composed of leading representatives of the national cultural world, ICAR Scientific Coordinators and Patients' Community.

Unrestricted educational grant of Gilead

**Community Village**

A specific area of the Congress Venue dedicated to the **Community Village**: a meeting point for all the participants to visit the booths of HIV/AIDS and Hepatitis patient associations and meet the Community activists.

Quick test for HIV and HCV

Healthcare personnel from Infectious Disease Departments of ASST S. Gerardo Monza and ASST Papa Giovanni XIII Bergamo Hospitals, will perform free rapid testing for HIV and HCV at the request of citizens in a confidential and anonymous way.

At Bicocca University on:

Monday, June 6 from 14.00 to 18.00

Tuesday, June 7 from 09.00 to 17.00

Wednesday, June 8 from 09.00 to 16.00

In collaboration with Cepheid and Meridian Bioscience Europe

Piazza ICAR and Artists

A dedicated area at the entrance of the Bicocca University and Congress Venue. Piazza ICAR is not only a meeting point. During the Congress' days, the students of Liceo Artistico della Villa Reale di Monza "Nanni Valentini" guided by Stefano Prazzoli, emerging painter, will realize original artworks inside the Piazza ICAR gazebos.



Unrestricted educational grant of Janssen

**Nice to ICAR you**

The Secretary Meeting point where all registered participants can ask for ICAR T-shirt and bracelet.

**Poster-4-you**

A free service for selected posters' Authors to create and print their own posters and pick them up at the Poster exhibition area inside the Congress Venue. **Poster-4-you** USB Pendrive can be requested showing the coupon at the Bristol-Myers Squibb booth. *Unrestricted educational grant of Bristol-Myers Squibb*

**Abstract USB Pendrive**

All registered participants can ask for the **ICAR Abstract USB Pendrive** showing the coupon at ViiV Healthcare booth: it contains all accepted abstracts. *Unrestricted educational grant of ViiV*

**Interactive Touch Screen Stations**

Seven touch screen stations within the Congress Venue for Poster Discussion Sessions, to connect to the ICAR website or to consult posters. *Unrestricted educational grant of Siemens*

**Wi-Fi zone**

Free Wi-Fi zone available within the exhibition area: personal password to be requested through coupon at Hologic booth. *Unrestricted educational grant of Hologic*

Website and Web Repository

After the Congress, the ICAR official website (www.icar2016.it) will publish the ICAR 2016 web repository with abstracts, presentations, oral communications, accepted posters, podcasts and photo gallery.

Social Media

www.facebook.com/ICAR2016



ICAR, insieme contro l'AIDS - three videos dedicated to HIV prevention and specially produced for ICAR by SAE Institute Milano

**Conference**

The 8th ICAR Conference has been accredited to the Italian Ministry of Health for 10,5 CME Credits.

Every single day has been accredited for the following professionals:

<i>Id ECM Number</i>	<i>Credits</i>	<i>Professionals</i>
Monday, June 6, 2016		Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Biologist Pharmacist Nurse Medical laboratory technician Psychologist
150-149622	2	
Tuesday, June 7, 2016		
150-149624	4,5	
Wednesday, June 8, 2016		
150-149626	4	

Pre-conference advanced Courses

The 8th ICAR advanced Courses have been accredited to the Italian Ministry of Health for each single course.

<i>Id ECM Number</i>	<i>Credits</i>	<i>Professionals</i>
Le premesse virologiche per il successo clinico		Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology Biologist Medical laboratory technician
150-149705	2	
Ruolo dell'infermiere nella ricerca e nell'ottimizzazione del percorso assistenziale		Nurse, Healthcare assistant, Professional educator, Obstetrician, Psychologist
150-149706	2	
HCV nel monoinfetto e nel coinfecto: analogie e differenze		Medical Doctor Infectious and Tropical Diseases Hygiene, Epidemiology and Public Health Microbiology and Virology Allergology and Clinical Immunology Internal Medicine Gastroenterology
150-149709	2	

Obtaining credits**Participants**

To obtain credits, registered participants are required to:

- Wear the identification badge during working sessions
- Provide signature and write entrance/exit times before and after attending working sessions
- Complete assessment and satisfaction questionnaires for each day

Speakers

Speakers will be given 1 credit for each half-hour of consecutive teaching.

Speakers, moderators and discussants can decide to obtain credits as participants (see Participants).

Attendance Tracking

Attendance will be tracked through participants' signature at the start/end of each day, and through assessment and satisfaction questionnaires.

CME Certificates

Credits will be given only if a participant attends 100% of the working sessions and provides correct answers to at least 75% of the questions included in the final assessment questionnaire. The Provider will send CME certificates to the participants after the Conference.

REGISTRATION FEES

Pre-conference advanced Courses

Free of charge (registrations available on a "first come, first served" basis)

Registration includes: congress kit (delegate bag, badge, certificate of attendance), CME registration and materials, working brunch and coffee breaks during the day of the course.

Conference**Conference Registration Fees (22% VAT non included)**

Physicians	€ 600,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 250,00
Post-graduate medical trainees	€ 50,00
Students/PhD	Free
Members of HIV/AIDS Community	Free

The registration fee includes: congress kit (delegate bag, badge, certificate of attendance), Opening Session and Welcome Cocktail on June 6, coffee breaks and lunches on June 7 and 8, CME registration, Conference USB/abstract and poster.

Daily Conference registration fees (22% VAT not included)

Physicians	€ 300,00
Physicians < 35 years of age, Biologist, Biotechnologist, Pharmacist, Nurse, Psychologist	€ 100,00
Post-graduate medical trainees	€ 25,00

The registration fee includes: attendance to the sessions of the day, congress kit (delegate bag, badge, certificate of attendance), Conference USB/abstract and poster, coffee break and lunch for the day, certificate of attendance for the sessions of the day.

THANKS FOR ICAR 2016 AWARDS

The 8th ICAR Chairs, Scientific Secretariat and Organizing Secretariat would like to thank the Scientific Societies SIMIT and SIVIM for the Special Awards addressed to Young Investigators:

**SIMIT Awards**

5 Awards of € 2.000,00 each one, for the best abstracts accepted as **Oral Communications**, presented by young investigators under 45 aa (born after 12/31/1970) and regularly SIMIT registered for 2015 and 2016.

**SIVIM Award**

1 Award of € 1.000,00 for the best abstract of **Basic and Clinical Virology**.

Abstracts will be selected in the Congress Venue by dedicated Commissions and winners will be announced during the ICAR 2016 Awards session which will be held on **Wednesday, June 8, 2016 from 16.55 to 17.05 in Aula Magna**.



MSD

References: 1. Intron A Registration Life Cycle Status as of January 21, 2011. [FDA]. 2. PegIntron®. Riassunto delle caratteristiche del prodotto 3. Victrelis®, Riassunto delle caratteristiche del prodotto 4. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483828.htm> 5. Navia NA, Fitzgerald PMD, McKeever BM, et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 1989;337(6208):615-620. 6. RCP Crixivan. 7. RCP Efavirenz. 8. RCP Isentress

www.msd-italia.it | www.msdsalute.it

Proprietà della MSD Italia SRL | Prima della prescrizione, consultare il riassunto delle caratteristiche del prodotto fornito dalla ditta produttrice. INFC-1184919-0001-RTG-EP-05/2018

1989

Scoperta del virus dell'Epatite C

1991

Interferone Alfa-2b, Ricombinante: primo interferone- α per il trattamento dell'Epatite C¹

2001

Peginterferone α -2b ricombinante: prima formulazione di interferone- α pegilato, da assumere in associazione con ribavirina²

2011

Boceprevir: primo Inibitore delle Proteasi nel trattamento dell'Epatite C³

2016

28 gennaio 2016
FDA approva la fixed dose combination:
**Inibitore delle Proteasi di 2^a generazione
+ Inibitore Polimerasi NS5A⁴**

30 anni di IMPEGNO e INNOVAZIONE in VIROLOGIA

1989

I ricercatori MSD stabiliscono il ruolo della proteasi nel ciclo di vita del virus⁵

1996

Indinavir: il primo inibitore della proteasi di MSD⁶

1998

Efavirenz: l'NNRTI scoperto nei laboratori MSD diventa uno dei primi NNRTI sul mercato⁷

1989


Raltegravir: Il primo inibitore dell'integrasi⁸

2016

L'impegno di MSD continua...⁸




ENTRANCE VIA PIERO E ALBERTO PIRELLI



U6 BUILDING
GROUND FLOOR

ENTRANCE PIAZZA ATENEU NUOVO



EXHIBITION AREA

1/2	MSD
3/4	Bristol-Myers Squibb
5/6	abbvie

7/8	GILEAD
9/10	janssen
11	Mylan

12/13	ViiV Healthcare
14	HOLOGIC
15	ReAdfiles
16	abbvie care

17	Hospitality suite	GILEAD
18	Wi-fi zone	HOLOGIC
19	Wi-fi zone	HOLOGIC

A	Meridian
B	SIEMENS
C	Alere
D	Cepheid

n. 7 Totem touch screen poster
SIEMENS

THANKS TO THE SPONSORS

The Chairs, the Scientific Secretariat and the CME Provider wish to thank for the support given to the Congress, as unrestricted educational grants, the following Companies:

PLATINUM SPONSORS



GOLD SPONSORS



OTHER SPONSORS



www.icar2016.it



CME PROVIDER and ORGANIZING SECRETARIAT

Effetti srl Via Gallarate, 106 - 20151 Milano, I

PHONE +39 02 3343281 FAX +39 02 38002105 MAIL: icar2016@effetti.it

CONGRESS VENUE

Università Milano-Bicocca

Piazza dell'Ateneo Nuovo, 1 - 20126 Milano I

QUICK LINKS

Organizing Secretariat icar2016@effetti.it

Abstract Secretariat abstract.icar2016@effetti.it

ICAR Website www.icar2016.it